Investigating Shared Genetic and Environmental Aetiology between Psychiatric Disorders and Rheumatoid Arthritis by Euesden, Jack
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Investigating Shared Genetic and Environmental Aetiology between Psychiatric




Download date: 06. Nov. 2017
 1 
 
Investigating Shared Genetic and 
Environmental Aetiology between 




























Submitted in fulfilment of the requirements for the degree of 





This research would have been impossible without the invaluable co-operation of all 
participants. In the United Kingdom, these are not limited to the RADIANT major 
depressive disorder patients, the controls recruited to the same study, the National Child 
Development Study participants, the Wellcome Trust case-control consortium 
participants and all of those individuals who participated in the data generation for the 
UK Biobank study – including my mother. Outside of the United Kingdom, my research 
over the last four years would have been impossible without the data volunteered by the 
people of Iceland to the deCODE biobank resource, and by the cohort in Mtubatuba to 
the Africa Centre for Population Health, in kwaZulu-Natal. 
 
I could not have completed this thesis without the constant reassuring support of 
friends, both at King’s College London and elsewhere, and emotional support 
throughout from my family – my parents and sisters. I would also like to thank my 
partner, Líse, for being there for me, at some of my lowest moments. Finally, none of 
this would have been possible without the excellent supervision I received from Cathryn 




STATEMENT OF AUTHORSHIP .................................................................................... 6	
LIST OF ABBREVIATIONS .............................................................................................. 8	
CHAPTER 1: INTRODUCTION ....................................................................................... 9	
PRIMARY HYPOTHESES ....................................................................................................................... 9	
PHENOTYPES UNDER INVESTIGATION ....................................................................................... 10	
EPIDEMIOLOGICAL RELATIONSHIPS BETWEEN PSYCHIATRIC AND AUTOIMMUNE 
DISORDERS ........................................................................................................................................... 12	
EXPERIMENTAL EVIDENCE FOR SHARED PATHWAYS BETWEEN PSYCHIATRIC AND 
AUTOIMMUNE DISEASES .................................................................................................................. 14	
GENETIC DETERMINANTS OF COMMON DISEASE ................................................................... 18	
EVIDENCE FOR GENETIC OVERLAP ............................................................................................. 25	
INTRODUCTION TO RESEARCH METHODS ................................................................................. 27	
SUMMARY ............................................................................................................................................... 36	
OUTLINE TO THESIS ......................................................................................................................... 36	
TABLES .................................................................................................................................................... 38	
CHAPTER 2: PRSICE: POLYGENIC RISK SCORE SOFTWARE. ............................... 40	
CHAPTER 3: THE RELATIONSHIP BETWEEN SCHIZOPHRENIA AND 
RHEUMATOID ARTHRITIS REVISITED: GENETIC AND EPIDEMIOLOGICAL 
ANALYSES. ....................................................................................................................... 50	
SUPPLEMENTARY MATERIALS: ....................................................................................................... 59	
APPENDIX – THE GENETIC OVERLAP BETWEEN PGC2-SCZ AND RHEUMATOID 
ARTHRITIS ............................................................................................................................................. 79	
CHAPTER 4:  A BIDIRECTIONAL RELATIONSHIP BETWEEN DEPRESSION 
AND THE AUTOIMMUNE DISORDERS - NEW PERSPECTIVES FROM THE 
NATIONAL CHILD DEVELOPMENT STUDY ........................................................... 85	
ABSTRACT .............................................................................................................................................. 87	
INTRODUCTION ................................................................................................................................... 89	
MATERIALS AND METHODS ............................................................................................................. 92	
RESULTS ................................................................................................................................................. 97	
DISCUSSION ........................................................................................................................................ 101	
TABLES AND FIGURES ...................................................................................................................... 106	
SUPPLEMENTARY MATERIALS ...................................................................................................... 109	
FUNDING AND ACKNOWLEDGEMENTS ...................................................................................... 117	
BIBLIOGRAPHY .................................................................................................................................... 118	
 4 
CHAPTER 5: THE RELATIONSHIP BETWEEN MENTAL HEALTH, DISEASE 
SEVERITY AND GENETIC RISK FOR DEPRESSION IN EARLY RHEUMATOID 
ARTHRITIS ..................................................................................................................... 123	
CHAPTER 6: PRSLICE: A LOCALISED POLYGENIC RISK SCORE METHOD ..... 161	
ABSTRACT ............................................................................................................................................ 163	
INTRODUCTION ................................................................................................................................. 164	





SUPPLEMENTARY MATERIALS ...................................................................................................... 184	
CHAPTER 7: DISCUSSION ........................................................................................... 188	
EVIDENCE FOR AN EPIDEMIOLOGICAL LINK BETWEEN PSYCHIATRIC AND AUTOIMMUNE 
DISORDERS ........................................................................................................................................... 189	
LEVERAGING GENETIC RISK TO UNDERSTAND AETIOLOGY, PROGNOSIS AND TREATMENT
 ................................................................................................................................................................ 197	






Complex diseases are defined by having a multifactorial aetiology, consisting of multiple 
genetic and environmental risk factors. Complex diseases are often associated with 
unusual patterns of comorbidity. They are also typified by suboptimal nosology, being 
classified according to historical diagnostic boundaries that may not be strongly justified 
given emerging evidence on pathophysiology.  Epidemiological studies have shown an 
unusual pattern of comorbidity between the psychiatric and autoimmune disorders – two 
broad categories of complex disease, however the aetiology underlying this overlap is yet 
to be established.  
 
We present three investigations into the overlap between the psychiatric and 
autoimmune disorders. First, we review the epidemiological literature of the phenotypic 
relationship between schizophrenia and rheumatoid arthritis and perform a meta-analysis 
of studies meeting inclusion criteria. Next we investigate evidence for an enrichment of 
schizophrenia genetic risk amongst controls for rheumatoid arthritis using a number of 
existing statistical genetic techniques. We find no evidence that common genetic 
variation influences the low prevalence of rheumatoid arthritis in schizophrenia cases. 
 
In a longitudinal population cohort we model depression genetic risk and its influence on 
the onset of depression, autoimmune disorders, and the comorbidity between the two. 
We find evidence that autoimmune disorder onset increases the risk of subsequent 
depression onset, independent of depression genetic risk.  
 
In a cohort of rheumatoid arthritis patients, we investigate the role of depression genetic 
risk and rheumatoid arthritis severity on disease progression. We find that low mood is a 
significant predictor of worse treatment outcomes, including inflammatory components 
of rheumatoid arthritis disease severity. 
 
To interrogate the genetic aetiology underlying comorbidity, we extend the polygenic risk 
score (PRS) approach in two ways. First, we develop software, PRSice, to perform PRS 
analyses. Secondly, we develop a novel PRS method to calculate PRS in cross-disorder 
scenarios.
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There is considerable evidence for an autoimmune or inflammatory component to risk 
of psychiatric disorders, and this may be directly related to the patterns of comorbidity 
observed between these families of disorders. Within the most intensively studied 
psychiatric disorders - such as schizophrenia - evidence for an autoimmune component 
to disease is growing (Khandaker, Pearson, Zammit, Lewis, & Jones, 2014; Wium-
Andersen, Orsted, & Nordestgaard, 2014a) and may guide the development of new 
pharmacological interventions in the future.  
 
The aim of this thesis is to investigate causes of the overlap between the psychiatric 
disorders – with a focus on depression and schizophrenia – and the autoimmune 
disorders – with a focus on rheumatoid arthritis – at an epidemiological and genetic level. 
Our primary hypotheses concern the phenotypic relationships observed between the 
autoimmune and psychiatric disorders. Firstly, that these are genuine and not 
confounded by a systemic bias such as a harvesting effect - whereby individuals with 
schizophrenia and higher vulnerability towards rheumatoid arthritis, perhaps due to a risk 
factor such as smoking or urbanicity, may have a higher mortality rate the therefore be 
less likely to live to age at onset for rheumatoid arthritis - a reporting bias or a treatment 
effect. Secondly, that these relationships are due to some common aetiological factor that 
has pleiotropic effects - that is to say, has downstream effects influencing both 
psychiatric and autoimmune disorders, perhaps in different directions. This may act at a 
genetic level, where a common genetic risk profile is responsible for comorbidity 
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between two phenotypes. Alternately, it may act at a physiological level, where a 
particular perturbation of a biological pathway results in multiple downstream 
phenotypes. Therefore our primary hypotheses are firstly that the overlap between 
psychiatric and autoimmune disease isn’t simply a result of confounding. Secondly, if an 
overlap is present, it would necessarily be due to shared risk factors; if genetic, these 
would be pleiotropic. Thirdly, we hypothesise that evidence for shared environmental 
risk factors can be supported via the rejection of the hypothesis that there is a genetic 
component to epidemiological relationships. Fourthly, we test the hypothesis that the 
identification of shared genetic risk can be performed currently by a number of available 
tools. Finally, we test whether these may be improved via novel methods and 
approaches.  
 
We will investigate these hypotheses using individual-level genotype data, genome-wide 
summary data for association with a phenotype, and phenotypic data detailing the time-
course of a phenotype and its relationship with the environment. Finally, we will extend 
current methods in a number of ways to develop more accurate predictors of genetic 
risk, which may in turn aid in our understanding of the genetic architecture of comorbid 
complex phenotypes. 
 
Phenotypes Under Investigation 
 
Autoimmune Disorders 
The autoimmune disorders are a class of physical disorders typified by a failure of ‘self 
tolerance’. The Mammalian ‘active’ immune system kills cells it encounters by default; 
tolerance of ‘self’ cells, recognised by proteins in their cell membranes, prevents 
destruction of ‘self’ tissue. A breakdown in this learned self tolerance defines the 
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pathophysiology of the autoimmune disorders. Here we will focus on rheumatoid 
arthritis as an example of the autoimmune disorders. We do this firstly due to its 
relatively high prevalence – 552 per 100,000 in a Sardinian population (Sardu et al., 2012), 
the second highest prevalence autoimmune disorder reported by the authors after 
autoimmune thyroiditis, and 860 per 100,000 in a meta-analysis of studies in the USA 
(Jacobson, Gange, Rose, & Graham, 1997) the second most common reported after 
Graves disease. Secondly, rheumatoid arthritis is associated with a comparatively short 
time lag between onset and diagnosis – median time 36 weeks (Chan, Felson, Yood, & 
Walker, 1994) – which will effectively minimise undiagnosed cases in the population and 
thus improve the power of cohort studies and those relying on self-report. Indeed, in a 
cohort of 2458 pregnant women, deep phenotyping revealed a prevalence of 
undiagnosed rheumatoid arthritis of 0.24% (Spinillo et al., 2012). This contrasts to, for 
example, celiac disease, where authors have found that 95.6% of cases in a Netherlands-
based study were undiagnosed (Schweizer, von Blomberg, Bueno-de Mesquita, & 
Mearin, 2004).  Finally, although rheumatoid arthritis is associated with a relatively late 
age at onset – mean of 58.0 (Cooper & Stroehla, 2003; Doran, Pond, Crowson, O'Fallon, 
& Gabriel, 2002) – however the authors report a standard deviation of 16 years, 
producing wide estimated confidence intervals (95% CI = 26.6 – 89.4). This has the 
effect of leading to a relatively high incidence rate of rheumatoid arthritis per 100,000 
person years – 17 before the age of 16 and 23.7 thereafter – the highest incidence rate 
reported in a review of autoimmune disorder incidence rates (Cooper & Stroehla, 2003). 
These epidemiological properties – in addition to its well-studied genetic component, 
discussed below - make rheumatoid arthritis especially amenable to study via population 
cohort methods compared to other autoimmune disorders. 
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Psychiatric Disorders 
The psychiatric disorders are defined here as medical disorders – measurable and 
impairing deviations from normality – that affect an individual’s behaviour without a 
measurable physical aberration. The psychiatric disorders represent a substantial burden 
to societies worldwide, however their genetic components have only been intensively 
studied relatively recently. A recent report shows that MDD is the leading cause of 
disability worldwide (World Health Organisation, 2012).  
 
Epidemiological Relationships between Psychiatric and 
Autoimmune Disorders 
 
Schizophrenia and the autoimmune disorders 
There are a number of studies investigating the phenotypic overlap between 
schizophrenia and the autoimmune disorders. Benros et al present a detailed (table 1), 
investigating many of these epidemiological relationships in a Danish population cohort 
(Benros, Pedersen, et al., 2014). Despite the aggregate tendency towards comorbidity 
between schizophrenia (SCZ) and any autoimmune disorder, the authors find varying 
effects with different disorders. They find no evidence for a relationship between SCZ 
and ulcerative colitis, and an apparently protective relationship between SCZ and 
rheumatoid arthritis (RA). 
 
In a meta-analysis of previous literature, we demonstrate evidence that this protective 
effect of schizophrenia on RA is consistent across prior studies (Euesden, Breen, 
Farmer, McGuffin, & Lewis, 2015), (chapter 3). A number of explanations have been 
proposed for this relationship, most notably the well-established anti-inflammatory 
activity of antipsychotic medication.  
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MDD and the autoimmune disorders 
Odegaard's dictum (Odegaard, 1952) - that all schizophrenia sufferers eventually pass 
through a hospital - makes SCZ much more amenable to large population-based studies 
of its epidemiology, compared to MDD. Nevertheless, a few studies of MDD and its 
overlap with autoimmune disease have been conducted. In order to compare the overlap 
between schizophrenia and the autoimmune disorders with evidence for an overlap 
between MDD and the autoimmune disorders, we discuss these with reference to the 
disorders investigated in conjunction with SCZ above. Similar findings to Benros et al 
(2014) have been observed in multiple sclerosis (Patten, Beck, Williams, Barbui, & Metz, 
2003), type 1 diabetes (Anderson, Freedland, Clouse, & Lustman, 2001), ulcerative colitis 
- when preceding MDD onset by under 1 year (Kurina, Goldacre, Yeates, & Gill, 2001), 
Crohn's disease (also when preceding MDD by under a year, Kurina et al 2001) and 
seropositive rheumatoid arthritis (Dickens, McGowan, Clark-Carter, & Creed, 2002), 
who calculated a phenotypic correlation rather than an odds ratio, by meta-analysis 
(summarised in table 2).  
 
It is not immediately clear why there is limited research on the epidemiological patterns 
of disorders comorbid with MDD, when large record linkage studies in schizophrenia are 
frequently published. In part this may be due to the comparatively poor detection of 
MDD in primary care (Farmer & Griffiths, 1992; Lane, Shellenberger, Gresen, & Moore, 
2000). This in turn necessitates deep phenotyping of cases – to maximise power – and 





Experimental evidence for Shared Pathways between 
Psychiatric and Autoimmune Diseases 
 
A natural extension of the above epidemiological results is an extension of the biological 
mechanisms responsible. It is often argued that the first evidence for an interaction 
between psychological and immune pathways came in 1982. Bovbjerg, Ader & Cohen 
investigated (1) the graft-host response - an immune response to donor tissue caused by 
non-self antigens stimulating cytotoxic T lymphocytes – and (2) classical conditioning - a 
form of implicit learning that is likely to be distributed across the synapses of the 
nervous system (Bovbjerg, Ader, & Cohen, 1982). By pairing a saccharine solution (a 
conditioned stimulus, CS) with injection of an immunosuppressant, Cyclophosphamide 
(CY, an unconditioned stimulus, US), rats developed a Conditioned Response (CR) to 
the CS, ultimately resulting in suppressed immune activity. Subsequent immune 
responses could be suppressed through the use of a CS, mimicking the 
immunosuppressant effect of CY. This important result - that immune responses can be 
modulated by psychological processes - provides a platform for understanding 
subsequent results regarding immune and autoimmune activity in MDD and SCZ. 
 
Immunity in MDD 
Herbert & Cohen demonstrated by meta-analysis that differential immune responses are 
a characteristic of MDD (Herbert & Cohen, 1993). The authors found reliable evidence 
for impaired immune activity (e.g. decreased lymphocyte proliferation in response to 
stimulation by a mitogen in vitro), and this has been reliably replicated in the two decades 
since. There is now an extensive body of literature investigating the pathophysiology of 
inflammation-related depression (A. H. Miller & Raison, 2016), with one proposed 
mechanism being the activation of the enzyme Indoleamine 2,3-dioxygenase (IDO) by 
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inflammatory cytokines, which catabolises tryptophan leading to a downstream depletion 
in serotonin (A. H. Miller & Raison, 2015) – indeed inflammation-related depression 
appears to dependant on the activation of IDO (O'Connor et al., 2009). In light of this, 
anti-inflammatory medication has been proposed as a treatment for inflammation-related 
depression 
 
The immune system has a number of integrated pathways for neutralising external 
threats – here we will focus on the cytokine system and the innate immune system and 
discuss evidence for systemic differences between MDD patients and controls in these 
pathways. Firstly we will consider the cytokine system, a family of intercellular signalling 
molecules released by CD4+ T-lymphocytes (helper cells) in response to stimulation by a 
protein identified as foreign - an antigen - in order to effect a downstream immune 
response. Secondly, we will consider elements of the innate immune system, the Pattern 
Recognition Receptors (PRR), that respond to stereotyped Pathogen Associated 
Molecular Patterns - that is to say proteins that form stereotyped parts of pathogen 
biochemistry and are therefore indicators of infection - and trigger the complement 
system. 
 
Cytokines in MDD 
Cytokines are signalling molecules released by an number of cells in the immune system 
that broadly fall into two classes - pro-inflammatory and anti-inflammatory. The pro-
inflammatory cytokines have a number of physiological roles, and many have been 
reliably associated with MDD. Interleukin-6 (IL-6) activates the Hypothalamic-Pituitary 
Axis (HPA) - a component of the stress response - and has been found at elevated levels 
in the serum of MDD patients (Alesci et al., 2005). IL-1 β has been found at increased 
concentrations in MDD patients versus controls (Schlatter, Ortuno, & Cervera-Enguix, 
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2004). In tandem with this, Anisman et al showed that IL-1β levels could actually 
predict HAM-D scores (a measure of MDD symptom severity) in MDD patients 
(Anisman, Ravindran, Griffiths, & Merali, 1999). Similarly, Tumour Necrosis Factor α
(TNF-α) has been found at elevated levels in MDD patients’ serum (Tuglu, Kara, 
Caliyurt, Vardar, & Abay, 2003). 
 
The Innate Immune System in MDD 
C-reactive protein (CRP) is a PRR that responds to phosphocholine, a marker of 
bacterial infection, forming part of the innate immune system. CRP has been found at 
elevated serum levels in MDD patients (Ford & Erlinger, 2004) and in male MDD 
patients (Danner, Kasl, Abramson, & Vaccarino, 2003). Mendelian randomisation is a 
method that uses genetic data to infer causality from phenotypic correlations. Wium-
Andersen et al apply Mendelian randomisation to the association between MDD and 
CRP levels; the authors argue that this relationship is actually merely correlational, with 
some shared risk factor leading to both increased risk of depression and increased CRP 
levels (Wium-Andersen, Orsted, & Nordestgaard, 2014b). Despite this, there is evidence 
that the CRP system is influenced by many other depression-related factors, including 
obesity, (Daly, 2013), CBT response, (Keri, Szabo, & Kelemen, 2014) and physical 
exercise (Eyre, Papps, & Baune, 2013). Furthermore, Wium-Andersen et al’s results 
should be viewed relatively sceptically – the authors present a negative result with no 
power calculations, suggesting their conclusions may be unsupported. Additionally, 
mendelian randomisation carries a number of limitations that must be adhered to strictly 
in order to ensure that results are interpretable (Davey Smith & Hemani, 2014). In 
summary, it is likely that studying the innate immune system will improve our 
understanding of the biological processes underlying the pathophysiology of MDD. 
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Immunity in Schizophrenia 
Whilst serological studies of MDD have focussed on the cytokines - signalling molecules 
released by many types of immune cell - serological studies of SCZ have focussed on 
antibodies. Antibodies – or Immunoglobulins (Ig) - are large protein complexes, released 
by B-lymphocytes, which fall into a number of categories denoting the specificity with 
which they bind antigens. Antigen is an operationalised term that defines proteins that 
antibodies bind to, and antigens expressed on the membranes of pathogens are 
important in eliciting an adaptive immune response. This binding leads to a number of 
downstream events (Porter, 1959) including marking invading cells for destruction via 
the complement system, which triggers the destruction of marked cells. One of the first 
studies to demonstrate a link between antibodies and SCZ (McAllister et al., 1989) found 
that CD5+ B-lymphocytes were elevated in the serum of SCZ patients at a level 
comparable with that observed in rheumatoid arthritis patients. CD5+ B-lymphocytes 
secrete Immunoglobulin M (IgM), the largest of the basic antibody families. Steiner et al 
found an elevated concentration of B-lymphocytes (using a less specific CD19+ assay), 
although the authors did not assay for CD5+ cells (Steiner et al., 2010). They authors also 
investigated T-lymphocyte levels and the CD4+/CD8+ ratio - a marker of immune 
regulation - however these results did not survive correction for multiple testing and will 
not be discussed here. Possibly the most compelling summary of the antibody literature 
in SCZ can be found work by Ezeoke et al (Ezeoke, Mellor, Buckley, & Miller, 2013), 
who demonstrated by meta-analysis that self-reactive antibodies for the N-methyl-D-
aspartate (NMDA) receptor are elevated in SCZ patients – summarised in table 3. This 
integrates with the B-lymphocyte literature above and the psychiatric nature of SCZ. The 
NMDA receptor is involved in the maintenance of learned behaviour within neural 
circuits (Bannerman, Good, Butcher, Ramsay, & Morris, 1995), and so it is possible to 
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tentatively infer a pathway from the cellular abnormalities observed in the serum of SCZ 
patients to the behavioural differences. 
Genetic Determinants of Common Disease 
Identifying the genetic contribution to common disease 
 
Statistical genetic techniques can be used to characterise biology. Genome-wide 
association studies (GWAS) aim to identify relatively common genetic variants associated 
with a given phenotype (Lewis & Knight, 2012). The most recently published GWAS of 
rheumatoid arthritis (Okada et al., 2014), the largest to date, was performed on 29,880 
RA cases, 73,758 controls and over 10 million loci studied. Such a large sample size 
provides high statistical power and increases the probability of identifying single 
nucleotide polymorphisms (SNPs) with only modest individual contributions to disease 
status; SNPs are polymorphisms at a single nucleotide, and are the genetic predictors 
used within GWAS. SNPs under investigation are usually restricted to those with a 
frequency in the population (Minor Allele Frequency, MAF) above some value, typically 
1%. Studying diseases with high heritability also increases the power of GWAS. 
Heritability is defined here as the proportion of variance in a trait attributable to genetic 
factors – and SNP heritability, a special case of this, is variance attributable to common 
SNPs, i.e. the heritability that can be identified through GWAS. Cases and controls are 
genotyped on a chip for approximately half a million common SNPs, and each SNP is 
tested in a univariate regression model for its prediction on case status. Due to the large 
multiple testing burden inherent in this paradigm, a conservative statistical significance 
threshold of α = 5x10-8 is typically applied (Dudbridge & Gusnanto, 2008). Furthermore, 
under natural selection, we implicitly expect genetic variants with a relatively high 
frequency in the population to have such minor effects on disease risk that they are 
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relatively invisible to selection. Due to these concerns amongst others, sample sizes in 
excess of the tens of thousands are usually required for GWAS. 
 
The genetics of autoimmune disorders 
 
Many autoimmune disorders have high heritabilities – for example, as estimated from 
twin studies, rheumatoid arthritis has a heritability of 53% (95% CI = 40-65%) in a UK 
sample (MacGregor et al., 2000). Most – but not all – of this heritability can be explained 
by haplotype sharing at the HLA region (Deighton, Walker, Griffiths, & Roberts, 1989), 
which is estimated to have a heritability of 37%. This is not reported with confidence 
intervals, however this is consistent with studies of common genetic variation genome-
wide excluding the HLA region. Stahl et al use GREML – discussed below – to estimate 
that rheumatoid arthritis has a SNP-heritability, i.e. heritability due to variants that can be 
identified by GWAS, of 32% (SE = 3.7%) (Stahl et al., 2012). The authors also find a 
SNP heritability for celiac disease of 33% (SE = 4.2%). Thus this high heritability of the 
autoimmune disorders has led to intensive investigation into their genetic determinants 
in order to develop more appropriate treatment for these chronic disorders. To date, 
four of the most widely studied autoimmune disorders are ulcerative colitis, Crohn's 
disease, type 1 diabetes and rheumatoid arthritis (UC, CD, T1D, RA). GWAS have been 
applied to these four disorders with considerable success, identifying between 41 and 101 
loci reaching genome-wide significance, in type 1 diabetes and rheumatoid arthritis 
respectively (Barrett et al., 2009; Okada et al., 2014). Consequently, this has led to an 
increased understanding of the biological pathways involved in these disorders. All four 
of these disorders are chronic, that is to say incurable and on-going, and are managed 
through a number of immunosuppressant drugs alongside sometimes radical lifestyle 
modifications. The economic burden of such phenotypes makes them natural targets for 
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medical research; it is hoped that an increased understanding of the biological pathways 
perturbed in these disorders will guide drug discovery and prophylactic initiatives.  
  
The genetics of rheumatoid arthritis 
The large number of validated loci reaching genome-wide significance for rheumatoid 
arthritis – 101 - allowed Okada et al to run a series of pathway-based analyses to 
understand these GWAS results in a biological context. By using epigenetic chromatin 
marks, Molecular Pathway Enrichment and Mouse Knockout Gene Networks, the 
authors demonstrate an enrichment of regulatory elements in CD4+ T-lymphocytes, and 
variation in genes expressed in T and B lymphocytes. These are fundamental parts of the 
immune system, and consolidate a model of the biological processes that are perturbed in 
RA. Secondly, the authors investigate polymorphisms in genes that are known drug 
targets of approved RA drugs. By annotating RA risk SNPs to nearby genes, and 
annotating approved RA drugs to genes, the authors demonstrate 3.7 fold enrichment 
for RA drug targets within RA risk genes. This approach is then extended to identify 
approved drugs for other disorders that may have an efficacy in the treatment of RA. 
Thus Okada et al demonstrate the utility of annotation and post-GWAS analyses to gain 
deeper insight into the biological pathways involved in in complex diseases and thus 
potential novel therapeutic approaches. 
 
Before the advent of the GWAS era, a number of ‘candidate genes’ – genetic variation 
that would be expected to contribute to risk of disease based on our understanding of 
the biological systems involved – were identified that increase risk of autoimmune 
disorders. T-cells, which co-ordinate and effect cell death in the active immune response, 
learn self-tolerance through a process called Thymic Selection, mediated by a class of 
protein called Human Leukocyte Antigens (HLA). Many HLA proteins are expressed on 
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the wall of the thymus and effect the identification and removal of any T-cells that might 
react to an individual’s own tissues. There are many different proteins that function in 
this way as HLA molecules, and variation in different genes has been associated with 
different autoimmune disorders. Rheumatoid Arthritis risk is increased by variation in 
the HLA-DRB1 gene, the most significantly associated risk allele being HLA-
DRB1*04:01 (Raychaudhuri et al., 2012); this variant also increases risk of type 1 
diabetes, as does the HLA-DQA1*03:01 allele (Pociot & Lernmark, 2016; Sanjeevi et al., 
1995). Variants in other genes coding proteins involved in T-cell activity have also been 
reliably associated with increased risk of autoimmune disease - such as PTPN22, which 
modulates the sensitivity of T-cells to thymic selection, and CTLA4, which codes a 
protein that modulates the activation of ‘killer’ T-cells by antigens identified as ‘non-self’. 
In this way, understanding of the pathophysiology of a disorder can target the discovery 
of novel genetic associations, and similarly the understanding of novel genetic 
associations can contribute to understanding biological pathways perturbed in disease. 
Since the advent of GWAS, many candidate gene findings have been shown to be 
spurious, and so, generally, the hypothesis-free nature of GWAS and its stringent 
significance threshold is now preferred for identifying the genetic components to disease 
risk. 
The genetics of psychiatric disorders  
 
Five psychiatric disorders have been the target of intensive GWAS investigation in recent 
years– Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder 
(BPD), Major Depressive Disorder (MDD) and Schizophrenia (SCZ). We focus on the 
latter two of these in this thesis. A recent report by the World Health Organisation 
shows that MDD is the leading cause of disability worldwide (World Health 
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Organisation, 2012); this is due to its comparatively early age at onset, impairment to 
work and the limited success of existing therapies. MDD is highly heritable (McGuffin, 
Katz, Watkins, & Rutherford, 1996) – with estimates from twin heritability ranging from 
0.48  to 0.75, based on varying assumptions about the population prevalence of MDD - 
and a substantial proportion of the heritability of MDD has been shown to result from 
the effect of common risk alleles (SNP heritability = 0.32, P < 10-3), (Lubke et al., 2012). 
Given that these estimates are significantly above zero, identifying risk alleles or risk 
profiles involved in the onset of MDD is feasible, and given the damaging consequences 
of MDD, it is a pertinent research question. Furthermore, a multitude of physical 
disorders are not only comorbid with MDD, but their prognosis is drastically 
exacerbated by such a comorbidity – e.g. cardiovascular disease: (Elderon & Whooley, 
2013; Garfield et al., 2014). 
 
Whilst MDD is the leading cause of disability worldwide, SCZ is amongst the leading 
causes of expense by healthcare systems, families and governments (Knapp, 1997). Costs 
carried in the USA by SCZ include $63 Billion spent annually by families on treatment 
and lost due to time out of work (Wu et al., 2005). SCZ, like MDD, has an early age at 
onset and is frequently chronic across the lifespan. Like MDD, it is associated with 
increased healthcare utilisation - many autoimmune disorders are comorbid with SCZ 
(most recently discussed by Benros et al 2014), and SCZ patients are far more likely to 
engage in risky behaviour such as heavy tobacco (McCreadie & Kelly, 2000) and cannabis 
(Green, Young, & Kavanagh, 2005) abuse. Furthermore, SCZ is associated with 
increased involvement with the criminal justice system, both as defendant (Large & 
Nielssen, 2011; Richard-Devantoy, Orsat, Dumais, Turecki, & Jollant, 2014) and 
prosecution (Fitzgerald et al., 2005). Therefore improving our understanding of the 
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biological processes behind this disorder and disorders comorbid with it is important in 
the management of a number of outcomes.  
The genetics of MDD 
To date, only one published study has identified loci reaching genome-wide significance 
that affect risk of Major Depressive Disorder (CONVERGE Consortium, 2015). The 
CONVERGE study sought to increase power to detect loci increasing risk of MDD by 
obtaining a more homogenous subgroup of patients via deep phenotyping. Cases were 
recruited based on gender – female only – and severity – recurrent cases only; the 
authors hypothesised that this would identify a more heritable form of MDD in which 
the effect of risk variants would be larger and so a GWAS cohort might be well-powered 
to detect them. The authors find two genome-wide significant variants, one each in the 
genes LHPP and SIRT1. LHPP has been previously associated with MDD from linkage 
in family studies (Neff et al., 2009), and codes for a poorly understood protein involved 
in post-transcriptional modification (Kee & Muir, 2012). SIRT1 is better understood, 
having a role in mitochondrial biogenesis, and may shed light on the pathogenesis of 
MDD. The authors of the CONVERGE study find that mitochondrial DNA levels are a 
predictor of number of stressful life events in a sample of MDD patients (Cai et al., 
2015). Thus the ‘hypothesis-free’ nature of GWAS can identify previously unconsidered 
biological mechanisms involved in disease pathogenesis. 
 
In addition to the results of the CONVERGE study, there are currently two unpublished 
studies that have identified loci reaching genome-wide significance in MDD. Power et al 
(in press) demonstrate that by obtaining deeper phenotype information on participants – 
in their case Age at Onset – it is possible to stratify participants and obtain a more 
homogeneous sample in which there is higher power to detect the genetic variants of 
small effect that one would expect to be involved in the pathophysiology of MDD 
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(Uher, 2009). The increase in power necessary to identify variants of small effect has also 
been achieved by the Psychiatric Genomics Consortium (PGC), who pool a large 
number of case-control cohorts investigating MDD (PGC-MDD in prep) and perform 
meta-analyses across these. As these two studies are currently unpublished, their results 
will not be discussed here in detail, other than to note that the small effect sizes that 
seem to underlie the effect of common genetic variation on risk of MDD requires a 
degree of innovation – such as relaxing the definition of MDD to self report cohorts to 
boost sample size in the case of PGC2, or stratifying based on age at onset to reduce 
genetic heterogeneity in the case of Power et al – in order to identify risk variants. 
 
The genetics of schizophrenia 
Genome-Wide Association Studies of schizophrenia have identified considerably more 
genetic risk variants than those in Major Depressive Disorder. The most recent Genome-
Wide Association Study identified independent association signals at 128 loci across 108 
genes; as the largest association study of a neuropsychiatric trait to date, the genetic 
architecture identified in the study of schizophrenia is likely illuminate the study of other 
psychiatric disorders (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). Many novel loci associated with schizophrenia in this study are in 
genes consistent with historical drug targets in schizophrenia – for example DRD2, 
which codes a type 2 Dopamine receptor subunit, is a target of many antipsychotics, 
such as haloperidol. Other identified loci validate a neuropsychiatric aetiology to the 
pathogenesis of schizophrenia, with genome-wide significant loci in the voltage-gated 
Ca2+ channel subunit genes CACNA1C, CACNB2 and CACNA1I, important for 
synaptic neurotransmission.  
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In addition to brain-expressed genes associated with schizophrenia, the PGC also 
identified variants suggesting an immune component to the aetiology of schizophrenia. 
Alongside identifying variants in brain-expressed genes, the authors identify a substantial 
enrichment of variants expressed in CD20+ B-lymphocytes. An involvement of immune 
function in the aetiology of schizophrenia has been a prominent finding in association 
studies; the most significantly associated risk variants for schizophrenia are in the Major 
Histocompatability Complex (MHC) between 26 and 33 Mb on chromosome 6, a 
genomic region that contains a high concentration of immune-related proteins. This is 
consistent with models of the biology of schizophrenia, which will be discussed below. 
 
Evidence for Genetic Overlap 
 
At the heart of the idea of genetic overlap is the idea of pleiotropy. Whilst a protein may 
perform a restricted role within a pathway, any deformity in this protein may result in a 
number of different downstream effects. If this deformity is caused by genetic factors, 
and downstream effects include symptoms of different diseases, this can constitute 
pleiotropy. 
Genetics of MDD and the immune system 
There have been a wealth of 'candidate studies', investigating association between 
polymorphism at a given base pair position or gene and a phenotype. Despite the 
extensive literature, which often produced replicable findings, not one of the candidate 
genes for MDD replicates in the most recent and higher powered GWASs for MDD 
(CONVERGE Consortium, 2015; Major Depressive Disorder Working Group of the 
Psychiatric GWAS Consortium et al., 2013). It is unlikely that considering the candidate 
gene literature (Flint & Kendler, 2014) will contribute to our understanding of the 
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genetic architecture of MDD. Furthermore, we were unable to identify any family-based 
studies investigating an association between family history of an autoimmune disorder 
and MDD in probands; such studies have met with considerable success in SCZ research 
(Benros, Pedersen, et al., 2014), and so there may be merit in conducting this 
investigation in the future. 
Genetics of SCZ and the Immune System 
The most robust genetic association with schizophrenia is within the MHC region on 
chromosome 6p. This region is responsible for encoding a number of cellular receptors 
involved in antigen presentation, important in the T-cell system. Recently, however, 
Sekar et al have localised this signal to the C4 genes, polymorphisms in which are 
associated with differential cortical pruning and thus related to the organic abnormalities 
seen in the post mortem brains of schizophrenia patients (Sekar et al., 2016). The authors 
find that this association is unrelated to classical HLA class I and class II genes, and thus 
is unlikely to relate to autoimmunity. Despite this, GWAS has identified schizophrenia 
risk loci across the genome – not just in the MHC region – and so this finding does not 
eliminate the possibility for genetic variation involved in schizophrenia also having an 
influence on immune phenotypes. From statistical genetic studies, evidence for this 
comes from pathway-based analyses of loci associated with schizophrenia, bipolar 
disorder or major depressive disorder – phenotypes often grouped together as ‘severe 
mental illness’ (Uher, 2014) – pooled to increase power. Pooling these phenotypes and 
meta-analysing pathways associated with risk alleles, O’Dushlaine et al find an 
enrichment for loci involved in synaptic function – as would be expected from 
neuropsychiatric phenotypes – but also in immune pathways, a finding that the authors 
note warrants further exploration (Network Pathway Analysis Subgroup of Psychiatric 
Genomics Consortium, 2015). 
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Furthermore, a family history of several heritable autoimmune disorders have been 
identified as risk factors for SCZ, including autoimmune thyrotoxicosis (Eaton et al., 
2006), T1D (Gilvarry et al., 1996), multiple sclerosis (Eaton, Pedersen, Nielsen, & 
Mortensen, 2010), and a plethora of others as reviewed by Benros et al (Benros, Eaton, 
& Mortensen, 2014). Thus there is evidence to postulate that some of the same genetic 
variants may influence risk of both SCZ and also several autoimmune disorders – 
although it is possible that shared environmental risk factors may be captured by studies 
of family history, and is an important caveat when interpreting these findings. 
. 
Introduction to Research Methods 
 
Statistical Genetics 
Complex disease genetics is the study of disorders with a genetic component to disease 
risk; crucially, this is comprised of many risk alleles, each of small effect. Alleles are 
measured as polymorphisms at single base pair positions, termed single nucleotide 
polymorphisms (SNPs). The most widely-used method to date for measuring an 
individual's genome-wide genetic variation is to use a genotyping chip, which genotypes 
– that is to say detects variation - at these SNPs. Widely used chips currently tag around 
500,000 SNPs genome-wide. Each of these is typically biallelic - i.e. can take one of two 
alleles - and autosomal SNPs are diploid - that is to say for every genotyped locus on 
chromosomes 1 to 22, an individual has two copies of each locus, one on each 
chromosome in a pair. For economical reasons, genotyping chips usually only tag alleles 
with a minor allele frequency (MAF) in a control population above a given threshold, 
typically about 0.5 - 1%, and data is usually cleaned to restrict SNPs to a similar 
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threshold, depending on sample sizes and thus statistical power. Alleles with a MAF 
above the cut-off threshold for a given study can be termed 'common alleles'. A 
fundamental challenge in statistical genetics, therefore, is to determine association 
between a large number of often correlated SNPs, genome-wide, and some trait, given 
that each of these SNPs is likely to have a very small contribution to disease risk if any at 
all 
 
Although the field of statistical genetics has a rich history before the advent of genome-
wide genotyping arrays, a substantial proportion of statistical genetic research focuses on 
the analysis of SNP data. 2007 is often stated as the year that the analysis of genome-
wide SNP data truly began to come into its own. The Wellcome Trust Case Control 
Consortium (WTCCC) published a landmark study on 7 complex diseases, using multiple 
univariate logistic regression to test association between ~500,000 genome-wide SNPs 
and each of 7 diseases (Wellcome Trust Case Control Consortium, 2007). This method 
was developed in the first successful GWAS (Klein et al., 2005), studying Age-related 
Macular Degeneration. The effect size of their risk allele, in the CFH gene, was large 
enough to detect in their sample of 146 individuals – an Odds Ratio of 7.4; most 
complex disease risk alleles have much smaller effect sizes – 1.1 to 1.3 - and so increasing 
the size of GWAS samples has proven a reliable way to improve the identification of risk 
alleles. There are also a number of statistical genetics techniques that have been 
developed to improve GWAS. Examples of this include Principal Component Analysis 
(PCA) and Imputation. PCA controls for heterogeneity between cases and controls, 
which might lead to identifying spurious associations (Price et al., 2006). Imputation 
leverages Markov-Chain Monte-Carlo methods to make a 'best guess' for missing 
genotypes - using this method, it is possible to genotype 500,000 variants directly but 
impute up to over 10 million variants, vastly improving resolution genome-wide 
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(Marchini, Howie, Myers, McVean, & Donnelly, 2007). Thus optimisation of the GWAS 
by novel methods and larger sample sizes demonstrate that this established technique has 
a future in identifying the genetic component to disease.  
 
Many authors (Juran & Lazaridis, 2011) have claimed that we are now in the post-GWAS 
era - this leads to the second broad domain of statistical genetics and use of human SNP 
data. Aside from GWAS, there are a number of other analyses available on SNP data, 
many of which will be discussed below. Many post-GWAS methods leverage existing 
GWAS summary data in order to perform posterior analyses; other post-GWAS 
methods use SNP data to answer questions on the genetic architecture of a phenotype 
without ever performing an association study. Such techniques include Genome-
Relatedness-Matrix Restricted Maximum Likelihood (GREML), (Yang, Lee, Goddard, & 
Visscher, 2011), which will be covered below. GREML builds a matrix of genetic 
similarity across a large sample of unrelated individuals and then fits a mixed model to 
predict the proportion of variance in phenotype explained by variance in genetic 
similarity. This is an approximation for heritability as estimated by twin studies. Twin 
studies dominated human genetics prior to DNA based methods such as GWAS and 
linkage - therefore calculating SNP-heritability generates results that are comparable in 
interpretation with historic estimates and has found substantial popularity in recent years. 
 
Genome-wide association studies (GWAS) are limited to discovering common risk 
alleles, due to the coverage of most chips. Aside from this, the small effect sizes 
predicted in complex disease genetics mean that the primary obstacle in identifying all 
common variants associated with risk of a disease is one of power. That is to say, the 
likelihood of detecting an effect given the significance threshold used, the sample size 
used and the size of that effect. Small effect sizes require a large sample size in order to 
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detect them. Therefore, it could be argued that the primary objective for complex disease 
genetics is the collection of large enough samples in order to detect the small effect sizes 
underlying disease risk. This can be seen directly in GWAS of schizophrenia, where 
progressive increases in sample sizes from 2009 – 2014 have generated increasing 
numbers of novel GWAS findings, from 3,322 cases and 3,582 controls identifying zero 
regions significantly associated with schizophrenia in 2009 (International Schizophrenia 
Consortium et al., 2009), to 9,394 cases and 12,462 controls identifying 7 SNPs in 2011 
(Schizophrenia Psychiatric Genome-Wide Association Study Consortium, 2011) and 
most recently 34,241 cases and 82,315 controls identifying 128 SNPs in 2014 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).   
 
Whilst the identification of individual risk alleles at genome-wide significance is a power 
consideration requiring large sample sizes, there are many other statistical genetics 
techniques available for use with datasets that are underpowered. Even MDD datasets, 
which have yielded few SNPs reaching genome-wide significance to date, can be 
leveraged via a variety of methods in order to make meaningful inferences about the 
genetic architecture of MDD. Here we will outline methods that use genome-wide SNPs 
outside of a GWAS framework and discuss how they may be applied to dissect the 
genetic architecture of comorbid disorders, a central goal to our investigation of the 
psychiatric and autoimmune disorders. 
Polygenic Risk Scoring 
 
 The functional unit of genetic epidemiology is the probability of an individual i of 
disease, given a number of predictors x. This is Pr(yi = 1 | xi ). Our task is to identify 
predictors, xi, that have a genetic origin. This in turn illuminates the biology and 
epidemiology of a disease. Polygenic Risk Scoring, PRS, combines genotype data and a 
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priori information about how these variants associate with a given disease, to produce a 
single measure per individual that captures the probability of an individual having a 
disease conditional on their genetics - a genetic risk profile 
 
The GWAS era has been fully fledged for almost a decade, and so a wide range of GWA 
studies’ results are now in the public domain. It is a simple task to download a list of 
genome-wide SNPs and their association with a given phenotype - summarised by a 
normalised association statistic and effect size – i.e. P-value and either natural logarithm 
of Odds Ratio or regression coefficient. When a large number of SNPs reach genome-
wide significance for a disease, we may construct a risk profile by summing an 
individual's risk allele count at each disease locus, each weighted by the effect size of the 
risk allele at this locus – this uses a method developed by Purcell et al (International 
Schizophrenia Consortium et al., 2009) and will be discussed in detail below.  
 
A large number of loci are involved in risk of complex traits, however a relatively small 
number (tens to hundreds) have been discovered at genome-wide significance - α = 5 x 
10-8 (Dudbridge & Gusnanto, 2008; Panagiotou, Ioannidis, & Genome-Wide Significance 
Project, 2012) – for a given trait.  This is due in part to statistical power. Formally, a P-
value is the probability of seeing the observed data or anything more extreme, under the 
null hypothesis – i.e. by chance. Many authors have sought to exploit the fact that this is 
a continuous measure, and therefore SNPs that are associated with a phenotype with a 
low but non-significant P-value are more likely to have a reproducible and robust effect 
on outcome than a SNP with a higher P-value. Given this, all SNPs from a GWAS – 
termed base in the PRS literature - can be ordered by P-value and selected based on some 
P-value threshold, PT. These can then be treated as if genome-wide significant to 
calculate a risk score using the protocol described above. We calculate risk scores in an 
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independent genotyped and phenotyped population – termed the target data - and 
calculate the prediction of risk score on phenotype at each threshold PT. We select the 
SNPs at the threshold that best predicts phenotype in the target dataset - this is a polygenic 
risk score. This can be thought of as an optimum trade off between signal - disease SNPs 
rejected due to low power and stringent α level - and noise - SNPs with a low P-value 
by chance and no role in disease aetiology 
 
A few methodological considerations are necessary when performing polygenic risk 
scoring (PRS). Firstly, as our risk model is additive on the log odds ratio scale, we will 
overestimate the effect of a particular risk variant if we include variants in high linkage 
disequilibrium (LD) with it. Therefore we clump SNPs in the base GWAS, using LD 
data as estimated in the target data, in order to obtain variants in approximate linkage 
equilibrium. For the same reason, authors frequently exclude the Major 
Histocompatibility Complex on Chromosome 6 entirely due to long range LD. As in a 
GWAS, it is necessary to adjust for population structure when testing the predictive 
value of polygenic risk score on disease status (Chen, Han, Hunter, Kraft, & Price, 2015); 
this can be performed using principal components. Finally, there are a number of 
methods for interpreting the predictive value of a PRS. The simplest is reporting the P-
value of this variable from a multivariate logistic model controlling for population 
structure. The model fit can also be expressed as a measure of the total phenotypic 
variance explained – that is R2 for continuous phenotypes, and Nagelkerke's Pseudo-R2 - 
a coefficient of determination for logistic regression transformed to fall between zero 
and one – for case-control phenotypes.  
 
Despite its development in 2009, the method of Polygenic Risk Scoring has only started 
to be widely used since the results of GWA studies have begun to be released publically 
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as the norm. This has led to a number of important papers applying PRS to illuminate 
our understanding of a number of behavioural phenotypes that had previously been 
hampered by power concerns. Power et al find that PRS for schizophrenia is a significant 
predictor of cannabis use, and arguing that these results support a model where a genetic 
predisposition to schizophrenia also predisposes individuals to try and use cannabis, 
rather than cannabis itself being a risk factor for schizophrenia – these findings may have 
important policy implications (Power et al., 2014). Secondly, Ruderfer et al use PRS for 
Schizophrenia to investigate the clinical dimensions amongst a cohort of bipolar disorder 
patients, finding that schizophrenia genetic risk significantly predicts manic symptoms 
but not negative, depressive or positive symptoms, thus illuminating the nature of the 
genetic overlap between schizophrenia and bipolar disorder (Ruderfer et al., 2014). 
Thirdly, a landmark study by Krapohl et al applied PRS for a large number of base 
GWASs to predict a large number of target phenotypes within the Twins Early 
Development Study (TEDS) data, with a focus on educational phenotypes (Krapohl et 
al., 2015). Although exploratory in nature, this study is important in that it represents a 
shift towards a more hypothesis-free approach to investigating the shared genetic 
relationships across multiple complex phenotypes. Thus, PRS can be used to dissect 
clinical heterogeneity in a sample, to infer causality to inform policy decisions and in an 
exploratory manner to identify patterns of genetic overlap within a well phenotyped 
cohort. 
 
In addition to these applications of the PRS method, there has been considerable interest 
in interpreting the theoretical considerations – including power and the interpretation of 
phenotypic variance explained – by a number of authors (Dudbridge, 2013; Lee, 
Goddard, Wray, & Visscher, 2012). Power in polygenic risk scoring is an important 
consideration, and can be shown to be a function of a number of factors – the threshold 
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PT used for PRS, the sample sizes of base and target samples, the P-value and variance 
explained for PRS on target phenotype, factors affecting ascertainment in base and target 
sample such as case control ratio and population disease prevalence, variance of marker 
effects in base and target sample and the number of markers used in PRS construction, 
and other factors which must be estimated and are not explicitly calculated when 
regressing PRS on phenotype, such as the covariance in marker effects between base and 
target sample, the proportion of the genome which is causal for a trait (typically denoted 
1-π0).  
 
The estimate for variance explained by PRS in a case-control target sample will not be 
immediately interpretable if the case-control ratio in the target sample is unequal to its 
ratio in the general population  – i.e. if cases have been over-ascertained relative to the 
phenotype’s population prevalence. Variance explained is dependant on the phenotypic 
variance – in the target sample, this is nk(1 – k) where n is the target sample size and k is 
the proportion of cases in the target sample. This will be maximised for fixed n when 
k=0.5, a typical case-control ratio in GWAS (Hong & Park, 2012). This artificial value 
for phenotypic variance in case-control studies gives an estimate of heritability that will 
not be immediately relatable to many epidemiological questions – heritability as estimated 
from a case-control cohort is termed heritability on the observed scale – often 
abbreviated to h2o. Heritability on the observed scale can be transformed to a more 
interpretable estimate, heritability on the liability scale – often abbreviated to h2l using a 
formula often referred to as the Robertson Transformation (Dempster & Lerner, 1950). 
This is h2l = h
2
o
 k (1-k) / z2, where z is the normal density function evaluated at the 
truncation threshold – i.e. φ(t) - that differentiates cases and controls on a normally 
distributed but unobserved continuum of liability – a linear combination of genetic and 
environmental risk factors – and can be estimated from a phenotype’s population 
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prevalence. Heritability on the liability scale illustrates variance explained in the general 
population, accounting for the lower prevalence and thus lower variance. Lee et al have 
provided formulae for the transformation of these estimates on the observed scale to the 
liability scale, based on estimates of prevalence and ascertainment, and more recently, 
methods such as ABC (Stahl et al., 2012) and AVENGEME (Palla & Dudbridge, 2015) 
allow PRS estimates to be compared to traditional heritability estimates. These 
transformations are valuable in the interpretation of PRS results and their dissemination. 
Genomic Relatedness Matrix Restricted Maximum Likelihood 
GREML is a two-step method developed by Yang et al that can approximate the 
heritability of a phenotype (Yang et al., 2011). In the first stage, a Genomic Relatedness 
Matrix (GRM) is calculated using pairwise genetic similarity across a large sample of 
individuals, using SNP data. Individuals with unusually high relatedness (𝜋 > 0.05) are 
typically removed; these correspond to individuals who are closer relatives than 5th 
cousins, and so it is possible that the effects of shared environment could confound 
estimates. 
 
The GRM can be used to fit a mixed model to calculate the proportion of phenotypic 
variance attributable to genetic similarity. It is usual to covary for population structure 
more stringently than in GWAS, using 20 principal components. Heritability is estimated 
in GREML using only 'common' SNPs - depending on the QC protocol used, this may 
be those with MAF >5% or similar. Therefore, the GREML estimate of heritability is 
heritability attributable to common genetic variation; these are the same variants that are 
under investigation in GWAS, so GREML heritability gives an estimate for the genetic 




Here we have demonstrated that there is substantial evidence for phenotypic correlation 
between many autoimmune disorders and two psychiatric disorders – schizophrenia and 
Major Depressive Disorder. We have presented evidence for immune-related pathways 
that seem involved in both Major Depressive Disorder (MDD) and schizophrenia (SCZ). 
These seem to segregate to being related to cytokines in MDD and antibodies in SCZ, 
although it is important to avoid binary distinctions in a field as interconnected as the 
mammalian immune system. SCZ genetics provides suggestive evidence for an 
autoimmune component to disease risk, however the same cannot be said of MDD, 
probably in part due to a lack of power (Flint & Kendler, 2014). Therefore our decision 
to use more sophisticated methods from statistical genetics to investigate the presence of 
shared risk factors seems well supported. 
 
Outline To Thesis 
 
In the following chapters, we investigate the questions posed above. Firstly, we explore 
the idea of ‘genetic overlap’ itself, in particular the method of Polygenic Risk Scoring 
discussed above, through the development of a novel software package and Polygenic 
Risk Scoring method, PRSice. We present this method alongside a more detailed 
explanation of the theoretical background to PRS and results from the application of 
PRSice, which is used throughout this thesis. We present three studies investigating the 
aetiological foundations of the overlap between the psychiatric and autoimmune 
disorders. Firstly, in a case-control study of rheumatoid arthritis, we investigate the role 
of schizophrenia genetic risk on rheumatoid arthritis status. Secondly, in a longitudinal 
population cohort, we use self report data on depression and autoimmune disorder onset 
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in order to compare the relative effects of genetic risk of depression and autoimmune 
disorder onset on subsequent hazard of depression – and the converse, the compare the 
relative effects of autoimmune disorder genetic risk and depression onset on subsequent 
hazard of developing an autoimmune disorder. Thirdly, within a clinical cohort of 
rheumatoid arthritis patients, we investigate the role of psychiatric symptoms, and 
depression genetic risk on the trajectory of patients’ rheumatoid arthritis severity. Finally, 
alongside the future directions arising from the results of these three studies, we present 
the development of a novel method for calculating genetic risk of a phenotype by 




Disorder OR in SCZ Patients 95% CI 
Any autoimmune Disease  
 
1.53  1.46–1.62 
Multiple sclerosis   1.57 1.29–1.90 
Type 1 diabetes   2.83  2.58–3.10 




Ulcerative colitis 0.99 0.84–1.16 
 
Table 1: Epidemiological relationship between SCZ and a selection of autoimmune 
disorders (Benros, Pedersen, et al., 2014) – these phenotypes have been selected as 
autoimmune disorders which have been well-investigated by Genome-Wide Association 
Study, and so whose relationships may be investigated further by statistical genetics 
 
 
Disorder OR for MDD 95% CI Study 
Multiple sclerosis   2.3  1.6-3.3 * Patten et al 
Type 1 diabetes   2.9,  1.6–5.5 Anderson et al 
Crohn’s disease   1.67  1.31-2.09 Kurina et al 
Seropositive 
rheumatoid arthritis 
 meta r = 0.21 P < 0 .0001 Dickens et al 
Ulcerative colitis  2.39  1.54-3.53 Kurina et al 
 
Table 2: Odds ratio for Major Depressive Disorder amongst autoimmune disorder 
patients relative to controls – i.e. a proxy for the overlap between depression and the 
autoimmune disorders in the same individuals, with values greater than one indicating an 
increased overlap than would be expected by chance. This approximates Relative Risk - a 
multiplier for Major Depressive Disorder prevalence amongst autoimmune disorder 
patients relative to controls - assuming a relatively low MDD prevalence around 10% 
(Viera, 2008). 







Dopamine Receptor P < 0.01 
GAD65 P = 0.52 
Gastric Parietal Cell P = 0.42 
NMDA P < 0.01 
Rheumatoid Factor P < 0.01 
Serotonin P < 0.01 
 
Table 3: Proportion of positive autoantibody titres in SCZ cases and controls, from 
meta-analysis, (Ezeoke et al 2013) 
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Abstract
Summary: A polygenic risk score (PRS) is a sum of trait-associated alleles across many genetic loci,
typically weighted by effect sizes estimated from a genome-wide association study. The application
of PRS has grown in recent years as their utility for detecting shared genetic aetiology among traits
has become appreciated; PRS can also be used to establish the presence of a genetic signal in under-
powered studies, to infer the genetic architecture of a trait, for screening in clinical trials, and can act
as a biomarker for a phenotype. Here we present the first dedicated PRS software, PRSice (‘precise’),
for calculating, applying, evaluating and plotting the results of PRS. PRSice can calculate PRS at a
large number of thresholds (“high resolution”) to provide the best-fit PRS, as well as provide results
calculated at broad P-value thresholds, can thin Single Nucleotide Polymorphisms (SNPs) according
to linkage disequilibrium and P-value or use all SNPs, handles genotyped and imputed data, can cal-
culate and incorporate ancestry-informative variables, and can apply PRS across multiple traits in a
single run. We exemplify the use of PRSice via application to data on schizophrenia, major depres-
sive disorder and smoking, illustrate the importance of identifying the best-fit PRS and estimate a
P-value significance threshold for high-resolution PRS studies.
Availability and implementation: PRSice is written in R, including wrappers for bash data manage-
ment scripts and PLINK-1.9 to minimize computational time. PRSice runs as a command-line pro-
gram with a variety of user-options, and is freely available for download from http://PRSice.info
Contact: jack.euesden@kcl.ac.uk or paul.oreilly@kcl.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The polygenic model of human phenotypes has long been
hypothesized, but only in recent years have the results from genome-
wide association study (GWAS) revealed that much of the genetic
basis for most complex traits comprises small effects of hundreds or
even thousands of variants. For clinical outcomes, this polygenic ef-
fect can be considered a genetic liability to disease risk. While pre-
diction of phenotype from an individual’s genetic profile is
compromised by this polygenicity, the application of polygenic risk
scores (PRS) has shown that prediction is sufficiently accurate for a
number of applications.
A PRS for an individual is a summation of their genotypes at
variants genome-wide, weighted by effect sizes on a trait of interest.
Effect sizes are typically estimated from published GWAS results,
and only variants exceeding a P-value threshold, PT, are included
(Dudbridge, 2013). Since even large GWAS achieve only marginal
evidence for association for many causal variants, PRS are usually
calculated at a set of P-value thresholds, e.g. PT ¼ 1" 10#5;
1" 10#4; . . . ; 0:05; 0:1; . . . ;0:5. A common application of PRS is to
test for shared genetic aetiology between traits. Here PRS on the
base phenotype are calculated, using GWAS results, in individuals
from an independent data set, and these are used as predictors of the
target phenotype in a regression (see Supplementary Note S1). This
technique was first applied by the International Schizophrenia
Consortium (2009), demonstrating that genetic risk for
schizophrenia (SCZ) is a predictor of bipolar disorder. This study
also acted as a proof-of-principle for PRS, showing that PRS based
on thousands of common variants genome-wide, including many
VC The Author 2014. Published by Oxford University Press. 1466
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with no effect and using effect size estimates from published GWAS,
can provide a reliable indicator of genetic liability. This has moti-
vated several other applications, including polygenic Mendelian
Randomisation (Hung et al., 2014), where causality of potential
intermediate phenotypes in a disease pathway can be tested (Ehret
et al., 2011), use of PRS as biomarkers, and the enrolment of clinical
trial participants according to risk (Hu et al., 2013).
Here we describe the first dedicated and fully automated soft-
ware package for the application of PRS - PRSice. PRSice has a
high-resolution option that returns the best-fit PRS, has a flexible set
of user options intended to capture current standard practices in
PRS studies and the different applications of PRS, and produces
plots for inspection of results. We also perform a simulation study
to estimate a P-value significance threshold for high-resolution PRS
studies.
2 Overview of PRSice
PRSice has been developed to fully automate PRS analyses, substan-
tially expanding the capability of PLINK-1.9 (Chang et al., 2014). A
key feature of PRSice is that it can calculate PRS at any number of
P-value thresholds (PT) and can thus identify the most predictive
(precise) threshold. It requires only GWAS results on a base pheno-
type and genotype data on a target phenotype as input (base and tar-
get phenotype may be the same); it outputs PRS for each individual
and figures depicting the PRS model fit at a range of PT. PRSice
allows users to include or remove SNPs in linkage disequilibrium,
handles genotyped and imputed data, and can calculate ancestry-in-
formative dimensions for use as covariates. These features integrate
R code with computations performed in PLINK-1.9 and extensive
bash scripts to minimize computational time. PRSice is a command-
line program that allows users to apply a large number of PRS,
under different parameter settings or across multiple base and target
traits. In addition to the standard approach, there is an option to use
summary statistics for the target as well as the base data, using the
gtx package (Johnson, 2013). For future updates of PRSice, see the
website: http://PRSice.info.
3 Results
Here we illustrate the use of PRSice to test for shared genetic aeti-
ology between traits. We first investigate the genetic relationship be-
tween schizophrenia (SCZ) and major depressive disorder (MDD),
both known to be complex and comorbid. We apply PRSice to repli-
cate the finding by Smoller et al. (2013) that SCZ PRS can predict
MDD status, using the RADIANT-UK MDD case-control data set
(Supplementary Note S2, Lewis et al., 2010). Applying PRSice, we
remove SNPs in linkage disequilibrium and include principal com-
ponents to control for population structure. We find significant evi-
dence that SCZ PRS predict MDD status, and under the approach of
only testing PRS at several broad P-value thresholds find the most
predictive threshold at PT¼0.05 (Fig. 1). Next we repeat the ana-
lysis using high-resolution PRS (Supplementary Note S3) and find
the most predictive PRS at PT ¼ 0:0265 (Fig. 2). The PRS at
PT ¼ 0:05 explains 1.5% of the variation in MDD (Nagelkerke R2;
P ¼ 1:3" 10#9) whereas the high-resolution best-fit PRS explains
2.1% (P ¼ 2:1" 10#12) and is based on 5252 fewer SNPs (12148
rather than 17400).
Next we apply PRSice to two tobacco-related phenotypes from
the TAG consortium (Thorgeirsson et al., 2013) and the RADIANT-
UK MDD data. These analyses reveal, for the first time, shared
genetic aetiology between the dichotomous trait ‘ever smoked’ and
MDD, but not between smoking consumption, as a quantitative
trait, and MDD (Supplementary Fig. S1). In the former, high-reso-
lution scoring again produces a substantially different best-fit PRS
than that from broad PT, in terms of model fit, significance and
number of SNPs included (Supplementary Fig. S1b).
Under high-resolution PRS in particular, multiple tests are
performed and so the P-value of the best-fit PRS will be inflated.
Therefore, we perform a permutation study utilizing the SCZ and
MDD data described above, and estimate an adjusted significance
threshold for the best-fit PRS of P¼0.004 (Supplementary Note
S4). Prior to a more extensive study, we suggest a more conservative
significance threshold of P¼0.001 if using the best-fit PRS for
association testing in PRS studies.
4 Discussion
Here we have described our PRSice software, illustrating its use with
three PRS studies. We have illustrated the potential benefit of ob-
taining the best-fit PRS and have estimated a corresponding signifi-
cance threshold. There is great potential for the future application of
PRS in genetics: for gaining insights into the genetic architecture of a
trait by comparing observed PRS with theoretical expectations
across a range of PT (International Schizophrenia Consortium,
2009), for assessing the genetic overlap of a trait(s) across popula-
tions, for use as biomarkers, as instrumental variables, or even to
provide evolutionary insights (Berg and Coop, 2014). The PRS ap-
proach, and PRSice software, could be extended to test the effects of
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Fig. 1. Bar plot from PRSice showing results at broad P-value thresholds for
Schizophrenia PRS predicting MDD status. A bar for the best-fit PRS from the
high-resolution run is also included
Fig. 2. High-resolution PRSice plot for SCZ predicting MDD status. The thick
line connects points at the broad P-value thresholds of Fig.1
PRSice 1467




that PRSice can simplify PRS studies greatly, expand the application
of PRS and aid the implementation of best-practice in PRS studies.
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PRSice: Polygenic Risk Score software 
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Supplementary Note 1: Polygenic Risk Scores applied between traits 
 
Polygenic risk scores are calculated across n individuals from the ‘target phenotype’ data 
set using a list of m SNPs, the genotypes of which have some effect (or not) on the ‘base 
phenotype’. The base and target phenotype may be the same, if assessing the shared 
genetic overlap of a phenotype between samples/populations. These genotype effects 
can be estimated from a univariate regression of base phenotype on each SNP, such as 
from a genome-wide association study (GWAS). In such a GWAS, for a SNP i, where     
i = 1, 2, ..., m, a P-value, Pi, is calculated for the association between the SNP genotypes, 
Gi,j = {0,1,2} for individual j where j = 1, 2, … , n, and the phenotype. Under the usual 
additive assumption made in GWAS, a corresponding effect size is estimated, byi, for 
the effect of a unit increase in genotype, Gij, on the phenotype. 
 
SNPs are generally selected for inclusion in a polygenic risk score based on the degree of 
evidence, according to P-value, for their association with the base phenotype in a GWAS 
– SNP i will be included in a PRS if Pi is smaller than a threshold, PT. PRS are typically 
calculated at a number of different P-value thresholds, PT. 
 
At threshold PT, the PRS for individual j can be calculated as: 
 
 !"#!!,! = ! !!!!,!!!!!  
 
 
PRS, which we see here are based on effect size estimates relating to the ‘base 
phenotype’, are calculated across all individuals giving n scores per threshold, PT. The 
association between these PRS and the target phenotype can then be evaluated in an 
appropriate regression model (depending on the data type of the target phenotype,  
eg. linear regression if the phenotype is continuous).   
 
This can be repeated across q P-value thresholds, PT, and the model fit of the regression 
of target phenotype on PRS compared.  
 
In real data there is usually some missing genotype data, unless genotypes have already 
been imputed. PLINK-2 imputes any missing data according to mean allele frequencies.
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Supplementary Note 2: Data sets analysed  
 
Base phenotype data set 
In the main analysis we used the publicly available results from the largest Schizophrenia 
GWAS to date (Psychiatric Genomics Consortium (2014)) for the base phenotype data 
set. In the additional analyses on Smoking behaviour and MDD, we used GWAS results 
from the Tobacco and Genetics (TAG) consortium on two phenotypes as the base 
phenotype: the binary phenotype ‘ever smoked’ and the quantitative trait smoking 
consumption, as measured by average number of cigarettes smoked per day 
(Thorgeirsson et al. (2013)). In each case we removed any SNPs with poor imputation 
quality (info score < 0.7). 
 
Target phenotype data set 
We used genotype data from the RADIANT-UK consortium (Lewis et al. (2010)), a 
sample of 1624 depression cases and 1588 psychiatrically screened healthy controls, for 
the target phenotype data set for each PRS analysis. These were genotyped on the 
Illumina HumanHap 610 QuadBead Chip. Quality control was performed, removing 
individuals with missingness > 1%, abnormal heterozygosity, conflicting sex and 
reported gender and those of non-European ancestry or close relatedness based on 
principal components. SNPs with MAF < 1% and SNPs not in HWE (P < 1x10-5) were 
also removed. 
 
We used the first two eigenvectors calculated using EIGENSTRAT as ancestry 
informative dimensions, to adjust for population structure. Linkage disequilibrium (LD) 
was accounted for by selecting the SNP in the base phenotype data set with the lowest 
discovery P-value in a sliding window of 250kb, only retaining variants with a pairwise 
LD r2 < 0.1, according to LD calculated in the target data set. We performed high-
resolution scoring by testing every threshold between PT = 0.0001 and PT = 0.5 at 
increments of 0.00005. This produces 9999 thresholds.
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Supplementary Note 3: High-resolution polygenic risk scoring 
 
High-resolution polygenic risk scoring, as performed in PRSice, calculates PRS at a large 
number of evenly spaced P-value thresholds, between a minimum and maximum bound. 
For the analysis here, we use a lower bound of P = 0.0001 and an upper bound of P = 
0.5, and increments of 0.00005. This generates 9999 thresholds. Assuming that there are 
~100k SNPs in approximate linkage equilibrium with P < 0.5, 10 SNPs would be added 
per threshold if P-values were uniformly distributed across SNPs. In practice, GWAS 
results will be enriched for small P-values, due to association with the base phenotype 
and due to P-value informed clumping preferentially extracting SNPs with small P-
values. Therefore, the number of SNPs included at each threshold will decrease at larger 
P-value thresholds. This high-resolution approach enables us to identify the best-fit PRS 
to a high degree of approximation; the true best-fit PRS can only be identified by testing 
PRS at every possible PT, but we instead test them at high-resolution in order to reduce 
total computational time substantially with negligible loss in accuracy. 
 47 
Supplementary Note 4: Multiple testing correction 
 
High-resolution polygenic scoring fits a large number of regression models, as described 
above, and so the ‘multiple testing problem’ should be addressed when evaluating the 
significance of the best-fit PRS. Currently, uncorrected alpha thresholds of 0.05 are 
routinely used to assess the significance of PRS. Under high-resolution a small number 
of SNPs are added to the model at each new P-value threshold. Thus, the resulting PRS 
is likely to be very similar to the previous, especially once a large number of SNPs are 
already included, so there is high correlation between the multiple tests performed. 
Therefore, a simple Bonferroni correction or similar for the number of tests performed 
will produce an overly conservative adjustment for the multiple testing. 
 
We performed three permutation studies to estimate an appropriate significance 
threshold that controls the family-wise error rate at 0.05 and accounts for the multiple 
tests performed in a high-resolution PRSice analysis. We calculated PRS repeatedly at 
high-resolution, using the GWAS results on Schizophrenia from the Psychiatric 
Genomics Consortium as base data and RADIANT-UK genotype data on MDD as 
target data (see Supplementary Note 2), under the null hypothesis of no association with 
the target phenotype by permuting case-control status in the MDD data set. We used 
data from chromosome 19, which should reflect genetic data across the genome, and 
permuted MDD case-control status in the RADIANT-UK data set 10000 times. As 
above, we performed clumping on the SNPs to remove the effects of SNPs in LD and 
adjusted for population structure with two principal components.  In this way we 
obtained an empirical distribution for the P-value of the best-fit PRS. In order to 
understand the effect of sample size on this distribution, we repeated our permutation 
study in 1000, 2000 and 3000 individuals randomly sampled from the target data. These 
results indicated that an alpha threshold of 0.004 must be applied to high-resolution best-
fit PRS in order to ensure a false-positive rate below 0.05 (table S1). Prior to an extensive 
study to estimate a more reliable significance threshold for high-resolution PRS, we 









Table S1: Empirical significance thresholds calculated from permutation, estimating the 
required significance threshold to interpret the results of high-resolution scoring, across 
different target data set sizes.
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Figure S1a: ‘Ever smoked’: PRS using GWAS from 
the Tobacco and Genetics (TAG) consortium for ‘ever 
smoked’ as base phenotype data (N = 74053), and the 
RADIANT-UK MDD data as target phenotype data. 
SNPs in linkage equilibrium, adjusting for population 
structure using two principal components, show 
substantial evidence for shared genetic aetiology 




Figure S1b: ‘Ever smoked’: High-resolution 
PRS for ‘ever smoked’ predicting MDD status 
(see Fig. S1a). The high-resolution best-fit PRS is 
at PT = 0.1115, while that based on broad 





Figure S1c. Number of Cigarettes Smoked per 
day: Genetic risk of smoking more cigarettes as a 
quantitative trait, predicting MDD. This demonstrates 
no evidence for shared genetic aetiology between the 
two phenotypes, since the P-value of best-fit PRS 
(calculated from the high-resolution PRS) is > 0.001 
(see Supp. Note 4). 
Figure S1d. Number of Cigarettes Smoked 
per day: High-resolution PRS for number of 
cigarettes smoked predicting MDD status. These 
high-resolution scores show that the results from 
the broad P-value thresholds of Figure S1c are 
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Epidemiological studies are inconsistent on the relationship
between schizophrenia (SCZ) and rheumatoid arthritis (RA).
Several studies have shown that SCZ has a protective effect on
RA,withRAoccurring less frequently in SCZcases thanwouldbe
expected by chance, whilst other studies have failed to replicate
this. We sought to test the hypothesis that this effect is due to a
protective effect of SCZrisk alleles onRAonset.Wefirst reviewed
the literature on the comorbidity ofRAandSCZandperformeda
meta-analysis.We then used polygenic risk scoring in anRA case
control study in order to investigate the contribution of SCZ risk
alleles to RA risk.Meta-analysis across studies over the past half-
century showed that prevalence of RA in SCZ cases was signifi-
cantly reduced (OR¼ 0.48, 95% CI: 0.34–0.67, P< 0.0001). The
relationship between SCZ genetic risk and RA status was weak.
Polygenic risk of SCZ explained a small (0.1%) and non-signifi-
cant (P¼ 0.085) proportion of variance inRA case control status.
This relationship was nominally positive, with RA cases carrying
more SCZ risk alleles than controls. The current findings do not
support the assertion that the relationship between RA and SCZ
is explained by genetic factors, which appear to have little or no
effect. The protective effect of SCZ on RA may be due to
environmental factors, such as an anti-inflammatory effect of
anti-psychotic medication or merely due to confounding limi-
tations in study designs. ! 2015 The Authors. American Journal of
Medical Genetics Part B: Neuropsychiatric Genetics published by Wiley Period-
icals, Inc.
Key words: Schizophrenia; Rheumatoid Arthritis; Comorbid-
ity; Autoimmune
INTRODUCTION
Rheumatoid arthritis (OMIM 180300) and schizophrenia (OMIM
181500) are, superficially, remarkably different disorders. They have
similar prevalences; rheumatoid arthritis (RA) has an estimated point
prevalence 0.6% [Helmick et al., 2008],whilst schizophrenia (SCZ)has
an estimated point prevalence of 0.46% [Saha et al., 2005]. Lifetime
prevalence for these disorders is substantially harder to measure,
especially RA due to its later age at onset, however estimates for the
lifetime prevalence of SCZ are as high as 0.72% [Saha et al., 2005].
Furthermore, bothSCZandRAshow familial patterns of aggregation–
heritability estimates for SCZ (0.81, 95% CI: 0.73–0.90) and RA (0.65,
95% CI: 0.50–0.77) are substantial [MacGregor et al., 2000]; [Sullivan
et al., 2003]. This implies a complex genetic aetiology, in which many
risk alleles of small effect size can aggregate in individuals to modulate
their risk of developing a disorder. Alongside its familial pattern of
aggregation, schizophrenia also shows an unusual aggregation of
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comorbidities with many autoimmune disorders, such as Sjo¨gren’s
Syndrome (OMIM %270150) [Eaton et al., 2006].
The relationship between SCZ and RA is much less clear, with
many studies finding no evidence of a significant association
[Eaton et al., 2006]. Here we review the findings of such studies
in order to evaluate the veracity of this relationship. RA seems to be
protective for SCZ, with studies reporting an OR for RA status in
schizophrenia patients as low as 0.44 (95% CI 0.24–0.81). This
suggests a substantial protective effect of the disorder [Mors et al.,
1999]. This may be due to some risk factor for RA reducing
schizophrenia risk, or vice versa. In order to understand this better,
we apply a statistical genetics technique – polygenic risk scoring – to
dissect the genetic relationship between the two disorders.
We are interested in explaining this relationship on three levels.On
a genetic level, we are interested in the predetermined risk profiles
carried by various individuals throughout their lifetimes; specifically
the variance in disease status explainable by an individual’s risk allele
count. Secondly,we are interested in an epidemiological perspective –
to explain the pattern of disease status and onset amongst a popula-
tion, via a meta-analysis of studies investigating this. Finally we are
interested in an aetiological perspective – the interactionbetweenpre-
existing risk and modulating factors that act to precipitate disease
onset; we will examine aetiological and genetic data in order tomake
inferences on the aetiology of these two disorders.
RA is a joint disorder characterized by an elevation in levels of
immune activity (e.g. increased T-cell proliferation) accompanied
by painful, swollen, and ultimately, eroded and fused joints.
Converging evidence from pharmacology, serology and genetics
suggests that RA is an autoimmune disease. Its relatively high
prevalence has made RA amenable to high throughput genetic
studies, leading to the identification of, to date, 101 risk loci
[Okada et al., 2014], providing invaluable clues to its aetiology.
The strongest association for RA is in the Human Leukocyte
Antigen (HLA) region. The HLA genes are located in the MHC
region, on the short arm of chromosome 6 [Shiina et al., 2006], and
are involved in adaptive immune response.
Schizophrenia is a psychiatric disorder, characterized by auditory
hallucinations, delusions and disorganized speech. Historically,
theories of psychiatric aetiology have been rooted in a Cartesian
dichotomy, with disorders of the ‘mind’ predicted to have limited
physiological aetiologyorphenomenology [Kendler, 2012].Thishas
led to a number of environmental aetiologies proposed for schizo-
phrenia – for example an environmentwith a high level of expressed
emotion [Bebbington & Kuipers, 1994]. Despite this, there have
been a number of studies arguing for an immune component to the
aetiology of schizophrenia – this began with McGuffin et al 1978,
based on serological studies. More recently, genome-wide associa-
tion studies (GWAS) have identified genetic markers showing a
significant association with schizophrenia. These genetic markers,
Single Nucleotide Polymorphisms (SNPs) are studied across the
genome in order to fine-map regions associated with disease and
subsequently predict disease risk in other cohorts. Most robust
amongst these associations is a region in the HLA, which shows
strong association in all studies (Ripke, 2011; S.[Ripke et al., 2013].
Summary
Wetherefore sought toexamineevidence for anepidemiological link
between SCZ and RA by meta-analysis of studies investigating RA
amongst SCZpatients. Given the polygenic architecture of these two
disorders, we also investigated whether the genetic predictors influ-
encing SCZ risk had an atypical distribution amongst RA patients.
RESULTS
Meta-Analysis
After following a protocol specified below, we identified 10 studies
reported in 9 papers reporting the prevalence of rheumatoid arthritis
FIG. 1. Meta-analysis results. We identified 10 studies reported in 9 papers. Oken & Schultzer (a)compares schizophrenia vs other psychiatric
patients in Canada meanwhile Oken & Schultzer (b) compares asimilar sample in New York State. We present the RA prevalence (events) in
SCZ cases vs controls acrossstudies. W: weight for each study under random and fixed effects analysis.
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(RA) within a schizophrenia (SCZ) sample and a sample of controls.
We used the results of these studies to perform ameta-analysis (Fig. 1).
Under a fixed effectsmodel, SCZ status conferred an odds ratio of 0.57
(95%CI: 0.50–0.65,P< 0.0001)onRAstatus, andanodds ratioof 0.48
(95% CI: 0.34–0.67, P< 0.0001) under a random effects model,
showing a significant protective effect of SCZ on RA status. There is
statistically significant heterogeneity between studies (P¼ 0.0027) and
therefore a random effects model is the most appropriate analysis
approach.
These studies varied in their selection of controls – population
controls, non-schizophrenic psychiatric patient controls and non-
schizophrenic medical patients, and the most recent in a series of
studies on a Danish population register comparing SCZ patients
with population controls [Benros et al., 2013]. To maximise
comparability, a major challenge in all epidemiological work, a
number of studies use non-schizophrenic psychiatric patients as
controls. This allows the effect of schizophrenia to be studied in
isolation. Five of these studies are based in individual psychiatric
hospitals - [Mohamed et al., 1982] Mohamed et al., 1982;
[Ross et al., 1950]; [Pilkington, 1956]; [Oken & Schulzer, 1999]
Ross et al., 1950). Two use record-linkage methods [Baldwin,
1980]; [Osterberg, 1978] on international and Swedish
populations respectively. Finally two studies used general
medical disorder patients as controls [Allebeck et al., 1985];
[Chen et al., 2012].
All studies estimated nominally lower risks of RA in SCZ
cases compared to controls, and this relationship was statistically
significant in four studies [Baldwin, 1980]; [Chen et al., 2012];
[Benros et al., 2013]; [Osterberg, 1978], replicating the canonical
‘protective’ effect of SCZ on RA. It is notable that these four studies
are the largest included, all using record linkage databases and thus
the remaining 6 studies, which failed to find any significant effect,
may have been simply under-powered.
Polygenic Risk Scoring
We used published SCZ GWAS results (S.[Ripke et al., 2013] to
calculate polygenic risk scores (PRS) in 1,989 RA cases and 1,588
controls.We used a series of thresholds, pT, to select SCZ risk alleles
based on GWAS p-value, and calculated risk scores for each of
these risk allele sets (Table 1, Fig. 2a). SNPs associated with SCZ at
pT < 0.01 explain under 0.2% of the variance in RA status in the
independent test cohort (Fig. 2b). This relationship is not statisti-
cally significant (p¼ 0.085) and is therefore no stronger thanwould
be expected by chance. This is consistent with results using a
considerably smaller SCZ sample (3,322 cases, 3,587 controls) as
a discovery dataset [International Schizophrenia Consortium et al.,
2009]. Standardised polygenic risk scores for SCZ at pT < 0.01 are
approximately normally distributed, with no significant difference
(p¼ 0.063) in mean score between cases (0.028) and controls
(-0.035), (Fig. 2c).
Genetic Profile Risk Scoring
We calculated a measure of SCZ genetic risk in our RA cases and
controls using the panel of SNPs proposed by Ayalew et al, identifying
proxieswherenecessaryusingSNAP[Johnsonet al., 2008;Ayalewet al.,
2012]. AfterQC,weobtained genotypes, imputed genotypes or proxies
for257SNPs.SCZgeneticriskdidnotpredictRAstatus–afteradjusting
for population structure, P¼ 0.858. We further explored the relation-
ship between this panel of SNPs and RA, using SNP-based and gene-
based summary statistic analyses (supplementary 8), and demonstrate
that they do not show significant association with RA –SNP-based P-
value¼ 0.13, gene-based P-value¼ 0.604.
Direction of Effect
Wecompared thedirectionof effect of risk alleles for SCZandRAusing
published GWAS results for each [Stahl et al., 2010; Ripke et al., 2013].
Aftermerging, 170,998 and171,707SNPs remainedwhen clumpingby
RA P-value and SCZ P-value respectively, in order to obtain SNPs in
approximate linkage equilibrium.The lack of association between SCZ
alleles andRAalleleswas confirmed throughdirectionof effect analysis.
We found no evidence for the proportion of alleles with a shared
directionof effect betweenRAandSCZdeviating fromour expectation
under the null (Table II), using a Sign Test.
DISCUSSION
Our SCZ polygenic risk scores analysis has shown that variance in
RA status cannot be predicted or explained by burden of SCZ risk
alleles genome-wide. This is supported by an analysis of Genetic-
Profile Risk Scores. On considering the epidemiology of these two
disorders, this finding is consistent with the notion that there is no
TABLE I. Polygenic risk Scores for SCZ across thresholds and variance in RA status explained
Threshold, pT Number of SNPs Variance in RA status Explained, Pseudo R2 P-Value
0.0001 82 0.0001 0.563
0.001 299 0.0004 0.276
0.01 1,393 0.0010 0.085
0.05 4,451 0.0007 0.154
0.1 7,396 0.0000 0.799
0.2 12,431 0.0000 0.816
0.3 16,708 0.0000 0.863
0.4 20,634 0.0000 0.770
0.5 24,122 0.0000 0.751
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‘protective’ effect of SCZ on RA – one would not be predicted from
genetic data alone.Despite this, we have also demonstrated through
meta-analysis that the negative association between the two dis-
orders appears consistent across studies. Below we review the
epidemiological andgenetic evidencepresented above, andpropose
some aetiological theories to reconcile them.
Epidemiology
The protective effect of SCZ on RA is supported in our meta-analysis,
with an infrequency of RA in SCZ cases, which would not be predicted
by chance. The possible protective effect of institutionalisation on RA
status can be parsed from the effect of SCZ by looking at studies using
institutionalised controls. Rothermich & Philips studied a prison
population in order to investigate the protective effect of long term
institutionalisation; although they found no significant relationship
between RA and SCZ when using RA in prisoners as a control
population, they found nominal, but non-significant, evidence of a
protective effect of SCZ on RA onset [Rothermich & Philips, 1963].
This is consistent with equally underpowered studies using general
psychiatric samples as controls.
Genetics
Both SCZ andRAhave been associatedwith a number of risk alleles
at genome-wide significance. Converging evidence for a lack of
FIG. 2. (a)Variance in RA status explained by SCZ polygenic risk scores in an independent test cohort.Scores are calculated across cutoff
thresholds, pT. (b) Standardised polygenic risk score distribution at pT < 0.01 in RA cases (striped) and RA controls(grey). Dotted line - top
quantile (highest 5%) for SCZ risk amongst controls (standardised score > 1.57). 5.1% cases and 5.0% controls above this value. (c) SCZ risk
in highest quantile (top 5%) and lowest quantile (bottom 5%) for SCZ risk between RA cases and controls.
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shared genetic substrate between RA and SCZ comes from family
studies of the two disorders [Benros et al., 2013]. The authors
explored family history of SCZ (a proxy for SCZ risk allele burden)
as a predictor of RA, finding no evidence of a significant association
– the relative risk for family historyof SCZonRA riskwas 0.94 (95%
CI: 0.84–1.06).
Aetiology
The aetiologies of both rheumatoid arthritis and schizophrenia are
still topics of active research. Evidence for anautoimmune substrate
to schizophrenia has coalesced in recent years, driven by the
genome-wide significant loci in the Major Histocompatibility
Complex [Ripke., 2011; S.[Ripke et al., 2013]. This complements
work in serological analysis of SCZ patients, notably [McGuffin
et al., 1978], who found an increase in HLA-BW5 and a decrease in
HLA-AW29 and HLA-BW17 in serum of SCZ patients (McGuffin,
Farmer, & Rajah, 1978).
The association between SCZ and immune-related biomarkers
may be reconciled as autoimmune over-activity specific to a com-
ponent of the nervous system. A systematic review of blood protein
expression in SCZ patients found evidence of increased autoanti-
bodies for the N-methyl-D-Aspartate receptor (NMDA-R) [Ezeoke
et al., 2013],whichunderlies the formationof associativememoryby
mediating the strengthening of synapses [Bannerman et al., 1995].
An autoimmune pathology could therefore underlie damage to
neural tissue, and therefore networks, resulting in the cognitive
symptoms observed in schizophrenia [van den Heuvel et al., 2013].
Despite the plausibility of thismodel, we donot find evidence for
a genetic overlap between SCZandRA.This suggests that, if someof
the biological pathways involved in RA and SCZ are shared, it may
be environmental rather than genetic aberrations perturbing these.
Negative results must always be viewed cautiously in the context of
power, and we discuss this limitation below.
Effect of Medication
Weconsidered the epidemiological data on SCZ andRA in the light
of their respective ages at onset. SCZ has a mean age at onset of
around 26 years (95% CI 14.34 – 38.14) [Sham et al., 1994]. By
contrast, RAhas amuch later age at onset, with the peak age at onset
between 65–75 in men and 55–64 in women [Symmons and
Deborah, 2002]. We considered that, by age at onset for RA,
SCZ patients were likely to be medicated. If these two disorders
do share an aetiological basis, antipsychoticmedicationmay have a
prophylactic effect on RA onset later in life.
The epidemiological studies presented above, exploring the
relationship between SCZ and RA, do not stratify patients by
medication status. It is unlikely, however, that medication status
mediates the negative association. Chlorpromazine was first intro-
duced clinically in the early 1950’s, and clinical uptake of anti-
psychotics in the USA was gradual from the mid-1950’s to the
mid-1970 s [Shen, 1999]. Despite this, there is substantial evidence
that typical antipsychotics such as haloperidol may have an anti-
inflammatory role that may protect against RA. Synovitis and CRP
levels in RA patients has been observed to improve following
administration of haloperidol for acute mania in case studies,
and in blood cultures stimulated acute inflammation led to a
marked inhibition of the release of TNF a and IL1-b [Moots
et al., 1999]. These inflammatory cytokines have been directly
linked to RA [Elliott et al., 1995; McNiff et al., 1995]. Thus
schizophrenia patients taking haloperidol may be protected from
RA onset by the suppression of TNF-a and IL1-b levels.
Limitations
We identify four main limitations in our study. Firstly, as presented
above, SCZ and RA have substantially different ages at onset, and the
former is associated with substantially reduced life expectancy
[Crump et al., 2013]; thus many SCZ patients may die before age
at onset for RA. Many epidemiological studies above are unable to
adjust for age amongst SCZ patients— in a record linkage paradigm,
this data is not collected—and therefore we present unadjusted odds
ratios for all studies. A ‘harvesting effect’ may confound the negative
association between RA and SCZ [Sawchuk et al., 2013]; this is
unlikely to account for the entire effect, as individual population
registry studies, which collect sufficient data with sufficient power,
replicate the negative association after adjusting for age [Benros et al.,
TABLE II. Direction of Effect Sharing for SNPs in Approximate Linkage Equilibrium, Between SCZ and RA GWAS’s
Clumped By Threshold, p < N SNPs P, Pearson’s x2 Proportion SNPs in same direction
RA 0.01 5,063 0.670 0.492
0.1 35,795 0.569 0.503
0.2 61,785 0.238 0.502
0.3 83,174 0.241 0.502
0.4 101,328 0.199 0.503
0.5 117,664 0.152 0.503
SCZ 0.01 1,784 0.845 0.484
0.1 16,503 0.966 0.496
0.2 33,388 0.200 0.499
0.3 50,159 0.217 0.498
0.4 67,313 0.285 0.498
0.5 84,613 0.179 0.498
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2013]. Furthermore, work on the Swedish Population Register has
replicated the protective effect of SCZ on subsequent RA diagnosis
using Cox regression models and adjusting for age (Hazard Ratio¼
0.69, 95% CI¼ 0.59–0.80) [Sellgren et al., 2014].
Our RA cases and controls present a second limitation. They are
genotyped on different microarrays, so we can only use SNPs shared
across both platforms for calculating SCZ polygenic risk scores. As
polygenic risk scoring requires SNPs in approximate linkage equilib-
rium, the number of SNPs remaining inour test dataset for polygenic
scoring is similar to what would be expected when using a sample
genotyped on a single platform. Although our controls have been
screened forMajorDepressive Disorder (MDD,OMIM608516) and
are not a true population cohort, GWAS have been consistently
shown to be underpowered to detect risk variants associated with
MDD [MDDWorking Group of the Psychiatric Genomics Consor-
tium et al., 2013] and so this is unlikely to affect our results.
Power considerations are a persistent concern in polygenic risk
scoring. Calculation of power requires a series of assumptions to be
made on the underlying architecture of the diseases studied, such as
the correlation between genetic effects in the discovery and test
datasets. Power calculations (Supplementary 6) show it is likely that
we would have sufficient power to detect an epidemiologically
meaningful correlation in genetic effects – assuming genetic effects
at 1% of SNPs, we have 80%power to detect amodest genetic effect
correlation (magnitude¼ 0.078) at a¼ 0.05. Nevertheless, the
possibility that our polygenic scoring results are a false negative
is an important caveat.
Finally, as discussed above, RA and SCZ risk are both modulated
by genotype at HLA loci. We have modelled this influence to an
extent by including themost strongly associatedSCZrisk SNP in this
region in the calculation of polygenic risk scores. We estimated that
SCZ status is protective forRA statuswithOR¼ 0.48 (95%CI: 0.34–
0.67, P < 0.0001). The effect sizes of risk alleles in complex disease
genetics are substantially smaller than this - the most significant
MHC association with SCZ has an OR of 1.21 [Ripke et al., 2013].
Therefore it isunlikely thatSCZriskat theMHCalonecouldmediate
the epidemiological effect calculated in meta-analysis above
Summary
Despite the mounting evidence for an autoimmune aetiology in
schizophrenia, and epidemiological literature on the co-occur-
rence of these two disorders, we found no evidence for a shared
genetic substrate between rheumatoid arthritis and schizophre-
nia, although this could be due to lack of power in the current
samples. Epidemiological data may be confounded due to some




We performed a systematic review and meta-analysis of studies
investigating the prevalence of RA within SCZ patients. This was
performed by searching Embase and Medline for articles published
between1945 andNovember 2013 containing the terms schiz$AND
rheuma$. We included only studies collecting data on RA within
SCZ cases and a sample of SCZcontrols.We restricted this to studies
using population samples, non-schizophrenic psychiatric patients
or other physical disorder patients.
We included all Journal Articles and retainedReviewsmeeting these
criteria.We then read thebibliographies of all reviews and included any
articles with relevant abstracts. Finally we read all articles extracted and
retained those containing epidemiological studies of RA and SCZ
prevalences, which also reported RA prevalences for SCZ controls.
We extracted the following data; study name, authorship and year, case
and control sample size, RA incidence in each of these populations and
selection criteria for controls.
We excluded case studies and studies that did not also collect
controls (see S3 for full details of method used). Literature search,
data extraction and quality assessment was performed in an un-
blinded manner by J.E. We combined studies and calculated meta-
analysis odds ratios under randomeffects and fixed effects using the
R package meta.
Genetic Data Used
As a SCZ discovery data set, we used the most recent publically
available results of GWAS of schizophrenia from ameta-analysis of
the PGC1-SCZ study and a Swedish cohort (S.[Ripke et al., 2013],
(full details of cohort in S5). This reported the p-value, odds ratio
and test statistics for 9,898,079 SNPs imputed to the 1000Genomes
project [Siva, 2008]. For the RA target study, we used RA cases from
the WTCCC study and controls from the RADIANT depression
study. These controls were not included in the discovery study and
therefore our discovery and test datasets are independent, as
required for polygenic risk scoring. This contained data on 1,999
cases and 1,588 controls.
TheWTCCCRAcases (n¼ 1,999)were collected acrossmultiple
UK studies co-ordinated by the Arthritis Research Campaign’s
Epidemiology Unit [Wellcome Trust Case Control Consortium.,
2007]. All cases satisfied the criteria for RA specified by the
American College of Rheumatology [Arnett et al., 1988].
The 1588 RADIANT controls were collected from the staff and
student body of King’s College London or recruited via theMedical
Research Council’s general practice research framework [Lewis
et al., 2010]. They were screened negative for a lifetime history
of any psychiatric diagnosis, using a modified version of the Past
History Schedule (P. McGuffin, Katz, & Aldrich, 1986) and all
reported to be of white European ancestry.
Cleaning Test Dataset
The RADIANT andWTCCC samples were genotyped on separate
platforms (Illumina 610 quad bead and Affymetrix 500 k respec-
tively), leading to a degree of attrition when merging datasets;
after merging, 70,130 SNPs remained. We performed detailed
quality control on the merged RADIANT-WTCCC dataset.
The final data set contained 1,989 RA cases and 1,588 controls
(table S1) with genotype data on 69,621 SNPs.
Cleaning Discovery Dataset
In thePGCand Swedish combined schizophreniaGWAS results as a
discovery dataset, we removed SNPswith an info score less than 0.7,
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indicating poor imputation quality and SNPs not present in the
cleaned test dataset. Finally, in order to obtain SNPs in approximate
linkage equilibrium, theHLA region (26–33Mb on chromosome 6)
was omitted, except for most significant SNP in this region
(rs2517611). We used P-value-informed clumping, extracting
SNPs based on linkage disequilibrium (LD) in HapMap2 CEU
samples.This left 24,126 independentSNPs inourdiscoverydata set.
Polygenic Risk Scoring
Polygenic risk scoringwas performed in the RA test data set, based on
SNPs extracted from the SCZ discovery data set meeting P-value
thresholds pT of 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5. At each
threshold, pT, SNPs with SCZ association P-values below the thresh-
old were used to construct polygenic risk scores (PRS) for each
individual in the RA test data set by summing the number of risk
alleles at each SNPweighted by the natural logarithmof its odds ratio.
We then tested whether the SCZ PRS predicted variance in RA
disease state in a logisticmodel, regressing disease state on PRS plus
five ancestry-informative dimensions accounting for population
structure. The variance in disease state explained by this model was
calculated as Nagelkerke’s pseudo R2 (NR2). We report the differ-
ence inNR2 between thismodel and amodel based on the ancestry-
informative dimensions alone.
Genetic Profile Risk Scoring
Weused the panel of 542 SNPs reported by Ayalew et al, which have
been previously shown to serve as reliable predictors of SCZ status
within independent cohorts and cohorts of different ethnicity
[Ayalew et al., 2012], in order to construct genetic profile risk scores.
We imputedour cases and controls to 1000Genomes andperformed
stringent QC. Of the 542 SNPs listed by Ayalew et al, we obtained
genotypes or proxies with R2> 0.6 for 257. We calculated weighted
scores for SCZ genetic risk in our RA cases and controls using these
SNPs and the effect sizes reportedbyAyalewet al, andfitted a logistic
regressionmodel adjusting forpopulation structureusing5 ancestry
informative dimensions calculated on genotyped SNPs.
Direction of Effect
In order to assess for consistency of direction of effect for SNPs
between two schizophrenia and rheumatoid arthritis, we used
published GWAS data from each disorder [Stahl et al., 2010];
[Ripke et al., 2013]. We performed quality control for imputation
quality (as outlined above) and used P-value informed LD clump-
ing to obtain relatively independent SNPs, using the same protocol
above. For each clumpedGWAS,wemergedwithGWAS results for
the other disorder, extracted all SNPs below a particular P-value
threshold, and classified SNPs as having the same direction of effect
(both ORs > 1 for the same SNP allele), or different direction of
effect. Consistency of SNP effect was tested for using Pearson’s x2
statistics, commonly termed a ‘sign test’.
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Supplementary 1: Cleaning Test dataset 
 
Firstly, in order to account for any possible issues arising from using data from two 
different platforms, we analysed the WTCCC control dataset, genotyped on the 
Affymetrix 500k (3004 individuals, genotyped by the WTCCC, drawn from UK blood 
donors and the 1958 birth cohort, (Wellcome Trust Case Control Consortium, 2007)). 
We merged this dataset with the RADIANT controls, tested for association between the 
two data sets and removed any SNPs with P < 10-5 for association from subsequent 
analyses. We also removed any SNPs with different physical positions between the two 
platforms, any SNPs with MAF < 0.05 in either control group, any SNPs with a 
difference in frequency > 0.15 between the two groups and any SNPs failing our general 
QC criteria outlined below. We removed any SNPs with genotyping rate < 0.99 or a P-
value for Hardy-Weinberg Equilibrium P < 5.7x10-7. We also removed individuals with 
missingness > 0.03.  This left 69,623 SNPs. Finally, we removed 10 SNPs reaching 
genome-wide significance (P < 5.7 x 10-8 which were not within 1 Mb of previously 
reported genome-wide significant loci for rheumatoid arthritis (Eyre et al., 2012), leaving 
69,613 SNPs. We tested for cryptic relatedness, however no pairs of individuals met our 
exclusion criteria (𝜋 > 0.2).   The genomic control λ value between controls on the two 
chips to 1.097 indicating good consistency (fig S1.a). 
 
The primary criticism of our approach, using two different chips, would be the concern 
that between-chip differences, unaccounted for by covariates for ancestry, would lead to 
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spurious results. We tested this by investigating the genomic inflation, λ, after using 20 
dimensions accounting for population structure (calculated using MDS) to covary for 
effects of ancestry. We calculated dimensions in PLINK by first producing a set of 
genome-wide SNPs in linkage equilibrium. We removed the MHC (an area of high 
linkage disequilibrium) and pruned using a sliding window of 50bp, moving by 5bp, and 
removing SNPs which produce a variance inflation factor (VIF) greater than 2 within 
that window. This left 47,951 SNPs, which were used to calculate dimensions.  
 
We calculated 20 dimensions, and then regressed control group membership 
(RADIANT vs WTCCC1) on genotype plus increasing number of dimensions, noting 
genomic inflation for each model. The genomic inflation factor, a measure of population 
structure, calculated using the median chi-squared statistic, was λ = 1.0395 when using 
5 dimensions as covariates, indicating that there was minimal population structure which 
couldn’t be accounted for by the use of dimensions accounting for population structure. 
This is a critical justification for our rationale, as we rely on our ability to assume that 
differences between cases and controls in our test dataset are due to alleles differentially 
associated with RA, rather than simply physical differences genotyping chips used.  
 
This case-control analysis is also used to determine the number of eigenvectors necessary 
to account for population stratification between our case and control datasets. We used 
multi-dimensional scaling (MDS) to calculate eigenvectors for our merged dataset. MDS 
requires SNPs in linkage equilibrium. We therefore removed the MHC (26 – 33 Mb on 
chromosome 6, an area of high linkage disequilibrium), and pruned the remaining SNPs 
using PLINK-1.07 under the protocol outlined above - using a sliding window of 50bp, 
moving by 5bp, and removing SNPs which produce a variance inflation factor (VIF) 











Fig S1:  
a. Genome-wide association between the controls used in the test dataset (from the 
RADIANT study) and the WTCCC controls. We were interested in removing SNPs 
differing substantially between the platforms these two groups were genotyped on. After 
cleaning, there was no substantial difference between the two groups 
 
b. GWAS of RADIANT controls vs WTCCC-RA cases. We have replicated the 
WTCCC’s original (2007) result, with a substantially associated region in the MHC on 
chromosome 6 
 
c. Manhattan Plot of association with RA for with SNPs in cleaned test dataset. P-values 






We calculated the first 20 dimensions that mapped identity by state across independent 
SNPs. The first two dimensions showed substantial deviation from expectation (fig S2), 
and so we removed individuals with a score on dimension 1 less than -0.06, or on 
dimension 3 less than -0.06. This produced a more conventional plot of all the first 4 
dimensions. We therefore had 1,989 cases and 1,588 controls remaining – this left 3,577 









































































































































































































































































































































































































































































































































































































































Fig S2: Axes of dimensions accounting for population structure; in all graphs, 
cases are in red, controls are in black, Europeans (CEU) are in green, Chinese 
(CHB) are dark blue, Japanese (JPT) are light blue and Yorubans (YRI) are 
purple. The complete RADIANT controls, Wellcome Trust Cases and 
HapMap2.3 samples are presented on the left column. We removed individuals 
with a score on dimension 1 less than -0.06, or on dimension 3 less than -
0.06.The remaining individuals are presented on the right column. 
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This is broadly in line with the Principal Component plots that should be expected under 
a null assumption of no population stratification. We then ran a series of logistic 
regression models in PLINK adding increasing numbers of dimensions used as 
covariates. When using 5 dimensions as covariates, genomic inflation was λ = 1.095, 
indicating good control of ancestry or platform differences in the merged data sets. The 
results of this association test are presented as a Manhattan plot (fig S1.c). The 





RA Controls Total 
Male Female Unknown Total Male  Female Unknown Total  




Table S1: Distribution of sex and affection status in test dataset 
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Supplementary 2: Polygenic Risk Scoring excluding MHC SNP 
 
We repeated genome-wide polygenic scoring without the addition of any MHC-SNP. 
The results of this are below (table S2, fig S3.a). 
 
Threshold, PT
 Number of SNPs 
included  




0.0001 81 0.0001 0.519 
0.001 298 0.0004 0.259 
0.01 1,392 0.0011 0.072 
0.05 4,450 0.0007 0.152 
0.1 7,395 0.0000 0.858 
0.2 12,430 0.0000 0.938 
0.3 16,707 0.0000 0.944 
0.4 20,633 0.0000 0.826 
0.5 24,121 0.0000 0.800 
 
 
The upper 5% tails of the distribution, which capture those with high SCZ PRS scores, 
had similar proportions of RA cases and controls (cases: 5.7%; 95% CI 4.6% - 6.7% 
compared to controls 5.0%, 95% CI 4.0% - 6.1%) and similar results were seen in the 
lower 5% tail (Figure S3.b).  These results suggest that genetic factors do not predict 
















Table S2: Proportion of variance in RA status explained by polygenic risk score for SCZ 









We explored the logistic model regressing RA status on 5 dimensions accounting for 
population structure and standardised polygenic risk score (PT < 0.01) for schizophrenia. 
In this model, the beta for PRS was 0.06. That is to say, a two standard deviation increase 





a. Variance in RA status explained by polygenic risk scores for SCZ calculated using 
different cut-off thresholds. 
 
b. Proportion of RA cases (lined) and RA controls (grey) in lowest SCZ risk quantile 
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Predictive Accuracy of SCZ risk alleles 

















P= 0.858 P= 0.938 P= 0.944 P= 0.826 P= 0.8
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 RA case
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 RA control
High SCZ Risk, 
 RA Control
High SCZ Risk, 
 RA Case





























Supplementary 3: Systematic Review and Meta-analysis 
 
 
We performed a single meta-analysis of all studies extracted above. In addition to 
analysing the full systematic review results, we subdivided studies by control population. 
To account for effects of long term institutionalisation and aid in sample collection, 
many authors used non-schizophrenic psychiatric patients as their control group – a 
meta-analysis of the incidence of RA between SCZ patients and these reference patients 
only is shown below (fig S4). The effect of SCZ on reducing RA incidence is preserved, 
indicating a main effect of SCZ, rather that psychiatric illness in general, driving this 
association. 
 
The negative association between SCZ status and RA prevalence remained statistically 
significant, random effects OR = 3.43 (95% CI: 0.163 – 0.720, P = 0.0047). There was 





Fig S4: RA prevalence (events) in SCZ cases and non-SCZ psychiatric patients. The 
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Supplementary 4: Using PGC1 SCZ only as Discovery Dataset 
 
4.1 Cleaning Discovery Dataset 
 
In order to use the PGC schizophrenia GWAS results (table S3) as a discovery dataset, a 
few quality control procedures are necessary. We removed SNPs from the GWA results 
with an info score less than 0.7, indicating poor imputation quality. We then removed 
SNPs not present in the cleaned test dataset. Finally, in order to obtain SNPs in 
approximate linkage equilibrium, we used P-value and LD-informed clumping, extracting 
SNPs based on LD in HapMap2 CEU samples.  Specifically, we selected the SNP with 
the lowest P-value in each LD block of r2 < 0.1, length ≤250kb, leaving 23,150 
independent SNPs in our discovery data sets. 
 
 
SCZ Cases SCZ Controls Total 
Male Female Unknown Total Male  Female Unknown Total  







4.2 Polygenic Scoring 
 
After all quality control, our final test dataset contained genotype data on 1989 cases and 
1588 controls. After removing the MHC region (26-33mb on chromosome 6), 23,301 
SNPs remained. We calculated the proportion of variance in RA status explained by 
these polygenic risk scores after removal of the MHC (table S4, fig S5a) 
 
We standardised polygenic risk score (PT < 0.05) for schizophrenia – the most predictive 
threshold (fig S5.b).  Standardised polygenic scores for SCZ risk were significantly 
higher in RA cases than controls (P = 0.0127). 
Table S3: Sample characteristics of PGC1 SCZ Study, used as discovery 








Figure S5:  
a. Variance in RA status explained by polygenic risk scores for SCZ calculated using 
different cut-off thresholds. 
 



































Predictive Accuracy of SCZ risk alleles 





































Standardised Polygenic Risk Score 
  in Cases (striped) and Controls (grey)

























Number of SNPs Additional variance 
explained  
P-value of Polygenic Risk 
Score  
0.001 276 0.000275 0.568 
0.01 1,274 0.000849 0.376 
0.05 4,059 0.00204 0.120 
0.1 6,880 0.00166 0.0160 
0.2 11,778 0.000929 0.0300 
0.3 15,955 0.00143 0.0440 
0.4 19,812 0.00154 0.0363 





Table S4: Polygenic Scoring testing variance in RA status explained by SCZ polygenic 
risk scores, using PGC1 SCZ data only as a discovery dataset 
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Supplementary 5: PGC1 + Swedish Data – Sample Characteristics 
 
 
The PGC1+Swedish dataset contains summary GWAS results for a meta-analysis of two 
GWAS studies of schizophrenia. The first is the PGC1 SCZ results reported above (table 
S3) excluding the samples from Sweden – 8,832 cases, 12,067 controls. Secondly the 
authors performed GWAS of 5,001 cases and 6,243 controls. The results of this analysis 
are publically available via the PGC. https://pgc.unc.edu/Sharing.php and are analysed 






Proportion Male 0.595 0.512 




Table S5: Swedish sample characteristics. Meta-analysed alongside PGC1 results in 
order to produce Swedish+ PGC1 dataset. 
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Supplementary 6: Power Calculations for PRS 
 
We used the polygenescore software developed by Dudbridge to calculate power in our 
polygene scoring analysis of SCZ risk in RA cases (Dudbridge, 2013). We calculated 
power to detect shared risk alleles between RA and SCZ at our most predictive score 
threshold (PT < 0.01) in table S6b; this calculation takes the following parameters (table 
S6a). We repeat power calculations at an unselected cut-off threshold of PT<0.5 in table 
S6c in order to investigate the effect of selection bias at the most predictive threshold 
generating spurious results.  
 
We tested three values of potential correlations between genetic effect sizes, based on 
genetic pleiotropy work by Lee et al (Lee, Yang, Goddard, Visscher, & Wray, 2012). We 
calculated power at α = 0.05 for genetic correlations of 0.05, 0.1 and 0.15. We also test 
5 possible values for proportion of null-SNPs genome-wide, from 0 – indicating all SNPs 
are causal – to 0.99, as the effect of 100% non-causal SNPs cannot be calculated. We 













Number of samples in discovery dataset 13,833 cases,  
18,310 controls 
Number of SNPs in analysis 69,621 
Number of samples in test dataset 1,989 cases, 
1,588 controls 
Variance in Discovery dataset explained by 
all genetic effects (GREML estimate from 
PGC 2013) 
0.26 
Variance in Test dataset explained by all 
genetic effects (GREML estimate from 
Stahl et al 2012) 
0.32 
Prevalence of SCZ 0.01 
Prevalence of RA 0.006 
Proportion Cases in Discovery 0.422 
Proportion Cases in Test 0.556 
 
 
Polygenic scoring to investigate genetic overlap between RA and SCZ has power ranging 
from 0.07 to 1.00 depending on the genetic architecture of the overlap between these 
two phenotypes, at α = 0.05. This indicates our study is well powered to detect 
pleiotropic effects of the same magnitude observed in other pairs of disorders – for 
example Dudbridge estimates a genetic effect correlation between SCZ and bipolar 
disorder of 0.706 (95% CI: 0.513-0.897), (Dudbridge, 2013), assuming a high proportion 







Table S6a: Parameters used for polygenic risk scoring power calculations 
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 Proportion of null SNPs, i.e. those with no genetic effects 
on phenotypic correlation 





0.05 0.066 0.067 0.081 0.345 0.495 
0.1 0.117 0.120 0.177 0.878 0.974 
0.15 0.204 0.211 0.338 0.997 1.000 
 
Table S6b: Power for PRS to detect effects in our main analysis, calculated using 
polygenescore, assuming a number of different values for the correlation between genetic 
effects in discovery dataset (SCZ GWAS) and test dataset (RA GWAS), and a number of 
different values for proportion of null SNPs genome-wide 
 
 
 Proportion of null SNPs, i.e. those with no genetic effects 
on phenotypic correlation 





0.05	 0.164	 0.165	 0.167	 0.177	 0.179	
0.1	 0.498	 0.499	 0.507	 0.539	 0.544	
0.15	 0.835	 0.836	 0.844	 0.870	 0.874	
 
Table S6c: Repeating the above power calculations looking at PT<0.5 in order to 




Finally, we used software provided by Dudbridge to demonstrate that, assuming 5% of 
SNPs have effects, we have 80% power here to detect a genetic effect correlation of 
0.090. Assuming 1% of SNPs have effects, we have 80% power to detect a genetic effect 
correlation of 0.072. These are much less than genetic effect correlations estimated for 
canonically pleiotropic conditions with similar epidemiological relationships – such as the 
estimated genetic effect correlation between SCZ and bipolar disorder of 0.706. 
Therefore, provided the proportion of null SNPs is high, we would have reasonable 
power to reject the null in the presence of a genetic effect in this analysis. 
 75 
Supplementary 7: Direction of effect for SNPs within the MHC 
 
A study using FDR-informed SNP ordering recently demonstrated that SCZ-associated 
SNPs acted in the same direction as those associated with Multiple Sclerosis more 
frequently than would be expected by chance – evidence of pleiotropy (Andreassen, 
Thompson, & Dale, 2014). Furthermore the authors demonstrated that this effect was 
driven by SNPs in the MHC region. We therefore repeated our direction of effect 
analysis above, focusing specifically on SNPs within the MHC (26 – 33Mb on 
Chromosome 6).  
 
After correcting for multiple testing, none of the results of sign tests for shared direction 
of effect were statistically significant (table S7). Therefore these results are consistent 
with those above, demonstrating a lack of genetic association between RA and SCZ, and 
nominal evidence for shared risk alleles. 
 
Clumped By Threshold, P < N SNPs P, Pearson’s 
χ2   
Proportion 
SNPs in same 
direction 
RA 0.01 95 0.201 0.526 
 0.1 132 0.025 0.515 
 0.2 145 0.090 0.531 
 0.3 149 0.129 0.523 
 0.4 152 0.152 0.520 
 0.5 152 0.152 0.520 
SCZ 0.01 83 0.826 0.482 
 0.1 114 0.835 0.491 
 0.2 128 1.00 0.508 
 0.3 136 1.00 0.507 
 0.4 142 0.977 0.514 
 0.5 148 1.00 0.507 
 
 
Table S7: Shared direction of effect between independent SCZ and RA risk alleles in the 
MHC region, across published GWAS 
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Supplementary 8: Genetic Profile Risk Scoring 
 
SCZ genetic risk scores calculated using the panel of 542 SNPs proposed by Ayalew et al 
did not associate with RA status (Ayalew et al., 2012). We explored this further by 
investigating these SNPs within the most recent publically available RA GWAS (Stahl et 
al., 2010). Within an RA GWAS, the P-values for association with RA status were 
uniformly distributed (Kolmogorov-Smirnoff test P-value = 0.13). The SNP panel 
provided by Ayalew et al orders SNPs based on the genes they lie within. We therefore 
obtained this list of genes (n=42), and calculated gene-based P-values for rheumatoid 
arthritis using the summary data available from Stahl et al and the utility VEGAS (Liu et 
al., 2010). RA gene-based P-values were uniformly distributed across the 42 SCZ risk 
genes identified by Ayalew et al (Kolmogorov-Smirnoff test P-value = 0.604), indicating 
that genetic variation across these SCZ risk genes is not associated with RA status. 
 
Displayed on a Manhattan plot of our RA case-control data after imputation and QC, no 
GPRS SNPs or their proxies show a suggestively significant association (α = 5x10-5) 





Figure S6: Manhattan plot of imputed SNPs in RA case-control analysis. GPRS542 













Appendix – The Genetic Overlap between PGC2-SCZ 
and Rheumatoid Arthritis 
 
Introduction 
Following the publication of our investigation into the genetic overlap between 
schizophrenia (SCZ) and rheumatoid arthritis (RA) (Euesden, Breen, Farmer, McGuffin, 
& Lewis, 2015), there have been two notable developments that allow our study to be 
updated with higher power to reinforce our conclusions. Firstly, in our original study we 
constructed Polygenic Risk Scores for Schizophrenia using the PGC1+Swedish Genome 
Wide Association Study (Ripke et al., 2013). This GWAS is now superseded as the largest 
publically available Genome-Wide Association Study of Schizophrenia to date by the 
PGC2 study (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 
2014), whose sample characteristics are described below (Table A1). Secondly, we have 
demonstrated elsewhere (Euesden, Lewis, & O'Reilly, 2015) that the standard Polygenic 
Risk Scoring (PRS) approach used extensively by others, and in our initial investigation 
of SCZ and RA, may be improved upon by the use of a larger number of thresholds PT 
and any multiple testing burden offset through the use of a more stringent significance 
threshold of α = 0.001. Here we therefore present updated results from our study of 
SCZ and RA, using the PGC2 SCZ GWAS (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014) for its higher power, and using PRSice with 
high-resolution scoring for its optimised detection of the most significant threshold for 




We used the same RA case-control sample from our original investigation (Euesden, 
Breen, et al., 2015) as a target data set. Our base sample is the PGC2 schizophrenia data, 
whose sample characteristics are below (Table A1). 
 
We implement high-resolution scoring in PRSice, at 10,000 thresholds, from PT=0.001 to 
PT=0.5 at increments of PT=0.0005. All scores are calculated using default clumping 
protocols in PRSice, with the Major Histocompatibility Complex removed. Scores are 
regressed on rheumatoid arthritis status at each threshold; these logistic models are 
adjusted for the first 5 MDS dimensions as calculated and reported previously (Euesden 
et al 2015). 
 




 European Asian Total European Asian Total    
PGC2 
 
32,405 1,836 34,241 42,221 3,383 45,604 2,470 82,315 128 
PGC1+ 
Swedish 
13,833  13,833 18,310  18,310  32,143 22 
PGC1 9,394  9,394 12,462  12,462  21,856 7 
 
 
Table A1: Sample characteristics of the PGC2 schizophrenia data used as base in this 
supplementary analysis.  As comparison, the PGC1 sample, presented in the 
supplementary materials to chapter 3 is included. These individuals are meta-analysed 
with a sample of 8,832 SCZ cases and 12,067 controls recruited from Sweden to give the 
final analytic sample of 13,833 SCZ cases cases and 18,310 controls that are used in the 
main analysis in chapter 3. The number of Genome-Wide significant loci identified in 




At the most predictive threshold, PT=0.3918, Schizophrenia PRS predicts rheumatoid 
arthritis case status with a P-value of 0.005. Whilst suggestively significant, this lies above 
our suggested α threshold of 0.001, which is necessary to adequately account for the 
multiple testing burden resulting from the use of 10,000 P-value thresholds for PRS 
calculation. Furthermore, as in our previous analysis, we find a nominally positive effect 
of SCZ PRS predicting RA case status.  For a 1-standard deviation increase in SCZ PRS, 
the odds ratio for RA is 1.11 (99.9% Confidence Interval – corresponding to α = 0.001 
– is 0.98 – 1.24), suggesting that it is unlikely that increased SCZ PRS is reducing risk of 
rheumatoid arthritis in the general population, or that this could contribute to the 
epidemiological relationship we have reported, which is in the opposite direction. These 























Figure A1: PRS for Schizophrenia predicting rheumatoid arthritis case-control status 
across thresholds. Results using high-resolution scoring are presented (a) as a bar chart  
and (b) as a point-plot with the results of PRS at a limited number of thresholds 
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 PGC2 Data PGC1+Swedish Data 








0.001 0.2220 0.0005 771 0.276 0.0004 299 
0.05 0.0400 0.0015 5776 0.154 0.0007 4,451 
0.1 0.0225 0.0018 8695 0.799 0.0000 7,396 
0.2 0.0280 0.0017 13477 0.816 0.0000 12,431 
0.3 0.0119 0.0022 17316 0.863 0.0000 16,708 
0.3918 0.0049 0.0028 20446 NA NA NA 
0.4 0.0062 0.0026 20690 0.770 0.0000 20,634 
0.5 0.0126 0.0022 23652 0.751 0.0000 24,122 
 
Table A2: Results of SCZ PRS predicting RA case-control status at a select number of 
P-value cut-off thresholds including the most significant threshold of PT=0.3918. We 
present threshold, P T used to select SNPs for PRS construction, the P-value for SCZ 
PRS predicting RA Case-Control Status (α = 0.001 ), The variance in RA Case-Control 
Status explained by SCZ PRS (Nagelkerke’s Pseudo R2), and the number of SNPs (N) 
included in scores calculated at this threshold. No thresholds produce scores that are 
significant predictors of RA status at our suggested α threshold of 0.001. For 
comparison, results are presented alongside those obtained from the PGC1+Swedish 
data in chapter 3 – NB we do not present the results at PT=0.3918 in the 
PGC1+Swedish data as this is derived from high-resolution scoring. 
 
Discussion 
We find, in line with our previous analyses, that there is no evidence for a significant 
genetic overlap between schizophrenia and rheumatoid arthritis. This supports our 
previous assertion that the relationship observed in epidemiological cohorts may be 
driven by non-genetic factors, such as a harvesting effect due to the decreased life 
expectancy of schizophrenia patients, or an effect of medication whereby antipsychotics 
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Depression and the autoimmune disorders are comorbid - the two classes of disorders 
overlap in the same individuals at a higher frequency than chance. The immune system 
may influence the pathological processes underlying depression; understanding the 




We used population cohort data from the National Child Development Study to 
investigate the ages at onset of depression and 23 autoimmune disorders. We used self-
report data to ascertain life-time history of depression, autoimmune disorders and their 
ages at onset. We modelled the effect of depression onset on subsequent autoimmune 
disorder onset, and vice versa, and incorporated polygenic risk scores for depression and 
autoimmune disorder risk. 
 
Results 
In our sample of 8174 individuals, 315 reported ever being diagnosed with an 
autoimmune disorder (3.9%), 1499 reported ever experiencing depression (18.3%). There 
was significant comorbidity between depression and the autoimmune disorders (OR = 
1.66, 95% CI = 1.27-2.15). Autoimmune disorder onset associated with increased 
subsequent hazard of depression onset (HR = 1.39, 95% CI = 1.11 – 1.74, P = 0.0037), 
independently of depression genetic risk. Finally, depression increased subsequent hazard 
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of autoimmune disorder onset (HR = 1.40, 95% CI = 1.09 – 1.80, P = 0.0095), 
independently of autoimmune disorder genetic risk.  
 
Discussion 
Our results show a bidirectional relationship between depression and the autoimmune 
disorders.  This suggests that shared risk factors may contribute to this relationship, 
including both common environmental exposures that increase baseline inflammation 





An epidemiological link between psychiatric and autoimmune disorders has been 
observed for almost a century (Nissen & Spencer, 1936). The mechanism underlying this 
overlap is unclear, particularly in depression, one of the most common psychiatric 
disorders (Kessler et al., 2005).  
 
Several relatively small-scale clinical studies have explored the association between 
depression and specific autoimmune disorders. In rheumatoid arthritis, multiple sclerosis 
and the inflammatory bowel diseases, authors have robustly demonstrated an increased 
overlap between depression and autoimmune disorder diagnosis in the same individuals, 
above that expected from their prevalences (Dickens, McGowan, Clark-Carter, & Creed, 
2002; Kurina, Goldacre, Yeates, & Gill, 2001; Patten, Beck, Williams, Barbui, & Metz, 
2003). These relatively small clinical studies have been supplemented by a recent Danish 
population-based study, which reported that depression is associated with a significantly 
increased risk of subsequent autoimmune disease (IRR= 1.25, 95% CI 1.19–1.31) 
(Andersson et al., 2015). 
 
In addition to any clinical implications, investigating the relationship between depression 
and autoimmune disorders, and identifying the factors driving it, will inform theories that 
the aetiology of depression involves immune processes (Raison, Capuron, & Miller, 2006; 
Raison & Miller, 2013). In rheumatoid arthritis, low mood may predict subsequent 
worsening of symptoms in autoimmune disorder patients (Euesden et al, submitted). The 
aetiology and pathophysiology of depression is currently poorly understood, and current 
pharmacological treatments lack efficacy for mild to moderate depression (Fournier et 
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al., 2010). It is therefore of great clinical importance to identify the mechanisms 
responsible for the onset of depression, and leverage this information in future work 
such as the repositioning of pharmaceuticals. 
 
One approach to dissecting this relationship is to examine the relative ages at onset of 
the two disorders in order to infer elements of causality.  If one disorder consistently 
precedes another, it may reliably increase risk of the second.  This has long formed a 
criterion for establishing causality between two events, as first proposed by Hume and 
expanded on by others (Holland, 1986). If there is no clear trend in the order of disorder 
onset, there are two possible interpretations. Firstly, a shared environmental risk factor 
may increase risk of both disorders. Secondly, this relationship may be due to pleiotropy, 
common genetic risk factors increasing risk of both disorders, as is seen between 
depression and a number of other comorbid psychiatric disorders such as schizophrenia 
(Cross-Disorder Group of the Psychiatric Genomics, 2013).  
 
As far as we are aware, only one study has explored relative ages at onset in depression 
and the autoimmune disorders to date. Depression has been shown to elevate hazard of 
autoimmune disorder onset in a Danish population cohort, using confirmed hospital 
diagnoses to identify cases (Andersson et al 2015). This study design has the advantage of 
minimising ascertainment bias and any confounding effects of attrition.  However, 
relying on date of first clinical contact as an indicator of age at onset may estimate an 
artificially late age at onset, as there is typically a latency between depression onset and 
clinical diagnosis (Beiser, Erickson, Fleming, & Iacono, 1993).   
 
In this study, we use data from the National Child Development Study (NCDS), a large 
epidemiological cohort comprised of all children born in England, Scotland and Wales, 
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in one week of 1958. This sample has been followed up through their adult lives, 
providing data that allow the temporal analysis of onset of depression and autoimmune 
disorders.   In addition, the availability of genetic data on NCDS cohort members 
enabled us to examine the contribution of genetic risk to disease onset, alongside 
traditional epidemiological methods. Risk of both depression and almost all autoimmune 
disorders studied to date including type 1 diabetes, rheumatoid arthritis,ankylosing 
spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis  
are influenced by large numbers of common polymorphisms (Single Nucleotide 
Polymorphisms, SNPs) of small effect, which often act to increase risk of a number of 
phenotypes concomitantly (Bulik-Sullivan et al., 2015; Ellinghaus et al., 2016; Major 
Depressive Disorder Working Group of the Psychiatric GWAS Consortium et al., 2013; 
Okada et al., 2014; Wellcome Trust Case Control Consortium, 2007). We therefore 
investigated the role of these common genetic risk factors within a longitudinal 
population cohort in order to dissect environmental and genetic risk factors influencing 
the relationship between depression and autoimmune disorders. 
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Materials and Methods 
 
Sample 
We used data from the National Child Development Study (Power & Elliott, 2006), a 
sample of the 17,638 individuals born in Scotland, England and Wales in one week of 
1958. This cohort has been followed up on multiple occasions across childhood and in 
adulthood. We used self-report data from waves 5 (age 33), 6 (age 42) and 7 (age 46), 
collected in the years 1991, 2000 and 2004, along with genotype data derived from the 
biomedical survey undertaken in 2002-4, when cohort members were aged 44-45 years.  
Ethical approval was given by the South East Multi-Centre Research Ethics Committee.  
Measures 
Autoimmune Disorders 
In wave 7 of the NCDS, participants were queried about their medical histories via 
telephone interview; disorders were stored as ICD-10 codes alongside self-reported ages 
at onset. We investigated the following 23 autoimmune disorders, pooling them to form 
a single autoimmune disease phenotype: Addison's disease, autoimmune haemolytic 
anaemia, autoimmune thrombocytopenia purpura, celiac disease, dermatomyositis, 
Graves' disease, Hashimoto's thyroiditis, idiopathic myocarditis, idiopathic pulmonary 
fibrosis, insulin-dependent diabetes mellitus, inflammatory bowel disease (Crohn’s 
disease and ulcerative colitis), multiple sclerosis, myasthenia gravis, pernicious anaemia, 
polyarthritis, psoriasis, rheumatoid arthritis, scleroderma, Sjogren disease, systemic lupus 
erythematosus, vitiligo, and Wegener's granulomatosis. We pool disorders in order to 
increase power due to many autoimmune disorders being rare individually, and to 
mitigate any biases introduced through possible misclassification within the autoimmune 
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disorders during interview. Participants were considered unexposed before autoimmune 
disease onset (or first autoimmune disease if a participant reported more than one), and 
exposed at age at onset and thereafter. All data were considered censored at age 46, the 
time-point of the most recent biomedical investigation.   
  
Depression 
We drew on three measures of depression onset in the main analysis. In wave 5 (age 33), 
participants were asked if depression had ever been a problem, and if so at what age it was 
first a problem. In wave 6 (age 42), participants were asked the age they had started 
feeling depressed. Finally, in wave 7 (age 46), psychiatric histories were taken alongside 
age at onset (Table 1). 
 
Participants were considered exposed from their earliest report of depression and 
exposed thereafter; as for the autoimmune disorders, reports of depression onset were 
censored at age 46. We took a number of steps to ensure the consistency in reports of 
age at onset across sweeps, and excluded any cases with inconsistent reports (see 
Supplementary 3.  
 
Genotyping 
Blood samples and consent for genotyping were collected in the course of the 
biomedical survey.  Genome-wide genotype data from a subset of NCDS participants 
were available from previous studies using five different genotyping chips.   Quality 
control was performed on each chip separately: SNPs were removed based on MAF < 
1%, Hardy Weinberg equilibrium P < 10-5, and missingness > 1%.  Individuals with 
missingness > 10% were removed. In our phenotype-cleaned data set, 5762 participants 
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were genotyped in total: 2896 participants were genotyped on the Illumina Immunochip, 
1271 on the Illumina 1.2M chip, 1456 on the Infinium Humanhap, and 139 on the 
Affymetrix v6 chip. 
 
Polygenic Risk Scores - Depression 
Polygenic Risk Scores (PRS) for depression for each genotyped NCDS participant were 
calculated using genome-wide results from the Psychiatric Genomics Consortium MDD 
study (Major Depressive Disorder Working Group of the Psychiatric GWAS 
Consortium et al., 2013).  PRS give a measure of genetic risk for each individual by 
summing the number of risk alleles carried, weighted by the natural logarithm of the 
odds ratio for each SNP as identified in GWAS.  PRS were calculated using PRSice, 
including SNPs reaching P-value threshold of  PT = 0.3, previously shown to produce a 
reliable predictor of MDD in independent samples (Major Depressive Disorder Working 
Group of the Psychiatric GWAS Consortium et al., 2013; Peyrot et al., 2014); (Euesden, 
Lewis, & O'Reilly, 2015). PRS were computed by genotyping chip and standardised to 




Polygenic Risk Scores – Rheumatoid Arthritis 
Of publically available GWAS results for autoimmune disorders, rheumatoid arthritis 
(Okada et al., 2014) is one of the highest powered by both sample size - 29,880 RA cases 
and 73,758 controls - and the number of genome-wide significant variants identified 
(n=101).  The NCDS contributed 1,999 controls to the WTCCC study (Wellcome Trust 
Case Control Consortium, 2007) which is part of the RA GWAS meta-analysis; we 
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therefore removed the effect of these samples from the Okada GWAS summary 
statistics by performing an association study on the WTCCC rheumatoid arthritis cases 
and controls, and perform an inverse meta-analysis in order to obtain a GWAS summary 
statistics which can be used to calculate PRS in the NCDS – this cleaning of GWAS data 
is outlined in detail in supplementary section 4. 
 
The summary results from this adjusted RA GWAS meta-analysis were used to construct 
rheumatoid arthritis PRS for all genotyped NCDS individuals. To obtain the optimum 
SNP P-value threshold, we identified all NCDS rheumatoid arthritis and polyarthritis 
cases, and classified others as controls. We tested the ability of rheumatoid arthritis PRS 
to predict this case-control arthritis status at a number of SNP P-value thresholds. 
Logistic regression for case-control status was performed for each chip separately, and 
the PRS regression coefficient was meta-analysed across chips at each P-value threshold.  
This showed that the most predictive threshold was PT=0.001, consistent with the high 
power of the RA GWAS meta-analysis (Dudbridge, 2013).  RA PRS at this P-value 
threshold were standardised by chip and used in modelling below.  
 
Statistical Analyses 
All analysis, unless stated otherwise, was performed using R version 3.2.2 (R 
Development Core Team, 2008). We fitted Cox Proportional Hazards models to 
investigate the time-course of depression on autoimmune disorder onset and vice-versa, 
using Breslow’s method to estimate the baseline hazard function. In each case, the 
predictor variable is coded as a time-varying covariate; this is achieved by specifying 
multiple observations per individual, one before any exposure, one before any outcomes 
and a third thereafter.  Individuals were considered unexposed the year before reported 
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age at onset for a phenotype and exposed thereafter. For example in testing for the effect 
of depression on age at onset of autoimmune disorder, a participant reporting depression 
onset at age 20 and an autoimmune disorder at age 40 would be considered unexposed 
for depression until age 20, exposed for depression but not autoimmune disorder up to 
age 40, and then exposed for both depression and autoimmune disorder until age 46, the 
most recent point at which data was collected.  Models were fitted using autoimmune 
disorder as the event, coding by exposure to depression at different time points, and 
similarly using depression as the event, coding for diagnosis of autoimmune disorder.  All 
models were adjusted for gender as this is a strong predictor of both depression 
(Weissman & Klerman, 1977) and autoimmune disorder (Whitacre, Reingold, & 
O'Looney, 1999).  For each model, we tested the null hypothesis that the exposure 
(depression, autoimmune disorder) had no effect on the event (autoimmune disorder, 
depression).  Finally, PRS for MDD were incorporated into the Cox Proportional 
Hazards models in order to estimate the genetic contribution to hazard of depression – 
firstly in a univariate model investigating hazard of depression and secondly in a 
multivariate model adjusting for any effect of autoimmune disorder onset; we then 
incorporate the same procedure to test the effect of PRS for rheumatoid arthritis 
predicting hazard of autoimmune disorder onset, extending this to a multivariate case 






Overlap between autoimmune disorders and depression 
After harmonisation across time-points and data cleaning, 8174 individuals (48% female) 
remained in our analytic sample. By age 46, 315 (3.85%,; 55.6% female) reported ever 
being diagnosed with an autoimmune disorder (an event-rate per 10,000 person-years of 
8.38), and 1499 (18.3%; 65.6% female) were positive for our measure of depression.   
Depression and autoimmune disorders co-occurred in the same participants at a higher 
rate than would be expected by chance (84 individuals, Odds Ratio = 1.66, 95% CI = 
1.27 – 2.15, Fisher’s exact test P = 1.92 x 10-4).  
 
Dissecting Directionality via Relative Ages at Onset 
 
The mean reported age at onset for autoimmune disorders was 33.2 years (SD=10.9), 
and for depression was 34.4 years (SD=6.3).  Reported ages at onset were not 
significantly different for men and women for autoimmune disorders (P = 0.105), and 
were significantly later in males than females in depression (P = 6.93x10-6). The ages at 
onset of depression and the autoimmune disorders are shown on histograms in figure 1, 
on the x and y axes respectively; ages at onset in individuals with both disorders are 
shown as points, with darker points indicating multiple individuals with the same 
combination of ages at onset.  
 
Cox Proportional Hazards models allow us to explore time-dependent changes in hazard, 
and to use time-varying covariates. We fitted Cox Proportional Hazards models treating 
autoimmune disorder as a time-varying covariate for depression onset, and depression 
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onset as a time-dependant covariate for autoimmune disorder onset. Autoimmune 
disorder onset increased the hazard of subsequent depression onset, with a Hazard Ratio 
of 1.39 (95% CI = 1.11 – 1.74, P = 3.7 x 10-3), adjusting for sex. We also found evidence 
for an effect of depression onset increasing subsequent hazard of autoimmune disorder 
onset (HR = 1.40, 95% CI = 1.09 - 1.80, P = 9.5x10-3), adjusting for sex. These results 
are displayed graphically as Kaplan-Meier curves (figure 2). 
 
Shared genetic risk 
 
To test for shared risk genes increasing hazard of both depression and the autoimmune 
disorders, we incorporated PRS from genotype data on subset of the NCDS sample (N 
= 5762). As individuals were genotyped on one of 5 chips, we verified that standardised 
Polygenic Risk Scores (PRS) for depression did not differ across chips (ANOVA F = 
0.57, P–value = 0.69). In a univariate model, MDD PRS was a significant predictor of 
depression hazard (HR = 1.09, 95% CI = 1.03 – 1.12, P = 5.3 x 10-3), and after adjusting 
for gender (HR = 1.08, 95% CI = 1.02 – 1.15, P = 9.1 x 10-3).  
 
Including autoimmune disorder onset and MDD PRS in a Cox model adjusting for 
gender, we found that both MDD PRS (HR = 1.08, 95% CI = 1.02 – 1.15, P = 8.7 x 10-
3) and autoimmune disorder onset (HR = 1.32, 95% CI = 1.01 – 1.72, P = 0.046) were 
significant, independent predictors of subsequent depression onset.  Although the 
smaller Ns in the genotyped sample reduced the statistical power of this model, the point 
estimate for the Hazard Ratio of autoimmune disorder status on depression onset was 
closely similar to that in the phenotypic analysis reported above. 
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For RA PRS, we confirmed that scores did not differ by genotype chip (ANOVA F = 
0.93, P-value=0.45), and that it predicted rheumatoid arthritis and polyarthritis case-
control status (P=0.005). In a Cox Proportional Hazards model adjusting for gender and 
depression onset, RA PRS predicted autoimmune disorder hazard (HR = 1.15, 95% CI = 
1.01 – 1.31, P = 0.03), with a nominally significant independent effect of depression 
status (HR = 1.31, 95% CI = 0.97 – 1.38, P = 0.08).  
 
Whilst the effect of depression onset predicting AD onset is not statistically significant 
when adjusting for RA PRS, it is likely that this is due to power concerns. Firstly, we 
demonstrate below that RA PRS does not predict depression status, and so it is unlikely 
that adjusting for RA PRS accounts for any effect of depression predicting AD onset. 
Secondly, the model adjusted for RA PRS has reduced power to detect modest effect 
sizes, a general principle of models with dichotomous outcomes and additional 
covariates predicting outcome but not exposure (Mefford & Witte, 2012). Thirdly, the 
hazard ratio for depression predicting subsequent AD onset estimated when adjusting 
for RA PRS (HR = 1.31) remained similar to the hazard ratio obtained before adjustment 
(HR=1.40). Thus our interpretation of the effect of depression predicting subsequent 
AD onset after adjusting for RA PRS as suggestively significant (P=0.08) appears broadly 
justified. 
 
We finally tested whether RA PRS predicted depression onset, and whether MDD PRS 
predicted AD onset. Neither of these associations were significant: HR = 0.99 (P=0.79) 
and HR = 0.97 (P=0.68) respectively. We repeat all of the above analyses using cluster 
robust standard errors in order to account for the effect of longitudinal dependence 
across observations. The results of these analyses are presented – in comparison with the 
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results of the above analyses – in supplementary 5 and table S3, and confirm that 




We explored the relationship between depression and autoimmune disorders up to mid-
life using epidemiological and genetic data. We replicated the finding that autoimmune 
disorders are frequently comorbid with depression, using a longitudinal national birth 
cohort and self-report data, which is increasingly used in the study of depression (Smith 
et al., 2013). We also demonstrated an effect of autoimmune disorder onset increasing 
hazard of subsequent depression onset; this effect was independent of the effect of 
genetic risk factors influencing hazard of depression. These results highlight the utility of 
a longitudinal approach to problems of medical comorbidities in epidemiology; our 
epidemiological results replicate those of Andersson et al (2015), and build on them by 
including individuals who had not sought specialist mental health care, but who had 
explicitly answered questionnaires on history and current status of depression, within a 
population-based sample. There are a number of alternative explanatory models for the 
observed findings 
 
Causative effect of depression on autoimmune disorders 
Longitudinal studies have shown that depression shows a two-way association with 
systemic inflammation (Matthews et al., 2010), which is a key component in the 
pathophysiology of autoimmune disorders, such as rheumatoid arthritis (Smolen, 
Aletaha, Koeller, Weisman, & Emery, 2007). Our finding that depression onset can 
increase subsequent hazard of autoimmune disorder onset is consistent with this model 
(Sheehy, Murphy, & Barry, 2006).  
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Causative effect of autoimmune disorders on depression 
The role of immune abnormalities in the pathophysiology of depression has been the 
focus of intense research for the past two decades (Miller & Raison, 2015). For example, 
experimental stimulation with pro-inflammatory cytokines and bacterial compounds, 
such as lipopolysaccharides (LPS), induces a cluster of symptoms overlapping with 
depressive symptoms in animal models and humans (Dantzer, O'Connor, Freund, 
Johnson, & Kelley, 2008; Musselman et al., 2001). Furthermore, anti-inflammatory 
medications appear to have antidepressant effects (Kohler et al., 2014). Our finding that 
autoimmune disorder onset can increase subsequent hazard of depression onset is 
consistent with these findings. 
 
Shared Environmental Factors 
Many behaviours associated with MDD, such as smoking (Bjørngaard et al., 2013) are 
also associated with autoimmune disorders such as rheumatoid arthritis (Pedersen et al., 
2006). Whilst there is little debate that smoking increases risk of RA (Di Giuseppe, 
Discacciati, Orsini, & Wolk, 2014), there is considerable debate as to the direction of any 
causal association between smoking and MDD.  Bjorngaard et al found no evidence for a 
causal effect in MDD but negative results in Mendelian randomisation studies are 
difficult to interpret. The large number of behaviours associated with MDD and the 
multifactorial nature of both MDD and many autoimmune disorders make it difficult to 
differentiate between autoimmune disorder risk factors caused by MDD, and common 
risk factors shared by both MDD and the autoimmune disorders, however temporal 
ordering may provide one route. There is robust evidence for an association between 
childhood maltreatment and both depression and the autoimmune diseases (Dube et al., 
2009; Nanni, Uher, & Danese, 2012) and immune abnormalities appear concentrated 
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within a subgroup of depressed individuals with a history of childhood maltreatment 
(Danese et al., 2008); (Danese et al., 2011). Therefore, early life stressors may play a role 
in the comorbidity of these two outcomes. 
 
Shared Genetic Factors 
Inflammatory models of MDD would suggest a predisposition to higher inflammatory 
activity, similar to the inflammatory arthritis that precedes rheumatoid arthritis, in 
depression patients (Raison et al., 2006). Genetic risk of inflammatory over-activity may 
underlie the epidemiological relationship between these two families of disorders, 
however this conclusion would not be consistent with our results, as we found no 
evidence for genetic risk of rheumatoid arthritis increasing hazard of depression. Instead, 
we find evidence for independent effects of MDD genetic risk and autoimmune disorder 
onset on hazard of subsequent depression. 
 
We note that two separate causal mechanisms, one by which depression increases hazard 
of autoimmune disease and another by which autoimmune disease onset increases hazard 
of depression is a less parsimonious conclusion than the presence of a shared 
environmental risk factor. 
 
Clinical Implications 
Because depression can exacerbate systemic inflammation (Matthews et al., 2010) and 
symptoms of autoimmune disorders (Sheehy et al., 2006), assessment and treatment of 
depression in patients with autoimmune disorders is crucial. In addition, not all patients 
with depression benefit from currently available treatments (Fournier et al., 2010) (Nanni 
et al., 2012), and new treatments targeting patient subgroups with identified 
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vulnerabilities, such as immune abnormalities, could offer innovative, effective strategies 
(Kohler et al., 2014); (Raison & Miller, 2013). Finally, further investigations of shared 
pathways that may drive the observed comorbidity, including the roles of childhood 
maltreatment, can uncover key biological mechanisms (Danese & McEwen, 2012).  
 
Limitations  
Our findings need to be viewed in light of several limitations.  First, the low prevalence 
of the individual autoimmune disorders - although consistent with rates expected in 
community samples - required that we group them together into a single composite 
phenotype. Whilst it has the advantage of mitigating confounding due to 
misclassification within the autoimmune disorders and has increased power for 
modelling, this pooled autoimmune disorder phenotype prevented us detecting 
aetiologically distinct subgroups within autoimmune disorders.  It also precluded our 
investigating the role of the genetics of autoimmune disorders in depression onset, 
beyond the marker for genetic risk of rheumatoid arthritis used in the present study.   
 
A further limitation arising from our pooled autoimmune disorder phenotype is the 
difficulty in comparing reported prevalences by disorder. The event-rate for first 
autoimmune disorder in our sample is 8.38 per 10,000 person-years.  This is similar to 
the same event-rate (8.8) reported for any autoimmune-disorder hospitalisation by Dube 
et al (2009) between ages 19 and 44 and suggests that self-report is not leading to an 
over-reporting of medical history in our sample. 
 
A second limitation of this work is the reliance on self-report for indicators of both 
disease status and age at onset. Our confidence in the validity of our depression measure 
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comes from several sources. The prevalence of depression in our sample at 18.3% is 
consistent with previous reports in high-income countries, for example, Bromet et al 
(Bromet et al., 2011) report 14.6% (SD  = 0.2). The higher prevalence of depression in 
our sample may indicate that the repeated interviews minimise under-reporting of 
depression, as previously noted by Moffitt et al (Moffitt et al., 2010). As expected, we see 
later onset for depression in males, and a higher prevalence in females (Burke, Burke, 
Regier, & Rae, 1990; Van de Velde, Bracke, & Levecque, 2010). We note that our sample 
has a later average age at onset (34.4 years) than reported elsewhere (Kessler & Bromet, 
2013); if this reflected a systematic bias in our study, it would mask any causative effect 
of depression on autoimmune disorder onset, as depression onset would be reported 
artificially late in individuals with both disorders. Therefore, our depression measure 




We have replicated, and built on, previous studies in finding a significant association 
between major depressive disorder and the autoimmune disorders in an unselected, 
population-based sample. Furthermore, we have found significant evidence for 
depression temporally preceding autoimmune disorders in some patients, and vice versa. 
This suggests a causal effect of MDD on autoimmune disorder onset, perhaps via some 
depression-associated behaviour such as diet, or an environmental risk factor shared 
between the two phenotypes, such as cigarette smoking. Finally, we have used genetic 
data to demonstrate independent effects of autoimmune disorder status and MDD 
genetic risk scores on onset of depression.  
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Tables and Figures 
 
 








5 33 (1991) Age at which 
depression was first 
a problem 
390 (79.0%) 390 (79.0%) 
6 42 
(2000) 
Age first started 
feeling depressed 
1466 (66.1%) 1085 (61.5%) 
7 46 
(2004) 
ICD codes for 
medical disorders 
and self reported 
age at onset. F32, 33 
and 34 
101 (62.3%) 24 (37.5%) 
 
Table 1: Summary of depression metrics used to determine depression status and age at 





Measure Full Sample Genotyped Subsample 
Sample Size 8174 5762 
Female (%) 3919 (47.9%) 2902 (50.4%) 
Number depressed (%) 1499 (18.3%) 1067 (18.5%) 
Number (%) depression cases 
Female 
984 (65.6%) 736 (69%) 
Average depression age at onset 
(SD) 
34.4 (6.3) 34.4 (6.36) 
Average depression age at onset 
in women (SD) 
33.9 (6.54) 33.8 (6.62) 
Number with an autoimmune 
disorder (%) 
315 (3.85%) 226 (3.92%) 
Number (%) autoimmune 
disorder cases female  
175 (55.6%) 131 (58%) 
Average autoimmune disorder 
age at onset (SD) 
33.2 (10.9) 33.5 (11) 
Average autoimmune disorder 
age at onset in women (SD) 
34.1 (10.4) 34.4 (10) 
 
Table 2: Sample characteristics. Measures are presented separately for the full sample, 
and the subsample that have been genotyped – these are the participants used in the 
Polygenic Risk Score analysis. All controls are censored at age 46, so case status status 
denotes onset before this age, and age at onset is within individuals who have onset 






Figure 1: Age at onset distributions for depression and any autoimmune 
disorder (AD). Participants with both disorders are shown as points, with 
darker points representing more individuals with this pair of ages at onset. 
Of 6 participants reporting age at onset for autoimmune disorders before 









Figure 2: Curves illustrating (a) age of onset of depression by reported autoimmune 
disorder status, and (b) age at onset for autoimmune disorders by reported depression 
status. These are Kaplan-Meier curves modified to show 1 - survival 









































































Supplementary 1: Assessing evidence for non-random dropout 
 
We verified that attrition and data cleaning was not introducing bias into our sample. We 
obtained data at waves 0 – 7, harmonised based on identification number and performed 
the cleaning procedure as described in methods. In this sample, we investigated a 
number of variables as predictors of presence versus absence of individuals in a cleaned 
analytic sample using a multivariate logistic regression framework. 
 
We selected a number of biomedical predictors recorded at wave 3 (age 16) in order to 
test whether attrition is independent with respect to our outcome measures – these are 
‘Seen a Psychiatrist or Psychologist for Depression’, and some proxies for autoimmune 
disease – Diabetes, Psoriasis and Bowel Problems (the closest proxy to IBD available in 
the waves 0-3 data). We also selected a number of demographic variables – gender, 












 Estimate Std. Error z value Pr(>|z|) 
Intercept -1.03 0.10 -9.86 6.26x10-23 
General Ability Score 0.02 0.00 18.88 1.68x10-79 
Psoriasis -0.19 0.22 -0.86 0.39 
Diabetes 0.38 0.54 0.71 0.48 
Bowel Problems -0.09 0.12 -0.78 0.44 
Seen a psychiatrist for 
Depression 
-0.05 0.33 -0.14 0.89 
Female 0.22 0.04 6.06 1.38x10-9 
Father’s social class II 0.03 0.09 0.33 0.74 
Father’s social class III 0.04 0.10 0.38 0.70 
Father’s social class IV -0.08 0.09 -0.93 0.35 
Father’s social class V -0.10 0.09 -1.03 0.30 
Father’s social class VI -0.22 0.11 -1.97 0.05 
Father’s social class VII -0.32 0.12 -2.80 0.01 
 
Table S1: Predictors of attrition at wave 7 following data cleaning 
 
As expected from many prior studies, low general ability score in childhood, female 
gender, and low paternal social class did predict attrition (Matthews et al 2006). 
Importantly for the current analyses, however, the medical disorders were not significant 


























Supplementary 2: Prevalence of Autoimmune Disorders 
 
Below we have summarised the numbers of reported Autoimmune Disorders 
investigated in our sample, with data censored at age 46. 
 
Autoimmune Disorder Number of Cases ICD-10 Code 




Crohn’s Disease 26 K50 
Multiple Sclerosis 25 G35 
Psoriasis 24 L40 
Ulcerative Colitis 12 K51 
Celiac Disease 11 K90 
Type 1 Diabetes 5 E10 
Sjogren Syndrome 4 M35 
Pernicious Anemia 3 D51 
Graves’ Disease 2 E05 
Pulmonary Fibrosis 2 J84 
Hashimoto’s 1 E06 
Scleroderma 1 L94 
Addison’s Disease 0 E27 
Dermatomyositis 0 M33 
Granulomatosis 0 M31 
Haemolitic Anaemia 0 D59 
Lupus 0 M32 
Myasthenia Gravis 0 G70 




Thrombocytopenia Purpura 0 D69 
Vitiligo 0 L80 
 
Table S2: Number of cases for each autoimmune disorder investigated, with ICD-10 











Supplementary 3: Determining age at onset of depression 
 
As outlined in the Methods section, we drew on reports from 3 study sweeps (waves 5, 6 
and 7) to identify age at onset of depression.  Not unexpectedly, we identified a small 
number of discrepancies in reporting across sweeps, and dealt with them as follows: 
Participants reporting a history of depression at wave 5 (age 33), but not at wave 6 (age 
42) were excluded. Participants reporting depression at waves 5 and 6, but with reported 
ages at onset that differed by more than 10 years were removed. Participants with no 
reported onset at wave 5, but reported onset at wave 6 before age 23 were removed. Any 
individuals reporting age at onset for depression before age 7 were reassigned onset at 
age 7.   
 
As a final step, we used 9 items from the Malaise Inventory, a tool to assess low mood 
(Rutter et al, 1970), to validate self-reported depression at wave 5 (Malaise items 2, 3, 5, 
9, 12, 14, 16, 20, 21). We removed any cases who scored zero on the Malaise Inventory 










Supplementary 4: Preparing Data for Rheumatoid Arthritis Polygenic Risk 
Score 
 
In order to remove the effect of the WTCCC1 controls from the Okada et al (2014) 
GWAS, we first clean the WTCCC1 RA cases and controls using the following protocol. 
We first remove SNPs with minor allele frequency below 10% and Hardy-Weinberg 
Equilibrium P-value below 0.05, and individuals with missingness above 10%. We then 
remove SNPs with a genotyping rate below 99.5%. Finally, individuals with missingness 
above 1% on the remaining SNPs are removed. Following this protocol, 297,733 SNPs 
remain, and GWAS is performed on these cases and controls using logistic regression 
under an additive model. 
 
After merging with the Okada et al GWAS, we remove SNPs with an average posterior 
call rate (as determined by Chiamo) > 99.9%, and ambiguous SNPs (i.e. A/T and C/G). 
This leads to a total of 178,239 SNPs. 
 
We remove the effect of this GWAS using the formula below. This is a re-arrangement 
of the standard inverse variance weighted fixed effects meta-analysis formula, as 
presented elsewhere (Borenstein et al., 2009). 
 
Where a full GWAS contains only effects from GWAS A and B, and: 
 
β FULL is effect size from full GWAS 
βA is effect size from GWAS A 
βB is effect size from GWAS B 
SEFULL is standard error from full GWAS 
SEA is standard error from GWAS A 
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Supplementary 5: Repeating Main Analysis with Cluster Robust Standard 
Errors 
In order to investigate the possible effect of longitudinal dependence of observations 
biasing our results, we repeat the main analyses here, accounting for any longitudinal 
dependence using cluster robust standard errors implemented in the survival package in 
R. The results are presented below as table S3, and show that omitting cluster robust 
standard errors in our main analysis biased estimates towards the null, therefore 
providing support for our conclusions. This is an expected result when calculating cluster 
robust standard errors for predictors with a negative intraclass correlation – this will be 
the case in our data, where individuals only contribute multiple rows if their disease 
status changes across the study period, thus inducing a negative intraclass correlation in 
these variables. 
 
  Main Analysis Using Cluster Robust 
Standard Errors 












1.31 0.046 1.31 0.044 




















1.15 0.03 1.15 0.041 
Table S3: Comparison of using cluster robust standard errors with the main analysis 
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Reduced mental health is prevalent in rheumatoid arthritis (RA). Although longitudinal 
studies are limited, there is evidence that depression associates with worse disease outcomes. 
We evaluated reciprocal relationships between mental health, RA severity and genetic risks 
for depression over 2-years in a well-characterised cohort of RA patients.  
 
Methods 
We evaluated 520 early RA patients previously enrolled to two clinical trials. Mental health 
was measured using the SF-36 mental health (MH) domain and mental component summary 
scores (MCS). MCS/MH associations over two-years with disease activity (DAS28), 
disability (HAQ), pain visual analogue scale (VAS) scores, and a weighted genetic risk score 
(wGRS) for depression, were tested using linear mixed-effects and regression models. 
 
Results 
Poorer mental health associated with worse RA outcomes. Lower MCS scores (indicating 
worse mental health) were seen in patients with a greater genetic risk for depression (wGRS 
β=-1.21; P=0.013). Lower baseline MCS associated with lower 2-year improvements in 
DAS28 (β=-0.02; P<0.001), pain (β=-0.33; P<0.001), and HAQ (β=-0.01; P=0.006). Baseline 
MCS associated with changes in the swollen joint count (β=-0.09; P<0.001) and patient 
global assessment (β=-0.28; P<0.001), but not the tender joint count (P=0.983) and 
erythrocyte sedimentation rate (P=0.973). Only baseline pain VAS (β=-0.07; P=0.002) 






Reduced baseline mental health associated with lower improvements in disease activity, 
disability, and pain over two years, supporting current national guidelines recommending 
screening for depression in RA. Pain had a bidirectional relationship with mental health. 
Depression genetic risk had a significant association with mental health. 
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Reduced mental health is prevalent in rheumatoid arthritis (RA), with major depression 
present in 16.8% of patients [1]. The cause of this excess burden of mental health impairment 
is uncertain. Comorbid depression also appears to have a detrimental impact on the disease 
course of RA, being associated with increased healthcare utilisation and costs [2] and 
representing an independent risk factor for non-suicide related mortality [3]. Determining the 
cause and effect of depression in RA is, therefore, a key research goal. 
 
Research in this area has mainly involved cross-sectional studies in patients with long-
standing RA. These identified associations between depression, and pain [4], disability [5] 
and arthritis disease activity [6]. Their cross-sectional nature, however, made it impossible to 
infer causality. Whilst longitudinal studies are limited, there is some evidence for a 
bidirectional effect with pain in patients with musculoskeletal disorders, whereby depression 
influences pain and vice versa [7, 8]. There is also some evidence that depression influences 
the subsequent disease activity of RA, with an analysis of established RA patients finding a 
slower rate of decline in disease activity over time in patients with a history of depression [9].  
 
Depression also has a substantial genetic component [10], with a recent mega-analysis of 
genome-wide association studies (GWASs) identifying multiple markers of suggestive 
association with major depressive disorder (MDD) [11]. The role of these in determining 
mental health in RA has not previously been evaluated. 
 
The aim of our study was to evaluate the relationship between mental health and disease 
activity, disability, pain, and genetic risk for depression over 2 years in a well-characterised 
clinical trial cohort of patients with early RA. The direction of any associations was tested by 
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examining the impact of baseline mental health on changes in disease activity, disability and 




We studied patients in the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) 
cohort. It has been described in detail previously [12]. In brief, it comprises European 
ancestry RA patients enrolled to two multicentre randomised controlled trials (RCTs), 
CARDERA-1 and CARDERA-2 [13, 14]. Both recruited patients with early RA (<2 years 
duration) and active disease defined as three of ≥3 swollen joints, ≥6 tender joints, ≥45-min 
morning stiffness, or erythrocyte sedimentation rate (ESR) ≥28 mm/h. CARDERA-1 
recruited patients between 2000-2002; CARDERA-2 recruited patients between 2003-2010. 
CARDERA-1 randomised patients to receive either (1) methotrexate; (2) methotrexate and 
ciclosporin; (3) methotrexate and prednisolone; (4) methotrexate, ciclosporin and 
prednisolone. CARDERA-2 randomised patients to receive either (1) methotrexate or (2) 
methotrexate and anakinra. Follow-up was 2 years. The current analysis is restricted to the 
520 patients with baseline mental health data available.  
 
2.2 Disease Outcomes 
The following disease outcomes were captured. Firstly, disease activity (how active a 
patient’s arthritis is) was recorded using the disease activity score with 28-joint counts 
(DAS28). This composite score combines information on the number of swollen and tender 
joints (assessed by a clinician from 28 joint counts), the patient global assessment of disease 
activity (PGA, which involves a patient rating their overall disease activity on a 100mm 
visual analogue scale) and the erythrocyte sedimentation rate (ESR) in a mathematical 
131 
formula to give an assessment of RA activity ranging from 0 to 10. Lower scores indicate less 
active disease, with scores >5.1, <3.2 and <2.6 indicating high disease activity, low disease 
activity, and remission, respectively. Secondly, disability was recorded using the health 
assessment questionnaire (HAQ), a patient-completed questionnaire giving a score of 
function ranging from 0 to 3. HAQ scores of <1, 1-2, and >2 indicate mild, moderate, and 
severe disability, respectively. Thirdly, pain was recorded using a 100mm patient completed 
pain visual analogue scale (VAS). Fourthly, health-related quality of life (HRQoL) was 
recorded using the short form-36 (SF-36), which is described in detail below. In CARDERA-
1 the aforementioned outcomes were captured every 6-months. In CARDERA-2 they were 
captured at 0, 6, 12 and 24 months. 
 
2.3 Mental Health 
The SF-36 is a generic measure of health status, capturing HRQoL across 8 domains (four 
physical and four mental) [15]. These domains are scored 0-100, with higher scores 
indicating better HRQoL. They can be normalised, z-transformed and combined into mental 
and physical component summary scores (MCS and PCS, respectively) providing summary 
measures of overall mental and physical health, relative to a population mean score of 50 (SD 
10) [16]. 
 
We used the mental health (MH) domain score and MCS as measures of mental health in our 
analysis. Both have been used to screen for depression, with an MCS cut-off of 42 having a 
sensitivity and specificity of 74% and 81%, respectively for detecting depressive disorder 





CARDERA patients were genotyped on the Illumina ImmunoChip array (described in detail 
previously [12]). Single nucleotide polymorphism (SNP) markers were removed that had 
>5% missingness, were duplicates, were not in Hardy-Weinberg equilibrium (HWE; 
P<0.00001), and had a minor allele frequency (MAF) <0.01. From 196,524 pre-QC markers, 
138,873 were available in the final dataset. Imputation was subsequently performed using 
IMPUTE2 [19] and the 1,000 Genomes Phase 1 integrated variant version 3 (March 2012) 
reference panel (variants filtered with a European MAF <0.01). Post-imputation SNPs were 
removed with low INFO scores (<0.7), MAF<0.05, HWE P<0.000001 and genotyping rate < 
0.1, resulting in 429,193 available markers.  
 
2.5 Genetic Risk for Depression 
The recent Psychiatric Genomics Consortium MDD GWAS mega-analysis failed to find a 
locus of genome-wide significance, likely reflecting limited power caused by the genetic 
architecture of MDD (small effect sizes of individual genetic variants) and the high 
prevalence of MDD, which increases the difficulty in recruiting large samples of screened, 
low risk controls [11]. We therefore tested a weighted genetic risk score (wGRS) combining 
loci of nominal association with MDD for an association with mental health in CARDERA. 
This approach is commonly used in studies of common polygenic disorders, whose genetic 
architecture comprises thousands of very small effect common alleles [20, 21]. We linkage 
disequilibrium (LD) pruned SNPs and used a P-value threshold (PT) to include SNPs in the 
wGRS with an MDD GWAS P-value below 0.05, representing nominal association. A 
continuous wGRS based on MDD GWAS results has been shown to predict depression in 
independent cohorts, with a PT of 0.05 demonstrated to generate a wGRS with the greatest 
effect on MDD risk [22]. After LD pruning and thresholding, 3,010 SNPs were included in 
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the wGRS. The wGRS was generated for each individual in CARDERA by calculating the 
number of nominally associated risk alleles they carried, weighted by the log odds ratio (OR) 
from the MDD mega-analysis, summed across SNPs. 
 
2.6 Statistical Analysis 
2.6.1 Associations with Mental Health 
Two different modelling approaches were used to evaluate the relationship between mental 
health, RA severity measures and genetic risk for depression. The first approach established 
whether mental health was associated with either RA severity measures or the wGRS for 
depressive disorder over time. This used a linear mixed-effects model, which incorporated 
either MCS or MH measured at each time-point as the response variable, regressed on the 
corresponding predictors (wGRS, DAS28 and its components, HAQ, or pain VAS) from each 
time-point. The inclusion of random effects of individual and time accounted for the within-
individual correlation structure of these variables over time. The following variables were 
tested for their associations with MCS: age, gender, disease duration, and rheumatoid factor 
(RF) status. Of these, only gender improved the model fit and was included as a covariate 
(Supplementary Tables A.1 and A.2). The wGRS was standardised to a z-score, in order to 
provide interpretable β-values. Examination of residuals from a model containing time, 
gender and treatment only confirmed a good model fit (Supplementary Figure A.1), and 
variance inflation factors calculated for each predictor ensured multi-collinearity between RA 
outcomes and DAS28 components was not an issue (Supplementary Table A.3). 
 
The second approach evaluated the direction of associations between mental health and RA 
severity, by testing if mental health at study baseline associated with 2-year changes in RA 
outcomes over time, or vice versa. This used linear regression models to look at the 
association between a) baseline MCS or MH and 2-year changes in RA severity measures, 
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and b) baseline RA severity measures and 2-year changes in mental health scores. These 
models included the baseline response variable score, treatment and gender as covariates. 
Examination of model residuals confirmed good model fits (Supplementary Figure A.1). 
 
2.6.2 Missing Data Imputation 
In the original CARDERA-1 trial missing data at each time-point had previously been 
imputed using last-observation carried forward (LOCF) analysis for study end-points 
(DAS28, HAQ and SF-36). In the original trial an observed case analysis had excluded a 
significant impact of the LOCF assumption [13].  In the original CARDERA-2 trial missing 
data were not imputed. For consistency in the current analysis we imputed missing, 
previously non-imputed CARDERA-1 data (SJC, TJC, ESR, PGA, pain VAS) and missing 
CARDERA-2 data using LOCF. The largest amount of missing data was seen for pain VAS 
(11% of observations missing across all time-points). We repeated our analysis with non-
imputed data only; this excluded a significant impact of the LOCF assumption 
(Supplementary Table A.4). 
 
2.6.3 Statistical Software 
Analyses were performed in the statistical environment R (R Foundation for Statistical 
Computing, Vienna, Austria), PRSice (version 1.2) [23], IMPUTE2 [19] and PLINK (version 
1.9)  [24]. 
 
2.7 Ethics, Consent and Permissions 
CARDERA-1 (South Thames Multi Centre Research Ethics Committee (REC) reference: 
MREC (1) 99/04) and CARDERA-2 (South East REC reference: MREC 02/1/089) were 
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ethically approved. Approval was obtained to genotype archived DNA (NRES Committee 
East of England – Essex REC reference: 11/EE/0544). All patients provided consent. 
 
3. RESULTS 
3.1 Patient Baseline Characteristics 
Most patients were female (69%; Table 1) and RF-positive (67%). Baseline disease activity 
was high (mean DAS28 5.88), disability moderate (mean HAQ 1.56) and disease duration 
short (mean duration 3.3 months). Baseline mental health was reduced relative to the general 
population (mean MCS score 40.6, which is 9.4 units lower than the general population 
mean). 
 
3.2 Disease Severity Associations with Mental Health 
In a gender and treatment adjusted linear mixed-effects model, DAS28 (P<0.001), HAQ 
(P<0.001) and pain VAS (P<0.001) significantly associated with MCS (Table 2). On average 
over two years MCS scores were 2.22, 6.07 and 0.14 units lower per unit increase in DAS28, 
HAQ and pain VAS scores, respectively. This indicates that over time, the higher a patient’s 
disease activity, disability and pain levels, the worse their mental health. In multivariate 
models all three disease severity measures retained a highly significant association with MCS 
(Table 2): HAQ (β=-3.88; P<0.001), DAS28 (β=-0.91; P<0.001), pain VAS (β=-0.05; 
P<0.001). Similar associations were seen with the MH domain. 
 
3.3 MDD Genetic Risk Score Associations with Mental Health 
A significant association was seen between the wGRS for depression and MCS (P=0.013) 
and MH (P=0.041) (Table 2). The association with MCS (P=0.033) but not MH (P=0.080) 
was retained in multivariate models including DAS28, HAQ and pain VAS as covariates. 
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Higher wGRS scores, which indicate a greater genetic risk for depression, associated with 
worse mental health (lower MCS and MH scores) over time (MCS β=-1.21; MH β=-1.37).  
Repeating the analysis with a linear mixed-effects model that incorporated a wGRS*time 
interaction term provided some evidence that genetic risk for depression also influenced the 
rate at which mental health improved over time, with a significant association seen between 
the wGRS*time term and MH (P=0.039; β=-0.83) but not MCS (P=0.330; β=-0.30). 
 
3.4 DAS28 Component Associations with Mental Health 
In a gender and treatment adjusted linear mixed-effects model all four DAS28 components ‒ 
SJC, TJC, ESR and patient global assessment (PGA) ‒ associated with MCS and MH scores 
when tested individually (Table 2). Higher scores in each DAS28 component associated with 
lower MCS and MH scores; this indicates that more active disease is linked with poorer 
mental health. On average over two years MCS scores were 0.32, 0.07, 0.13 and 0.27 units 
lower per unit increase in SJC, ESR, PGA, and TJC scores, respectively. In multivariate 
models including all 4 DAS28 components the TJC failed to retain a significant association 
with MCS (P=0.461) and MH (P=0.519). 
 
3.5 Direction of Association between RA Outcomes and Mental Health 
3.5.1 Association between Baseline Disease Severity and Changes in Mental Health 
The only baseline RA severity measure that had a significant association with two-year 
changes in both MCS and MH scores was pain VAS (Table 3). Higher baseline pain VAS 
scores (indicating greater levels of pain) associated with lesser increases in MCS and MH 
scores (indicating lower improvements in mental health over time). The increase in MCS was 
0.07 units less per 1mm increase in baseline pain VAS. A significant association between the 
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baseline TJC and 2-year changes in MH domain scores was also seen (P=0.023), although 
this variable did not significantly associate with 2-year changes in MCS scores (P=0.122). 
 
3.5.2 Association between Baseline Mental Health and Changes in RA Outcomes 
Baseline MCS and MH domain scores had significant inverse associations with two-year 
changes in DAS28 (MCS and MH P<0.001), pain VAS (MCS and MH P<0.001) and HAQ 
(MCS P=0.006; MH P=0.008) (Table 3). Lower baseline MCS and MH scores (indicating 
poorer mental health) associated with lesser improvements in DAS28, pain VAS, and HAQ 
scores over time. The effect sizes were, however, modest: per 10 unit increase in baseline 
MCS, the two-year reductions in DAS28, HAQ and pain VAS were 0.20, 0.10 and 3.30 units 
greater, respectively (Table 3). 
 
Dividing patients into octiles based on their baseline MCS and plotting the mean disease 
severity measure in each octile demonstrated the effect of baseline MCS on RA outcomes 
(Figure 1). Trends towards a) worse disease outcomes at each time point and b) lower 
improvements in disease outcomes over 2-years across increasing baseline MCS octiles were 
seen (Figure 1).  Over two years, mean DAS28, HAQ and pain VAS scores changed by -1.14, 
-0.23 and -8.11 units, respectively in the lowest MCS octile (group 1) and -1.94, -0.49 and -
18.49 units, respectively in the highest MCS octile (group 8). 
 
Examining individual DAS28 components revealed that baseline MCS and MH scores had 
significant inverse associations with two-year changes in the SJC (MCS and MH P<0.001) 
and PGA (MCS and MH P<0.001) but not the TJC (MCS P=0.983; MH P=0.226) and ESR 
(MCS P=0.973; MH P=0.355) (Table 3). This differential impact on DAS28 components is 
shown in Figure 2.  Over two years, mean SJC, PGA, TJC and ESR levels changed by -0.17, 
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-13.91, -8.02 and -11.98 units, respectively in the lowest MCS octile (group 1) and -4.69, -




Our study evaluated the relationship between mental health and disease activity, disability, 
pain, and genetic risk for depression over 2 years in a well-characterised clinical trial cohort 
of patients with early RA. It has three key findings. The first, and most clinically important, is 
that low mental health associated with poorer disease outcomes. In a repeated measures 
analysis, lower MCS and MH scores had significant associations with more active disease, 
increased disability and greater pain over two years; as MCS and MH scores increased over 
time DAS28, HAQ and pain levels fell. Lower baseline MCS and MH scores (indicating 
worse mental health) associated with a reduced improvement in disease activity and 
disability, suggesting that depression influences the degree to which RA improves over time. 
The relationship between pain and mental health appeared bidirectional, with baseline pain 
associating with lower improvement in MCS and MH domain scores and vice versa; this is in 
keeping with existing studies of musculoskeletal disorders [7, 8]. 
 
The second finding was that swollen, but not tender joint counts had a significant association 
with reduced mental health. In a multivariate model incorporating all four DAS28 
components, the TJC failed to retain a significant association with MCS and MH scores over 
time. In established RA patients attending routine clinics the opposite relationship appears 
true, with an analysis of the CORRONA registry reporting that a lifetime depression history 
associated with slower improvements in the TJC but not the SJC [9]. One explanation for the 
lack of association between MCS/MH scores and the TJC in CARDERA is that the short 
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disease duration of patients means the pain pathway sensitisation characterising fibromyalgic 
RA − which could be particularly influenced by mental health − is yet to occur. An 
explanation for the association observed between MCS/MH scores and the SJC is that 
overlapping pro-inflammatory cytokines, which are present in high levels in early active RA, 
play important roles in mediating both reduced mental health and RA activity. Whilst this 
hypothesis is supported by evidence that administering IL-1β and TNF-α induces depressive 
behaviour in mice [25] and that these cytokines are elevated in the serum of depressed 
patients [26, 27], it fails to explain why baseline mental health scores did not predict changes 
in ESR levels. Further research is required in other early active RA cohorts to confirm the 
generalisability of our results. 
 
Our third finding was that genetic risk for MDD had a significant influence on mental health.  
Although a recent large MDD GWAS mega-analysis (including 18,759 subjects) failed to 
find a locus of genome-wide significance, the authors’ noted that their study lacked power to 
identify individual genetic risk variants given the genetic architecture of this common disease 
[11]. We therefore tested a wGRS combining 3,010 SNPs of nominal association with MDD 
in the GWAS for its association with mental health in CARDERA. Whilst a significant 
association with lower MCS and MH scores was observed, it was substantially weaker than 
that seen with non-genetic factors. These findings support the notion that depression is a 
complex disorder with a modest, albeit important, genetic contribution comprising thousands 
of alleles of a small effect size. 
 
Our study replicates existing research that depression and pain have a bidirectional 
relationship. In CARDERA, baseline MCS and MH scores predicted two-year changes in 
pain VAS and vice versa. This finding has been documented in psoriatic arthritis, with 
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Husted et al identifying a small bidirectional relationship between MCS and pain in 394 
patients followed up for a mean of 7.5 years [7]. It has also been reported in patients with 
persistent back, hip or knee pain [8], back pain [28, 29] and pain from a variety of disorders 
[30]. The complex nature of pain makes it difficult to discern mechanisms by which this pain-
depression bidirectional relationship could occur. Possible mechanisms include: (1) low 
mood could impact on pain through promoting maladaptive coping strategies, especially 
catastrophizing (perceiving a situation to be worse than it is) [31]; (2) pain could impact on 
mental health through reducing daily activities [32] and reducing social activities [33]; (3) 
imbalances in shared neurotransmitters (serotonin and norepinephrine) in affective and 
nociceptive pathways could  contribute to both mood and pain [32]. Further research is 
required to better characterise the mechanisms underlying this complex relationship. 
 
Supporting our finding that mental health predicts disease outcomes over time, other studies 
have reported a detrimental impact of reduced mental health on DAS28-defined anti-TNF 
responses [34, 35]. This effect is highly relevant to stratified medicine in RA. Although in 
CARDERA, the impact of baseline MCS on improvements in disease outcomes over two-
years was modest, if considered alongside other poor prognostic markers, such as ACPA 
status [36], HLA variants [37], smoking and gender [38], it could provide clinically-useful 
prognostic information, guiding decisions on treatment intensity and facilitating a stratified 
approach to managing early RA patients. 
 
Our study has several strengths. These include its large size, recruitment from multiple 
centres spanning two clinical trials, the measurement of multiple disease outcomes in a highly 
standardised manner, and the short disease duration of RA (mean 3.3 months) leaving it well 
placed to examine the effects of mental health in very early disease. It also has several 
141 
weaknesses. As a secondary post-hoc analysis of existing RCTs, it did not test a pre-specified 
hypothesis according to a pre-determined analysis plan.  It evaluated a clinical trial cohort of 
severe RA patients, limiting its generalisability to patients seen in routine clinical practice. 
Additionally, we only evaluated European ancestry individuals; the relevance of our findings 
to other ethnic populations is uncertain. 
 
Current National Institute for Health and Care Excellence (NICE) guidelines for RA 
management recognise the importance of assessing for co-morbid depression, recommending 
this as part of an annual review process [39]. Our findings strongly support this 
recommendation in early RA. One unresolved issue is the impact of treating depression on 
the disease course of RA. Whilst we did not evaluate the impact of mental health therapies on 
RA outcomes, there is some evidence that psychological interventions (such as cognitive-
behavioural therapy (CBT), disclosure therapy and biofeedback), are useful adjunctive 
management tools in RA patients. Two systematic literature reviews have evaluated the 
evidence base for this. Astin et al reported significant pooled effect sizes for psychological 
interventions at reducing post-interventional pain, disability, and psychological status across 
25 trials [40]. Similarly, Dissanayake et al found evidence for the efficacy of disclosure 
therapy and CBT with maintenance therapy across 4 and 5 studies, respectively [41]. The 
evidence base is, however, limited with both reviews noting that available trials had 
methodological limitations. Further research is required to better define the impact of specific 
psychological interventions at improving disease outcomes in large, well-conducted clinical 






In this cohort of 520 early, active RA patients reduced mental health (captured using the SF-
36) associated with worse disease outcomes. Lower MCS and MH scores (indicating poorer 
mental health) significantly associated with more active disease, increased disability and 
greater pain over two years. Worse baseline mental health associated with lesser 
improvements in RA outcome measures, suggesting that depression influences the rate at 
which RA improves over time. A bidirectional relationship was observed between mental 
health and pain, replicating existing work in musculoskeletal disorders. Depression genetic 
risk had a significant, albeit modest impact on mental health. Our findings support current 
NICE RA management guidelines recommending the annual screening of RA patients for co-
morbid depression. Further research is needed to establish the impact of specific mental 




Table 1. CARDERA Genetics Cohort Baseline Characteristics 
Characteristic Summary Statistic 
Demographic Number (%) Female 358 (69%) 
Mean Age in Years (SD) 54.7 (12.6) 
RA Specific Mean RA Duration in Months (SD) 3.3 (4.9) 
Number (%) RF-Positive 350 (67%) 
Mean DAS28 (SD) 5.88 (1.29) 
Mean HAQ (SD) 1.56 (0.70) 
Mental Health Mean MCS (SD) 40.6 (14.1) 
Mean MH (SD) 61.0 (18.0) 
Treatment Number (%) Receiving MTX 159 (31%) 
Number (%) Receiving MTX and CIC 108 (21%) 
Number (%) Receiving MTX and Pred 102 (20%) 
Number (%) Receiving Triple Therapy 107 (21%) 
Number (%) Receiving MTX and anakinra 44 (8%) 
 
Cohort size used in analysis = 520 patients; SD = standard deviation; MTX = methotrexate; 
CIC = ciclosporin; pred = prednisolone; triple therapy = MTX, CIC and pred; RF = 
rheumatoid factor; DAS28 = disease activity score on a 28-joint count; HAQ = health 
assessment questionnaire; MCS = SF-36 mental component summary score; MH = SF-36 
mental health domain. A DAS28 of 5.88 indicates highly active disease. A HAQ of 1.56 
indicates moderate disability. An MCS of 40.6 is 9.4 units lower than that observed in the 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    
 











































































































































































Figure 2. Mean DAS28 Components Stratified by Baseline MCS Octile 
 
MCS divided into octiles (8 quantiles); mean scores with standard error bars for octiles 1, 4, 5 
and 8 plotted at each time point; to facilitate visual interpretation octiles 2, 3, 6 and 7 are not 
plotted, although the same trends are observed (Supplementary Figure 3).
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P-Value	RF-Positive	 1	 0.780	Disease	Duration	 2	 0.354	Age	 3	 0.286	Treatment	 kept	 0.027	Gender	 kept	 0.001	Time	 kept	 <0.001	
 
A stepwise AIC was used to select modelling covariates that significantly predicted MCS 
scores over time within a linear mixed-effects model. After three iterations, only treatment, 
gender and time were significant predictors of MCS and were included as modelling 





Supplementary Table A.2. Associations between Modelling Covariates and MCS 
in Linear Mixed-Effects Model 
Variable	 β	 SE	 P-Value	
Treatment	 Methotrexate	Monotherapy	 Reference	 Reference	 Reference		 Ciclosporin-Methotrexate	 -2.50	 1.37	 0.069		 Prednisolone-Methotrexate	 -0.32	 1.40	 0.818		 Methotrexate-Prednisolone-
Ciclosporin	
2.27	 1.37	 0.099		 Methotrexate-Anakinra	 1.52	 1.89	 0.421	
Gender	 	 3.35	 1.04	 0.001	
Time	 	 1.71	 0.31	 <0.001	
 






Table A.3.  Variance Inflation Factors (VIF) for Predictors in Multivariate 
Linear Mixed-Effects Models 
 







Model includes MCS as response variable and treatment, gender, time, HAQ, DAS28, 
Pain VAS, and wGRS as explanatory variables. 
 
 







Model includes MCS as response variable and treatment, gender, time, ESR, TJC, 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PRSlice: A localised Polygenic Risk Score 
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Biomarkers, biologically derived variables that have utility in predicting disease, are 
sought-after in many medical fields. Here we present a novel method for using DNA to 
calculate a biomarker for genetic risk of disease, building on the established method of 
Polygenic Risk Scoring. Our novel method outperforms conventional Polygenic Risk 
Scoring approaches when using the genetic risk for one disease as a predictor of another 
correlated trait. We propose that this method will have growing utility as the diversity of 
phenotypes interrogated using complex disease genetics methods increases. We validate 
our method through application to real data, and produce simulated data in order to 
interrogate the performance of the method under well-characterised scenarios of genetic 







Over the last five years, Polygenic Risk Scoring (PRS) has emerged as a dominant 
strategy for calculating genetic risk of a disorder in samples of genotyped individuals and 
has already been exploited across a range of applications (Dudbridge, 2013; International 
Schizophrenia Consortium et al., 2009; Power et al., 2015; Power et al., 2014; 
Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). In 
addition to identifying evidence for shared genetic aetiology between traits, PRS are 
valuable as variables to model the genetic component of disease risk, and can be used to 
predict disease risk and proxy the genetic contribution to liability within large 
epidemiological cohorts – as discussed in chapter 4 - or to explore the more subtle 
aspects of the genetic architecture of a trait, such as gene-environment interactions 
(Mullins et al., 2016; Peyrot et al., 2014). 
 
The standard PRS approach, as developed by Purcell et al (2009), has been widely 
applied with relatively little modification, in a diversity of scenarios. The aggregate effect 
of risk variants, as identified by a ‘base’ Genome-Wide Association Study (GWAS) are 
tested on phenotype in an independent genotyped sample termed the ‘target’ data. 
Variants are obtained in approximate linkage equilibrium by performing ‘linkage-
disequilibrium (LD)-informed clumping’ on the base data using LD information from 
the target data. This allows SNP effects in the base data to be considered to be additive.  
This ‘clumped’ base GWAS is used to prioritise variants with nominal association with 
the base phenotype, by ranking variants by P-value and selecting those below some P-
value threshold – usually denoted PT. A Polygenic Risk Score, PRS, is calculated at this 
threshold PT for each individual in the target data by summing each risk allele – that is, 
alleles with P<PT in the base GWAS – weighted by its effect size in the base GWAS – 
that is, beta – for a continuous outcome - or the natural logarithm of its odds ratio - for a 
binary outcome. PRS for each individual in the target data is then regressed on the target 
phenotype, to test the prediction of the PRS. This is iterated across a number of values 
for PT in order to determine the most predictive score, as performed by PRSice 
(Euesden, Lewis & O’Reilly, 2015), which can then be used for further analysis.  
 
More broadly, the aim of understanding the genetic architecture across traits has given 




methods vary in both their requirements in terms of input and also in the interpretation 
of their results. LDpred (Vilhjalmsson et al., 2015) is developed from the assertion that 
the LD-informed clumping described above may be redundant as, given a plausible 
model for the expected distribution of causal effect sizes underlying observed GWAS 
results – such as an infinitesimal model – it is possible to shrink observed GWAS effect 
sizes, accounting for LD, in order to obtain GWAS effects to be considered independent 
and thus additive. The authors propose combining all SNPs genome-wide, weighted by 
these shrunken effect sizes, to produce a more accurate PRS, and demonstrate its 
performance in a number of real data and simulation-based scenarios, however the 
method is yet to be widely used. Secondly, LD Score Regression (LDSC) (Bulik-Sullivan 
et al., 2015), is a method that relies on a rearrangement of the formulae used for 
calculating heritability from kinship matrices (Yang, Lee, Goddard, & Visscher, 2011) to 
enable the same calculations to be performed on GWAS summary statistics in 
combination with an appropriate LD matrix. This method has an advantage over PRS in 
that it can be performed entirely using data that is typically released publically following 
the publication of a GWAS, however as it does not use individual-level data, it cannot be 
used to stratify at an individual level or predict risk, and has mainly been used to date to 
identify evidence for genetic overlap between pairs of disorders from GWAS summary 
data. Thus data availability and study aim may determine the preferred methodology for 
investigating genetic overlap. 
 
As the application of PRS across scientific questions widens, its underlying methodology 
will require modification in order to address different questions optimally. Here we 
introduce one such modification for a particular application of polygenic risk scoring – 
that of the polygenic risk score as a biomarker. In several cases within complex disease 
genetics, researchers may wish to calculate a variable for individuals’ genetic risk of a 
trait, for example Major Depressive Disorder (Psychiatric GWAS Consortium et al., 
2013). However, this score may be underpowered; both because of heterogeneity in 
MDD and because even the largest published GWAS to date on MDD are based on 
relatively small sample sizes. We propose that it is possible to leverage our knowledge 
that MDD shares a number of risk alleles with Schizophrenia (Cross-Disorder Group of 
the Psychiatric Genomics Consortium, 2013; Cross-Disorder Group of the Psychiatric 
Genomics Consortium et al., 2013; Euesden et al., 2015) – which has been explored far 




Psychiatric Genomics Consortium, 2014) – and so use this information to calculate a 
better predictor for our phenotype of interest, in this example MDD.  
 
 
Materials and Methods 
 
Method 
First we split the genome into chunks, each 5 Mb in length. For each chunk, PRS is 
calculated in the normal way, calculating scores at a large number of thresholds, 
regressing each on phenotype in the target data, and selecting the score at the best 
threshold. This approach allows the most predictive threshold for each region to be 
selected, allowing a large number of variants to be included from some regions and few 
from others. 
 
PRS at all chunks are then sorted based on their P-value for association with the target 
phenotype. Scores are calculated by adding one chunk at a time, in ascending order of P-
value and testing the predictive value of each aggregated score on the target phenotype. 
The sum of chunks that maximally predicts target phenotype is identified and used as a 
new PRS tailored for predicting across traits that share genetic architecture. This 
protocol is outlined graphically in Figure 1, and as pseudocode in supplementary 3. 
 
Due to the large multiple testing burden implicit in this analysis, we propose calculating 
an appropriate alpha threshold empirically. This is achieved by running the above 
method over a large number of iterations, permuting case-control (or quantitative trait 
phenotype data) in the target data, and using the test statistic from regression of the most 
predictive score predicting target phenotype at each iteration to generate a null test-
statistic distribution. 
 
This method – which we call PRSlice – makes use of pre-existing bioinformatics 
software developed myself, PRSice (Euesden et al., 2015), which incorporates PLINK2 
(Chang et al., 2015). We also distribute software to reproduce our analysis protocol here, 
currently available on request as PRSlice_v0.02, which is optimised to run on a Sun Grid 





We hypothesise that PRSlice will outperform PRSice in situations where genetic 
correlation between traits is modest but not complete. PRSlice enables risk loci specific 
to a single phenotype to be discarded from the final risk score, whilst regions that do 
appear to have an effect to both phenotypes are retained. This has the effect of removing 
noise from the calculation of the new risk score. By contrast, as genetic correlation tends 
towards one, we hypothesise that the improvement due to PRSlice - which discards 
regions associated with base phenotype but not target phenotype – will be weaker as 
fewer regions are associated with base phenotype but not target phenotype. 
 
Application to real data 
We apply PRSice and PRSlice to 24 real data scenarios to compare their relative 
performance in predicting one phenotype using the PRS of another. These scenarios 
correspond to all possible combinations of 4 target phenotypes – MDD in the 
RADIANT and UK biobank samples, BMI and Ever-smoked in the Northern Finland 
Birth Cohort data – and 6 base phenotypes – PGC2 Schizophrenia (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014), PGC1 MDD 
(Psychiatric GWAS Consortium et al., 2013), Global Lipids Consortium High-Density 
Lipids (HDL) and Low-Density Lipids (LDL) (Global Lipids Genetics Consortium et al., 
2013), GIANT Consortium BMI (Locke et al., 2015) and Tobacco and Genetics (TAG) 
Consortium ‘Ever Smoked’ (Thorgeirsson et al., 2013). The effect of the NFBC 
individuals, who are present in the GAINT consortium data, are removed using a 
method described elsewhere (Chapter 4, supplementary 4). We remove the effect of the 
RADIANT study from the PGC MDD GWAS by meta-analysing the other 8 PGC1-
MDD studies, as described elsewhere (Mullins et al., 2014). 
 
 Details on Target Data Sets 
The RADIANT Major Depressive Disorder (MDD) study (Lewis et al., 2010) is a case-
control data set comprising 1,624 cases and 1,588 controls. Cases are drawn from three 
studies focussing on recurrent MDD. Controls are psychiatrically screened. All cases and 





The Northern Finland Birth Cohort comprises a population cohort collected from 
individuals born in 1966 in Oulu, Northern Finland (Rantakallio, 1988). Of this sample, 
5402 individuals have been both genotyped on the Illumina Infinium 370cnvDuo array 
(Sovio et al., 2009), and phenotyped – however, completeness of phenotyping varies 
from measure to measure.  
 
The UK Biobank (UKBB) sample used here is from the first wave of genotyping 
released from this cohort, consisting of 117,310 individuals after quality control. This 
sample has been phenotyped on a wide range of measures, however under the limits of 
our current data application, we investigate depression exclusively as a target phenotype. 
Individuals were phenotyped for depression using the criteria described elsewhere (Smith 
et al., 2013). This sample was genotyped on two Affymetrix microarrays, the UK 
BiLEVE and UKB Axiom arrays. Genotype data is imputed to a combined reference 
panel of UK10K and 1000Genomes. Full data on quality control procedures are available 
(http://www.ukbiobank.ac.uk/wp-
content/uploads/2014/04/UKBiobank_genotyping_QC_documentation-web.pdf). 
Determination of Significance Threshold 
To determine the appropriate significance threshold likely resulting from a degree of 
overfitting, we first permute case-control status 100,000 times in the case of 
schizophrenia predicting MDD, calculating model fit of most predictive score at each 
permutation, allowing us to determine the appropriate alpha threshold to maintain a 
family-wise error rate of 5%. Due to the substantial running time of 100,000 
permutations, we test consistency compared to 10,000 and 1000 permutations. We apply 




We also validate our method by comparing the improvement between prediction using 
our novel method to prediction calculated when using a standard approach to Polygenic 
Risk Scoring, using simulated data. We use HAPGEN2 (Su, Marchini, & Donnelly, 2011) 
to simulate genotype data under a White Western European LD structure, using the 
HapMap3, release 2, CEU genotypes for haplotype data (International HapMap 





We simulate base and target populations under three different genetic models. In the 
first, “same-trait”, the genetic architecture in both the base and target data is the same. In 
the second, “cross-trait different effects”, case, we simulate similar but non-identical 
genetic architectures in the base and target data sets. In the third case, “cross-trait subset 
of effects”, case, we simulate only a subset of the effects present in the base data in the 
target data, reflecting only a subset of loci being pleiotropic. In each scenario, we 
simulate 100 Mb genomes for 20,000 individuals in a base data set (10,000 cases, 10,000 
controls) and 2,000 individuals in a target data set (1,000 cases, 1,000 controls) using 
SNPs from HapMap3 release 2. We simulate 15 causal SNPs in the base data with effect 
sizes – i.e. proportion of phenotype variance explained - drawn from a distribution with 
parameters fixed to ensure heritability sums to a pre-specified value. Minor allele 
frequencies for all SNPs are derived from the HapMap data. Full details of this protocol 
are outlined in supplementary 2. 
 
Phenotypes in all simulated individuals are calculated as case-control traits, under a 
liability threshold model, calculated in GCTA (Yang et al., 2011). These base and target 
data are used to run simulations. We compare the relative performance of PRSlice and 
PRSice in predicting phenotype in each case, using the framework outlined in 
supplementary 2.  
 
In all cases, we use LD Score Regression (Bulik-Sullivan et al., 2015) to calculate the 
enetic correlation - rG - between base and target samples, and test relative PRSice and 




Real Data Applications 
 
We apply PRSlice and PRSice to perform 24 real-data cross-trait analyses. The sample 
characteristics are summarised in Table 1. The results of applying the two methods to 






 Target Dataset and Phenotypes 
 RADIANT UKBB NFBC 
 MDD Depression BMI Ever Smoked 
N 3212 23,726 4594 4,699 
N cases 1624 8,074 NA 2996 
N controls 1588 15,652 NA 1703 
Mean (SD) NA NA 24.67 (4.21) NA 
 
Table 1: Sample characteristics across target cohorts 
 
We incorporate publically available data on the genetic correlation (rG) between pairs of 
disorders (Bulik-Sullivan et al., 2015), estimated from publically available summary 
statistics. This allows us to compare the performance of PRSlice versus PRSice against 
estimates of the underlying genetic architecture between pairs of disorders. We would 
expect PRSlice to perform best when the genetic correlation between traits is relatively 
low. We exclude pairs of disorders for which Bulik-Sullivan et al do not report significant 
evidence for a genetic overlap (P>0.05), and define the relative performance of the 
methods as PRSlice as –log10(PRSlice P-value) minus –log10(PRSice P-value). This 
measure circumvents concerns about the comparability of different pairs of phenotypes, 
as the influence of power on differences between scenarios will be mitigated. Absolute rG 
is associated in direction, but non-significantly, with reduced PRSlice power compared to 



























































































































































































































































































































































































































































































































































































































































































































































































3.2 Permutation Analyses 
The empirical alpha threshold appropriate for controlling the family-wise error rate at 
5% is broadly consistent across simulations (Table 3). Based on these results, we propose 
that an alpha threshold of P<10-12 is appropriate. 
 
Permutation scenario Number of Permutations Empirical Alpha 


























In each of our 1000 simulations of same effects in base and target trait, and 1000 
simulations of different effects in base and target trait, we calculate the statistical power 
as the proportion of simulations in which the P-value for PRSice exceeds the calculated 
alpha empirical threshold for PRSice in that simulated data set, and the proportion of 
simulations in which the P-value for PRSlice exceeds the calculated alpha empirical 
threshold for PRSlice in that data set. This provides an indication of the statistical power 
of PRSlice compared to the standard PRS approach of PRSice.  
 
In the first, “cross-trait same effects” case, we found that, using PRSice, power was 
higher for cross trait (Table 4, χ2, P<10-16), and when using PRSlice, power was also 
slightly higher for same trait (Table 4, χ2 P-value=2.6x10-3).  
 
We consider correctly identified genetic overlap as an outcome and use logistic models to 
identify factors predicting this from our simulation results. In a multivariate model, both 
PRSlice vs PRSice (coefficient = 1.17, P=8.2x10-16) and Same trait vs Cross-trait 




negative interaction effect between these two predictors (coefficient = -0.57, P=0.079) 
suggests that the outperformance of PRSlice vs PRSice is larger in cross-trait scenarios.  
 
In the second, “cross-trait different effects”, case, in which the simulated target 
phenotype, under the cross trait case is less genetically related to the base phenotype, we 
again find PRSlice outperforms PRSice in the cross trait scenario (χ2 P-value <10-16), 
and again find more modest evidence for PRSlice outperforming PRSice in the same-trait 
scenario (χ2 P-value = 5.1x10-3). In a multivariate model, as described above, we find 
PRSlice and Same-phenotype scenarios are significant predictors of higher power, 
however we also find substantial evidence for a PRSlice*Cross-trait interaction term (β 
=1.39, P = 3.2x10-6) indicating PRSlice gives higher power in cross-phenotype scenarios. 
 





PRSice Cross Trait Cross-trait 
same effects 
83.7% 
 Same Trait 95.9% 
PRSlice Cross Trait 95.0% 
 Same Trait 98.0% 




Same Trait 95.7% 
PRSlice Cross Trait 92.2% 
Same Trait 97.9% 
 
Table 4: Relative power of PRSice and PRSlice under different simulated genetic 
architectures, when modelling cross-trait scenarios using different genetic effects 
 
 
Incorporating rG Estimates into Simulation Results 
 
Due to our simulation protocol, the genetic correlation between base and target 
phenotype, in the correlated trait scenarios, will not be fixed across different simulated 
data sets, and will thus vary. We use LDSC to estimate the actual genetic correlation 
between base and target in each of our 2000 simulated scenarios. In some cases, due to 
the relatively small sample sizes of our target data sets, the estimation was underpowered, 




demonstrated that in cross-trait only simulations, PRSlice predicted a substantial increase 
in power (coefficient = 1.85, P=1.21x10-10) when adjusting for rG. However, PRSlice had 
no effect vs PRSice in same-trait cases when adjusting for rG (coefficient = 0.65, P=0.12).  
 
When investigating the “cross-trait different effects” subset of simulation results, with a 
lower genetic overlap between base and target data in the cross-phenotype case, we find 
consistent results. PRSlice predicted a substantial increase in power (coefficient = 2.08, 
P<10-16) when adjusting for heritability, with evidence for an interaction between ‘same 
trait’ and PRSlice predicting lower power (coefficient = -1.31, P=6.0x10-3) when 
adjusting for heritability, indicating that PRSlice has a greater improvement in power in 
cross-phenotype scenarios. These results are summarised below in Figure 4).  
 
Aggregating across all simulation results, we find base-target rG predicts improved power 
(coefficient = 2.12, P<10-16) as would be expected, and that when adjusting for rG 
PRSlice also predicts increased power versus PRSice (coefficient = 1.74, P<10-16). 
Furthermore, we find evidence for an interaction effect (coefficient = -0.65, P = 0.015) 
between using PRSlice and rG predicting power, indicating that PRSlice may outperform 





Polygenic Risk Scoring has a number of applications across medical and population 
genetics – these include, but are not limited to, identifying evidence for a polygenic signal 
in a GWAS (International Schizophrenia Consortium et al., 2009), identifying evidence 
for a shared genetic component between pairs of phenotypes (Power et al., 2015; Power 
et al., 2014) and as a biomarker to identify the effects of genetic risk within downstream 
modelling (Mullins et al., 2016; Peyrot et al., 2014). It is to this latter application that our 
method presented here is particularly tailored to. We have presented a novel method to 
improve the predictive accuracy of PRS when examining cross-phenotype scenarios.  
 
Our simulation framework demonstrates that PRSlice may outperform traditional 
polygenic risk scoring methods under scenarios of moderate but significant genetic 




allelic heterogeneity, or the preferential agglomeration of causal variants within particular 
regions, we are thus able to improve the predictive power of these scores. It is likely that 
this application will have a growing utility in the future as the asymmetry between 
phenotypes that have been well-studied by large genotyping efforts – such as 
schizophrenia or rheumatoid arthritis – and those that researchers may wish to predict in 
small cohorts, such as treatment response (Coleman et al., 2016), widens. 
 
Our new method suffers from a number of limitations. Firstly, it relies on a particular 
contingency – a well-powered base GWAS with a modest genetic correlation to the 
target trait of interest; this is not immediately identifiable in many cases, and requires 
either pre-existing evidence from the literature, or exploratory analyses via methods such 
as LD Score Regression to establish that the use of PRSlice is justified. Secondly, 
although we have provided a proposed significance threshold of α=10-12, the 
interpretation of scores generated using PRSlice is not necessarily straightforward, and 





Here we present a novel method for calculating PRS, optimised for a specific scenario in 
which PRS is being used as a biomarker, calculated from a GWAS for a trait with a 
moderate genetic correlation with the target phenotype of interest. This method, PRSlice, 
is publically available as software, and here we present its application to real data, provide 
an appropriate significance threshold, and demonstrate its value using simulated data. We 
propose that PRSlice will have greater utility in the future as the scenario for which it is 












































Figure 1: Protocol used for PRSlice. The genome is split into 5Mb chunks (step 2), and 
PRS is applied at each 5Mb chunk using the standard approach to obtain best threshold 
and the P-value with which PRS predicts phenotype at this chunk (step 3). Chunks are 
ranked by the P-value with which they predict target phenotype (step 4) and score at best 
threshold is summed cumulatively – the prediction of this cumulative score is tested with 
the addition of each chunk (step 5). The optimum combination of chunks is obtained 






















































Figure 2: Real data application. a) –log10 P-values for PRSice (upper panel) and PRSlice 
(lower panel). Effects in the same direction in base and target are positive values on the 
y-axis, effects in the opposite direction are negative values on the y-axis. Significance 
thresholds for PRSice (α = 10-3) and PRSlice (α = 10-12) are marked in red. b) Relative 
performance of PRSlice over PRSice (measured as –log10 P-value for PRSlice minus -log10 
P-value for PRSice) plotted against the reported genetic correlation between pairs of 
phenotypes as reported in Bulik-Sullivan et al (2015). Pairs of disorders that the authors 










P =  4.48e−33 
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PRSlice: SCZ predicting MDD
P =  3.12e−26 
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Figure 3: Selected region plots from real data application – SCZ predicting MDD in the 
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Figure 4: Performance (i.e. power) of PRSice and PRSlice in simulated data, under two 
scenarios - same phenotype in base and target, and cross phenotype in base and target. 
We present results using “cross-trait same effects” with the same five chunks causal in 
both cases (a) and “cross-trait different effects” with only 2/5 chunks causal in the cross-
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Supplementary 1: Generation of Data for Simulation Framework 
 
We use the following simulation procedure in order to test the performance of PRSice 
versus PRSlice in situations with known genetic architecture. 100Mb genomes are 
simulated using HapMap3 reference data to simulate LD in HAPGEN2. These 100Mb 
genomes can be considered comprised of 20 5Mb ‘chunks’. 
 
The effect sizes of 15 causal variants are chosen by drawing from a distribution 
generated using the formula below with parameters fixed to ensure 15 causal variants will 
explain a known total of variance explained, i.e. heritability. These 15 effect sizes are split 
into quintiles (i.e. five groups of three) based on effect size - very low, low, intermediate, 
high and very high - each group of three assigned to one of five 5Mb chunks randomly 
selected as being causal. The remaining 75Mb of the simulated genomes do not contain 
causal variants. Simulated phenotypes are derived from these simulated genomes using 
GCTA. 
 
We test the performance of our PRS methods under two simulated architectures. In the 
first architecture, effect sizes are the same for a given causal SNP in both base and target 
data; this simulates the effect of using a phenotype to predict the same phenotype in an 
independent sample. In the second architecture, the same 5 chunks are selected as 
containing the same causal variants in the base and target data, but the assignment of 
effect sizes to these SNPs - using the above categories very low, low, intermediate, 
high and very high - is randomised between base and target. This second architecture 
simulates the effect of different but correlated traits in the base and target data that show 
a degree of pleiotropy. 
 
We simulate 20,000 individuals in the base data (10,000 cases, 10,000 controls) and 2,000 
individuals in the target data (1,000 cases and 1,000 controls) for each of these two 
scenarios, fixing heritability at 15%, using the CEU European reference data from 







βi is the effect of SNP i on phenotype. We fix a known number of SNPs, n, to have an 
effect on phenotype, defined as ci = 1. These effects are defined as: 
 
 𝛽! =  0           𝑖𝑓 𝑐! = 0𝑓 𝑖,𝑛  𝑖𝑓 𝑐! = 1 
 
and 
𝑓 𝑖,𝑛 =  1𝐴 + 𝑖!1𝐴 + 𝑖!!!!!!!  
 
Where 
A = 0.6 
B = 0.8 




In the “cross-trait, different effects” subset of simulations, we simulate cross-trait data in 
order to reduce the genetic overlap between base and target. This may be less realistic, 
but the exaggerated non-overlap is intended to explore the performance of PRSlice when 
genetic overlap is low.  
 
Base data is simulated with 15 causal SNPs, split evenly across 5 causal chunks, as 
outlined above. Of the 5 causal chunks in the base data, two chunks are selected at 
random to be causal in the target data. 6 effect sizes are selected from the effects in the 
base data to be assigned to these chunks. Thus, whilst trait heritability in the base data is 
15%, the heritability in the cross-phenotype target data will vary and may be substantially 
lower. We then investigate the relative performance of PRSice and PRSlice in same-trait 




Supplementary 2: Comparison between PRSice and PRSlice 
 
 
We compare the relative performance of PRSice and PRSlice in our simulated data, 
generated in step 1, using the following protocol. Data is generated, the PRSice and 
PRSlice used to identify the most significant predictor – in the case of PRSice the most 
significant P-value threshold PT, in the case of PRSlice the optimum thresholding across 
chunks and optimum combination of chunks – for a given data set. We then permute 
phenotype in this data set, and run PRSice, and PRSlice, 1000 times each on these 
permuted data sets, in order to obtain a distribution of null P-values, 1000 each for 
PRSice and PRSlice respectively. The observed P-values for PRSice and PRSlice are then 
tested against their respective null-distributions in order to obtain an empirical PRSice P-
value and PRSlice P-value for a given simulation data set. Finally we repeat this protocol 
1000 times in order to obtain 1000 simulation-derived empirical P-values for PRSice and 






















Supplementary 3: Pseudocode Illustration of PRSlice Algorithm 
  
# Step 1 
Take GWAS with SNPs, genomic position of SNPs, reference 
allele and P-value and OR for association with base trait – Y1 
  
# Step 2 
Divide genome into n chunks 
  
# Step 3 
for i in 1:n 
  
  ##Step 3.1 Run standard PRS protocol on chunk i 
  for j in P-value threshold values (PT) – e.g. sequence from 
0-0.5 in increments of 0.001 
    Calculate PRSi,j for P < j for all individuals in target 
data 
    Build model for PRSi,j predicting target data phenotype Y2, 
glm1, Y2 ~ PRSi,j 
    Calculate P-value for PRSi,j predicting Y2 in glm1 
  Done 
  
  ##Step 3.2 Determine a number of variables   
  PT[i] -  The best threshold for predicting phenotype using 
only SNPs in chunk i 
  PvalPRS[i] – The P-value for SNPs in chunk i below PT[i] 
predicting Y2 
  PRSi – a vector of PRS values (i.e. PRSi,PT[i]) for every 
individual in the target data  
Done 
  
We now have minimum P value - PvalPRS[i] at optimum PT for 
every chunk i 
  
# Step 4 
Rank chunks by ascending order of PvalPRS and build an m x n 
matrix – where there are m individuals in the target data, and 
n chunks – PrsMat. Each column of PrsMat is PRS for every 
individual in the target data at a different chunk, columns 
are ordered by increasing values for PvalPRS 
  
# Step 5 
Produce a second m x n matrix CumPrsMat. Each column is a 
cumulative sum of all previous columns, with the first column 
being unchanged from PrsMat 
  
# Step 6 
for k in 1:n 
  Test cumulative score – CumPrsMat[,k] – predicting Y2 
  Store P-value from this model 
Done 
  
Find maximum value for k – this is the optimum combination of 




Chapter 7: Discussion 
 
Epidemiological relationships, that is to say patterns of overlap or non-overlap of 
multiple phenotypes within individuals at rates above - or below – expectation based on 
their individual population distributions and prevalences, form the heart of this thesis. 
These relationships may frequently provide routes to understanding aetiological overlap 
between phenotypes, and by extension a route to understanding the pathophysiology of 
previously poorly understood disorders. This paradigm has a number of important steps. 
Firstly, one must verify that an observed epidemiological relationship is not confounded, 
and therefore not merely a spurious association. Secondly, one must draw inferences on 
the direction of causality between two epidemiologically overlapping phenotypes. Once 
these two have been established, and a true shared pathway between comorbid 
phenotypes seems likely, it is possible to leverage biological information to identify 
candidates for this pathway. Finally, when the biological mechanism behind a disorder 
has been elucidated, drug targets can be identified and novel treatment and prophylaxis 
investigated. 
 
In this thesis, we have applied the above paradigm to the study of the overlap between 
the psychiatric and autoimmune disorders. We have used three data sources to 
investigate the presence and direction of comorbidity – case-control genotype data, 
survey and genotype data from a population-based birth cohort, and fine-scale clinical 
data from an hospital-based outpatient cohort. We have used existing statistical genetics 
techniques to investigate the evidence for overlapping pathways between pairs of 
disorders, and have developed a novel method to improve this approach. The 
conclusions of these findings will be discussed below, alongside a review of future 





Evidence for an Epidemiological Link between Psychiatric and 
Autoimmune Disorders 
 
We summarise the contents of three chapters below, in each case evaluating the strength 
of evidence for co-morbidity between psychiatric disorders – schizophrenia and 
depression – with autoimmune disorders, focussing on rheumatoid arthritis. Following 
this we discuss models for comorbidity consistent with our findings, and the implications 
of these models. Schizophrenia is arguably the best understood of the psychiatric 
disorders, from a genetic perspective, partly due to its higher heritability, partly due to 
the relative ease of phenotyping cases, and partly due to the absence of a need to screen 
controls, because schizophrenia has relatively low prevalence. These factors allow large 
case control cohorts to be collected, in turn generating more statistical power. 
Depression, by contrast, has been associated with the fewest genetic variants to date, 
however is the leading cause of disability worldwide. Thus we focus on these two very 
different psychiatric disorders in order to identify commonalities that might be 
extrapolated across the other psychiatric disorders. Rheumatoid arthritis is studied in 
particular as it is genetically well understood – associated with over 100 risk loci (Okada 
et al., 2014) – and clinically defined through a number of symptom dimensions. The 
poor prognosis of unmedicated rheumatoid arthritis (Fisher & Scott, 2001) also leads to 
increased healthcare utilisation, making the collection of detailed longitudinal data 








We report data on the lack of evidence for a genetic overlap between schizophrenia and 
rheumatoid arthritis (Euesden, Breen, et al., 2015), (Chapter 3), however over the course 
of the last five years, epidemiological literature on the relationship between schizophrenia 
and the autoimmune disorders has grown substantially. In our meta-analysis of studies 
published prior to November 2013, we find evidence for an epidemiological overlap 
between schizophrenia and rheumatoid arthritis. Furthermore, the disparate ages at onset 
between these two phenotypes suggest the possibility of a temporal relationship, which is 
often considered a precursor to establishing evidence for a causal relationship. Authors 
consistently find that rheumatoid arthritis is less common amongst schizophrenia 
patients than would be expected based on its prevalence – often termed an inverse 
relationship. Since the publication of our meta-analysis, Sellgren et al have performed 
analyses with improved granularity able to use time-to-event models in order to make 
stronger inferences regarding the direction of causation between the two phenotypes 
(Sellgren, Frisell, Lichtenstein, Landen, & Askling, 2014). The authors find that 
schizophrenia onset reduces subsequent onset of rheumatoid arthritis with a Hazard 
Ratio of 0.69, (95% CI = 0.59-0.80) consistent with our results from meta-analysis. This 
study has the considerable benefit of being performed on a population-level national 
registry population (n = 5,981,124), collected in Sweden between 1932 and 1989, and 
defining both schizophrenia and rheumatoid arthritis using hospital contacts. Thus there 
is strong evidence for a temporal relationship between schizophrenia and rheumatoid 
arthritis, both from our work and subsequent analyses. 
 
Schizophrenia is the best-understood psychiatric disorder from a genetic perspective, 




variance in schizophrenia risk on the liability scale, and a Polygenic Risk Score for 
schizophrenia explains 18.4% of variance in schizophrenia at the optimum threshold 
tested by the authors (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014). Therefore it is useful to consider the evidence for genetic factors 
responsible for the relationship between schizophrenia and rheumatoid arthritis. In our 
investigation of evidence for schizophrenia polygenic risk score (PRS) predicting 
rheumatoid arthritis case status, we use the PGC1 schizophrenia GWAS plus a 
subsample of Swedish genotypes (Ripke et al., 2013) as a base GWAS, and a target 
sample comprising rheumatoid arthritis cases from the WTCCC1 sample (Wellcome 
Trust Case Control Consortium, 2007) and controls from the RADIANT MDD study 
(Lewis et al., 2010), following rigorous quality control. This selection of controls is 
necessary, as the WTCCC1 controls are incorporated into almost every publically 
available GWAS data set, with the exception of PGC1-MDD. We find limited evidence 
for a significant relationship between schizophrenia and rheumatoid arthritis, with a 
nominally positive regression coefficient – which would indicate schizophrenia genetic risk 
increasing risk of rheumatoid arthritis, contrary to the epidemiological literature.  
 
Since the publication of our study, there have been three relevant pieces of literature 
investigating the same question. The first (Stringer, Kahn, de Witte, Ophoff, & Derks, 
2014) finds a strong effect of schizophrenia predicting RA, using very similar data to our 
study – the smaller and thus lower-powered PGC1 schizophrenia sample (Schizophrenia 
Psychiatric Genome-Wide Association Study, 2011) with the WTCCC1 controls 
removed as a base data set and WTCCC1 RA cases and controls as a target data set. The 
authors findings that schizophrenia PRS explains over 2% of variance in rheumatoid 
arthritis status, which is surprisingly large, as the proportion of variance in schizophrenia 




7% at the most predictive threshold tested (Schizophrenia Psychiatric Genome-Wide 
Association Study Consortium, 2011). A possible concern is that sample overlap between 
base and target samples may not have been fully accounted for, leading to an over-
estimation of the genetic overlap between these two traits. Alternatively, the results of 
this PRS analysis would indicate that the effects of environmental risk factors  - such as 
the effect of medication - in the negative comorbidity between rheumatoid arthritis and 
schizophrenia would be even stronger than discussed in chapter 3, in order to mitigate 
the effect of genetic risk factors acting in the opposite direction. Thus our conclusions 
on the effects of environmental risk factors being responsible for the negative 
comorbidity between rheumatoid arthritis and schizophrenia observed in cohort studies 
is consistent with the results of Stringer et al. 
 
Secondly, a study by Lee et al sought to validate a novel method to identify biological 
pathways responsible for phenotypes by investigating immune pathways related to 
schizophrenia (Lee et al., 2015). The authors build on the GREML method  - which 
partitions heritability into the component explained by common genetic variation and 
error – in order to partition heritability into a priori defined biological pathways based on 
their associated genomic regions. This method bears similarity to MultiBLUP (Speed & 
Balding, 2014), which performs a similar calculation in a biologically agnostic framework, 
dividing the genome by physical distance. Lee et al test a set of genomic regions 
annotated to CD4+ memory T-cells based on an a priori model of the genetic aetiology 
of rheumatoid arthritis, yielding 87,651 SNPs; the authors find that genetic variation 
across coding, regulatory, DNase I hypersensitivity and intronic regions predicts 
heritability in schizophrenia and rheumatoid arthritis in inverse directions. The method 
developed in this paper is of great use in dissecting the biological pathways involved in 




bias and appropriately correcting for the implicit number of multiple comparisons 
introduced by selecting a candidate pathway is challenging.  It is unlikely that the stated 
effect size of the CD4 pathway on schizophrenia and rheumatoid arthritis could explain 
the strength of the epidemiological relationship seen, with a genetic correlation (rg) of -
0.046 (SE = 0.026) corresponding to a coheritability of -0.01 (P=0.036). Whilst this 
effect is non-zero, it is still not comparable to the epidemiological effect observed 
between these two disorders. Adding additional pathways to attempt to explain more of 
the epidemiological relationship between schizophrenia and rheumatoid arthritis would 
require increased multiple testing as more pathways with weaker priors would need to be 
added. 
 
The third study of note validates our previous conclusions. Pouget et al perform a 
complementary analysis to our own, using GWAS data from a number of autoimmune 
disorders to predict schizophrenia within the PGC2-SCZ genotype data, using a 
polygenic risk score framework. The authors find a number of interesting relationships 
between autoimmune disorders and schizophrenia, validating several epidemiological 
relationships, such as a significant overlap between psoriasis and schizophrenia. When 
investigating schizophrenia and RA, however, the authors do not find evidence for a 
genetic overlap, consistent with our own findings. These results were presented as part of 
a conference symposium and are not currently available in print (Pouget, 2015). 
 
The evidence for a genetic component to the epidemiological relationship between 
schizophrenia and rheumatoid arthritis is conflicted, with current literature finding a 
positive genetic correlation (Stringer et al., 2014), a negative genetic correlation in 
specific genomic regions (Lee et al., 2015) and no evidence for genetic correlation 




disentangle, we did not find evidence in support of a genetic overlap. A number of 
explanations for this relationship have been proposed, and as non-genetic models they 
fall outside the scope of this thesis but will be discussed briefly. These include a 
protective effect of antipsychotic medication on rheumatoid arthritis. This theory is 
important, as anti-inflammatory medication such as tociluzimab – a TNF-α blocker – 
has already been trialled as an antipsychotic (B. J. Miller, Dias, Lemos, & Buckley, 2016). 
Evidence for the reverse – that anti-inflammatory medication may have an impact on 
psychiatric symptoms - is limited. There is evidence, however, that the burden of efficacy 
for an novel, repositioned, drug may be lower as it may have supra-additive effects when 
used within a combinatorial framework – for example, Choy et al find that aggressive 
combinatorial therapy is more effective than monotherapy in the treatment of 
rheumatoid arthritis (Choy et al., 2008). This suggests that the identification of novel 
pathways and drug targets within the autoimmune disorders may supplement and 
enhance existing therapies. Thus the value of verifying a non-genetic explanation for the 
relationship between pairs of disorders is still of great importance to the development of 
novel therapeutic strategies. 
Depression 
 
We investigate the epidemiological overlap between depression and autoimmune 
disorders in two very different cohorts. In a population-based cohort, the National Child 
Development Study, we use self-report data on depression to classify cases and controls, 
and investigate the prevalence of any autoimmune disorder – again based on self-report – 
amongst either group. We find an increased prevalence of any autoimmune disorder 
amongst depression cases, however individually low prevalences for each disorder 




therefore provides good evidence for an epidemiological link between the two families of 
disorders that merits investigation into the direction of causality. 
 
Our second investigation into the overlap between depression and the autoimmune 
disorders focuses on rheumatoid arthritis (RA) within the CARDERA study, a cohort of 
early RA patients. Rather than looking at the impact of case status alone on mental 
health, we use a number of metrics for RA symptom severity, and use a dimensional 
mental health scale – the MCS. This allows finer resolution into the impact of symptom 
severity of mental health and vice versa. We supplement findings on a population level 
by finding that increased RA symptom severity is associated with poorer mental health. 
In the case of both autoimmune disorder case status and autoimmune disorder symptom 
severity, we find evidence that these factors can increase risk of depression, but also that 
depression and low mood can increase risk of autoimmune case status, and worse 
prognosis and disease progression amongst RA cases. 
 
Based on these findings, we propose considering comorbidity as driven by some shared 
risk factor as the most parsimonious solution. There is a wealth of literature arguing that 
a number of inflammatory markers are associated with Major Depressive Disorder 
patients relative to controls, including inflammatory cytokines (Maes, 1999; A. H. Miller, 
Maletic, & Raison, 2009). This parallels similar findings across many autoimmune 
disorders, including rheumatoid arthritis (Lubberts & van den Berg, 2001), Crohn’s 
disease (Strober, Zhang, Kitani, Fuss, & Fichtner-Feigl, 2010) and Systemic Lupus 
Erythromitosis (Yap & Lai, 2013), amongst others. Furthermore, many other risk factors 
for depression are also associated with systemic inflammation, such as stressful life 





Stressful life events are a well-established risk factor for Major Depressive Disorder. 
Literature on this link classifies stressful life events (SLEs) into dependant and 
independent, based on their cause. Dependent SLEs are thought to be driven partly by a 
patient’s own behaviour, such as divorce or a change of job. Independent SLEs, by 
contrast, are defined by being caused by factors outside of a patient’s control, such as 
being the victim of violent crime. This distinction is relevant when considering the 
evidence for a causal link between depression and the autoimmune disorders, almost all 
of which represent chronic and severe sources of impairment, negatively affecting factors 
such as quality of life, mobility and diet.  
 
Mullins et al find that genetic risk of depression predicts number of dependent SLEs 
across depression cases and controls, but not independent SLEs (Mullins et al., 2016). 
Considering autoimmune disorders as a form of independent stressful life event - 
occurring independently of genetic risk of depression - aids the interpretation of our 
finding that depression genetic risk and autoimmune disorder status independently affect 
risk of depression in a population cohort. 
 
Understanding the epidemiological relationships between phenotypes occurs at the level 
of the individual, whereas a study of the relationship between aetiological factors, such as 
inflammation levels and stressful life events, occurs at a molecular level. Here we term 
these to be more distal and more proximal respectively. Our findings above give merit to 
the investigation of an abnormal inflammatory profile as a causative agent in the 
epidemiological overlap between depression and the autoimmune disorders, however 
further work is required, investigating more proximal measures, in order to draw more 
definitive conclusions. Polygenic Risk Scores can be calculated using proximal 




immune system (Roederer et al., 2015), CRP levels (Dehghan et al., 2011) and personality 
traits (de Moor et al., 2012; Genetics of Personality Consortium et al., 2015; van den 
Berg et al., 2014); as data on these more proximal phenotypes becomes publically 
available, it will be possible to investigate evidence for a shared inflammatory profile 
between depression and autoimmune disorders at a population cohort level, and with 
autoimmune disorder symptom severity within clinical samples., where deeper 
phenotyping is possible  
 
Leveraging Genetic Risk to Understand Aetiology, Prognosis and 
Treatment 
 
Above we have presented the results of analyses that identify future research areas in the 
study of the psychiatric and autoimmune disorders. Of particular merit may be the 
antipsychotic effect of anti-inflammatory medication and the effect of systemic 
inflammation as a shared risk factor for a number of adverse outcomes later in life. 
Below we summarise the importance of using proximal phenotypes in the study of 
disease – in terms of aetiology, prognosis and treatment – and summarise ways in which 
genetic data can be used to determine a more useful proximal phenotype. 
Proximal Phenotypes 
 
A proximal phenotype, or endophenotype, biomarker, can be defined as a measurable 
biological trait, often requiring the use of a measuring instrument to detect, which is 
associated with disease risk without being defined itself as a disease. Examples of this 




or a dimensional measure of neuroticism as a proximal phenotype for depression. We 
use the term proximal phenotype rather than endophenotype or biomarker, as the terms 
‘more proximal’ and ‘more distal’ allow a greater appreciation for the dimensional nature 
of these traits and their relative importances, whereas biomarker and endophenotype 
imply that traits are either pathological or not - the reality is likely substantially more 
nuanced. This can be illustrated in the case of hypertension. Hypertension can be defined 
as resting systolic blood pressure above 140mm Hg, resting diastolic blood pressure 
above 90mm Hg, or both (Poulter, Prabhakaran, & Caulfield, 2015). This is a relatively 
arbitrary threshold, based on a large body of clinical evidence, however it may be 
inappropriate across different ethnicities and lifestyles. Hypertension is thus classified as 
a disease, not an endophenotype, however higher systolic blood pressure is associated in 
turn with a higher risk of chronic kidney disease (Krzesinski & Cohen, 2007) – i.e. it is an 
endophenotype or biomarker. Thus we believe it is more useful to describe this 
relationship as hypertension being a more proximal phenotype than chronic kidney 
disease, with systolic blood pressure being more proximal, biological factors affecting 
blood pressure - such as blood lipid levels - as yet more proximal, and the genetic factors 
affecting lipid levels as more proximal still. 
 
More proximal phenotypes may be more useful than more distal phenotypes in the study 
of aetiology, prognosis and treatment of disease; regardless it is highly likely that they 
have been understudied compared to more distal phenotypes and thus merit at least 
equal consideration. Many of the most proximal phenotypes are continuous measures, 
providing increased resolution to make clinical judgements between patients. Secondly, a 
single more distal phenotype is likely to be influenced in a multifactorial way by multiple 
more proximal causes. This necessarily suggests that very similar clinical presentations 




inform improved selection of treatment regimes – this is ‘personalised medicine’. A 
substantial level of clinical heterogeneity has long been believed exist within multiple 
sclerosis (Lassmann, Bruck, & Lucchinetti, 2001), however only recently, incorporating 
genetic data, have these assertions been vindicated (Brynedal et al., 2007), and further 
study may inform the implementation of personalised treatment regimes. 
Genetic Proximal Phenotypes 
 
Under the biometric model (Galton, 1877), arguably all measurable biological traits have 
a multifactorial genetic origin – this is likely to be the case in particular for normally 
distributed traits as the central limit theorem suggests an aggregate effect across Bernoulli 
distributed genotypes. Individual alleles of small effect may thus be responsible for inter-
individual variation in more proximal phenotypes – such as triglyceride level and 
neuroticism – as well as the intensively studied disease phenotypes, and we propose that 
understanding the genetic architecture of these more proximal traits would be of 
particular merit. The simplest way to achieve this would be to perform genome-wide 
association studies (GWAS) on each more proximal phenotype individually, however the 
diversity of more proximal phenotypes makes this prohibitively expensive and 
impractical. Below, we discuss ways to leverage genetic information and methodological 
novelty in order to construct better proxies for proximal phenotype-based risk of disease. 
 
Pleiotropy – a scenario in which a given allele affects the expected values of more than 
one trait - is almost ubiquitous across human genetics. This is due to a number of factors 
including the way the concept of a trait is itself is defined. Medical disorders have 
traditionally been defined based on their phenomenology rather than their underlying 




can be seen in the distinction between schizophrenia and bipolar disorder, which was 
first proposed by Kraepelin (Kraepelin, 1913); prior to this the two phenotypes were 
classified together. This dichotomy illustrates how a multifactorial phenotype is by 
definition a combination of proximal causes, and so overlap in risk factors - and thus 
pleiotropy and comorbidity - is inevitable between diseases. It is also possible that 
ubiquitous pleiotropy is a fundamental by product of evolution by natural selection; 
proteins perform multiple roles within an organism (Gould & Lewontin, 1979) and the 
catabolites – the downstream chemical products - of biological pathways frequently feed 
into multiple pathways in turn (Krebs, 1938; Krebs & Eggleston, 1938; Krebs, Salvin, & 
Johnson, 1938). Thus a number of genetic methods can exploit the pleiotropy between 
two disorders – something often manifested in comorbidity – in order to create a black-
box metric for the aggregate risk conferred across more proximal but unmeasured – 
indeed unidentified – proximal phenotypes. 
 
Polygenic Risk Scores as Proximal Phenotypes 
 
As introduced above, the biometric model predicts that normally distributed traits will be 
influenced by many alleles of individually small effect. Some proportion of these can be 
identified at genome-wide significance by an adequately powered GWAS. Authors have 
previously found that a further number of risk-associated alleles may be included in a risk 
model by relaxing the genome-wide significance threshold from the typically used α = 
5x10-8 to include variants with nominal association (International Schizophrenia 
Consortium et al., 2009). The weighted sum of thus identified risk alleles an individual 
carries is termed a Polygenic Risk Score (PRS), and is used extensively in this thesis as 





In discussing the idea of more proximal phenotypes, we consider that diseases are human 
constructs, representing the aggregate deviation from normality of one or several more 
proximal phenotypes. This assertion has direct relevance for GWAS and thus the 
construction of PRS and can be demonstrated by techniques such as pathway analysis, 
which cluster the significant regions from GWAS based on annotation to more proximal 
biological pathways. In the psychiatric disorders, where aetiology is still a source of active 
debate, this approach has proved a useful hypothesis-generating method – Breen et al 
(Network Pathway Analysis Subgroup of Psychiatric Genomics Consortium, 2015) 
cluster significant regions from schizophrenia, finding enrichment for variants involved 
in histone methylation, immune and neuronal/neurotrophic pathways and the synapse. 
Thus an appreciation that genetic risk of a more distal disease phenotype can be seen as 
an aggregate effect of polymorphism affecting a number of more proximal phenotypes 
informs the construction of more accurate polygenic risk scores. 
 
Our first improvement to PRS (chapter 2) (Euesden, Lewis, & O'Reilly, 2015) indirectly 
exploits this fact. By optimising the computation of PRS through the development of the 
PRSice software program, we enable users to calculate the most predictive threshold at 
which to calculate PRS for a given pair of disorders, and for a given level of statistical 
power as determined by factors such as sample size and quality of phenotyping. We 
validate the increased predictive accuracy seen using PRSice, calculating PRS for 
depression cases and controls using GWAS data for schizophrenia, ever smoked 
cigarettes, and number of cigarettes per day. We find that schizophrenia genetic risk 
significantly predicts depression status, in line with previous findings (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013), and we report for the first time 




relevant to the notion of proximal phenotypes, as it suggests that some underlying 
biological pathways are influencing depression, tobacco use and schizophrenia. 
Furthermore, the exact proteins and genes involved in the pathway do not need to be 
known in order to perform useful prediction of phenotypes, and further downstream 
analyses such as stratification of cases. It is adequate and useful to consider the shared 
genetic risk between disease phenotypes as a means to calculate PRS and thus use this 
score as a proximal phenotype to measure risk of related traits. 
 
The goal of these cross-trait methods is to exploit the existence of shared biological 
proximal phenotypes between disorders in order to predict genetic risk of a trait more 
accurately. Implicit in this is the idea that the shared genetic component between two 
genetically overlapping disorders will be at least nominally associated in a well powered 
GWAS of either, however will not necessarily contribute to the most significant 
associations in either GWAS. For this reason we develop a second method, PRSlice, 
which leverages the existence of a relatively small number of well powered GWASs for 
some traits, and a number of other disorders which overlap with these, in order to 
develop a novel biomarker for traits that have not yet been intensively studied by GWAS 
(chapter 6). By applying this approach to simulated data, where the genetic architecture 
can be reliably controlled, we find that PRSlice appears to outperform PRSice in 
scenarios where genetic correlation, rG between base and target is modest but non-zero. 
We therefore propose that this may be used in scenarios predicting a target phenotype 









A number of future projects arise from work presented within this thesis. Within the 
study of schizophrenia and rheumatoid arthritis, the source of the epidemiological 
relationship has not yet been identified; verifying whether medication plays a role in this 
relationship will be important. Furthermore, it is possible that phenotypic and thus 
genetic heterogeneity within either RA or schizophrenia is masking a true effect of 
‘negative pleiotropy’, and in this case deeper phenotyping on base (GWAS) and target 
samples will be instructive, as will incorporating methods explicitly designed to identify 
latent heterogeneity such as BUHMBOX (Han et al., 2016). 
 
The hypothesis that inflammatory processes play a role in the overlap between 
depression and the autoimmune disorders may be elucidated further by using genetic risk 
scores that explicitly measure these proximal phenotypes. This is not possible in our 
analysis of the NCDS, as these individuals are included as controls in almost all publically 
available GWASs, with the notable exception of the PGC1-MDD GWAS, which we use 
here but is likely underpowered to identify any shared genetic component across 
depression and correlated phenotypes. We propose using other GWAS (base) 
phenotypes, such as CRP level – a proximal phenotype of inflammatory activity – in 
order to dissect the epidemiological relationship we observe further. 
 
Alongside future directions in epidemiology, we also note the merit of investigating the 
effect of therapies for depression amongst RA patients. Cognitive Behavioural Therapy 
(CBT) has already been shown to improve the prognosis of RA patients over time 




antidepressants, and their relative contribution to different components of poor mental 
health and different components of RA disease severity would be instructive in the 
management of this damaging and co-occurring phenotype. Furthermore, data on 
genetic risk may be incorporated in order to identify latent heterogeneity across patients. 
 
Finally, there have been a range of novel methods investigating improvements to the 
calculation of genetic risk over the course of the last three years, and there are a range of 
future directions depending on the required scientific question and the available data. 
One such method we propose is an alternative to PRSlice, in which the genome is 
chunked into regions annotated to biological pathways rather than by physical distance. 
Genomic regions can be annotated to particular pathways, using publically available 
resources such as Gene Ontology (GO) and the Gene Set Enrichment Analysis (GSEA) 
Canonical Pathways library. The best threshold within each pathway is then determined 
separately, much like PRSlice. This allows us to leverage the considerable and growing 
understanding of the biological function of genomic regions in order to gain an insight 
into the biological causes of disease pathophysiology. Whereas PRSlice may be more 
sensitive to partially overlapping sets of risk variants between disorders showing some 
degree of genetic correlation, this method could be extended to explicitly prioritise 
biological pathways and thus drug targets for downstream trials. This method – Pathway 










The pathway from identifying overlapping phenotypes with epidemiological methods to 
explaining the causes of this overlap by exploiting models of genetic risk forms the heart 
of this thesis. This is a relatively novel approach, partly due to the novelty of genetic risk 
models with adequate predictive accuracy. Applying these improved genetic risk scores 
to old epidemiological puzzles can add understanding to aetiology, and within a clinical 
setting add to understanding of prognosis and treatment. We have applied this paradigm 
to the overlap between the psychiatric and autoimmune disorders, finding little evidence 
for shared genetic components between schizophrenia and rheumatoid arthritis, and a 
body of supporting evidence for an inflammatory aetiology to depression, in line with 
other literature. Furthermore, we have developed two new methods to calculate more 
accurate markers for genetic risk, and proposed novel ways in which these might be 
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